WO2023073925A1 - 眼科組成物 - Google Patents
眼科組成物 Download PDFInfo
- Publication number
- WO2023073925A1 WO2023073925A1 PCT/JP2021/040030 JP2021040030W WO2023073925A1 WO 2023073925 A1 WO2023073925 A1 WO 2023073925A1 JP 2021040030 W JP2021040030 W JP 2021040030W WO 2023073925 A1 WO2023073925 A1 WO 2023073925A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salts
- ophthalmic composition
- component
- chondroitin sulfate
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 558
- 150000003839 salts Chemical class 0.000 claims abstract description 311
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 91
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 88
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 88
- 210000001508 eye Anatomy 0.000 claims abstract description 72
- 239000000739 antihistaminic agent Substances 0.000 claims abstract description 39
- 229920000642 polymer Polymers 0.000 claims abstract description 36
- 150000003751 zinc Chemical class 0.000 claims abstract description 26
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims abstract description 24
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims abstract description 24
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims abstract description 24
- 229940041616 menthol Drugs 0.000 claims abstract description 23
- BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229920002554 vinyl polymer Polymers 0.000 claims abstract description 20
- 229940125715 antihistaminic agent Drugs 0.000 claims abstract description 13
- 229960000337 tetryzoline Drugs 0.000 claims abstract description 11
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 68
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 38
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 38
- 235000019155 vitamin A Nutrition 0.000 claims description 38
- 239000011719 vitamin A Substances 0.000 claims description 38
- 239000000850 decongestant Substances 0.000 claims description 36
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 36
- 235000019165 vitamin E Nutrition 0.000 claims description 34
- 239000011709 vitamin E Substances 0.000 claims description 34
- 235000019156 vitamin B Nutrition 0.000 claims description 33
- 239000011720 vitamin B Substances 0.000 claims description 33
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 28
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 26
- 230000001387 anti-histamine Effects 0.000 claims description 26
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 24
- 235000003704 aspartic acid Nutrition 0.000 claims description 23
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Chemical class OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 23
- 229920003174 cellulose-based polymer Chemical class 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 20
- 239000004327 boric acid Substances 0.000 claims description 20
- 210000003205 muscle Anatomy 0.000 claims description 20
- 235000001014 amino acid Nutrition 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 229960002362 neostigmine Drugs 0.000 claims description 17
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical class [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 claims description 17
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 15
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 14
- 229960000458 allantoin Drugs 0.000 claims description 14
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 12
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 12
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 11
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 11
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 11
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 11
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 11
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 11
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 11
- 229940124581 decongestants Drugs 0.000 claims description 10
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 10
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 10
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 9
- 229940101267 panthenol Drugs 0.000 claims description 9
- 235000020957 pantothenol Nutrition 0.000 claims description 9
- 239000011619 pantothenol Substances 0.000 claims description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 9
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 229960003291 chlorphenamine Drugs 0.000 claims description 7
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims description 7
- 229960004926 chlorobutanol Drugs 0.000 claims description 6
- 235000008160 pyridoxine Nutrition 0.000 claims description 5
- 239000011677 pyridoxine Substances 0.000 claims description 5
- 229940011671 vitamin b6 Drugs 0.000 claims description 5
- 229930003270 Vitamin B Natural products 0.000 claims description 3
- 235000002639 sodium chloride Nutrition 0.000 description 343
- -1 alkali metal salts Chemical class 0.000 description 182
- 239000012085 test solution Substances 0.000 description 159
- 230000000694 effects Effects 0.000 description 124
- 238000009472 formulation Methods 0.000 description 97
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 96
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 84
- 238000012360 testing method Methods 0.000 description 78
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 63
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 62
- 239000000872 buffer Substances 0.000 description 58
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 54
- 230000008859 change Effects 0.000 description 51
- 239000004359 castor oil Substances 0.000 description 48
- 235000019438 castor oil Nutrition 0.000 description 48
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 48
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 45
- 239000003889 eye drop Substances 0.000 description 42
- 230000002708 enhancing effect Effects 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- 230000009467 reduction Effects 0.000 description 35
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 34
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 32
- 239000007788 liquid Substances 0.000 description 32
- 229940045997 vitamin a Drugs 0.000 description 32
- 229910052783 alkali metal Inorganic materials 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 31
- 238000007796 conventional method Methods 0.000 description 30
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 30
- 239000004615 ingredient Substances 0.000 description 30
- 230000003204 osmotic effect Effects 0.000 description 30
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 29
- 230000001747 exhibiting effect Effects 0.000 description 29
- 229930003427 Vitamin E Natural products 0.000 description 28
- 229940046009 vitamin E Drugs 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- 229940108325 retinyl palmitate Drugs 0.000 description 27
- 235000019172 retinyl palmitate Nutrition 0.000 description 27
- 239000011769 retinyl palmitate Substances 0.000 description 27
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 26
- 238000013329 compounding Methods 0.000 description 26
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 24
- 238000000034 method Methods 0.000 description 24
- 229960005261 aspartic acid Drugs 0.000 description 23
- 229940012356 eye drops Drugs 0.000 description 23
- 230000004397 blinking Effects 0.000 description 22
- 229920000139 polyethylene terephthalate Polymers 0.000 description 22
- 239000005020 polyethylene terephthalate Substances 0.000 description 22
- 239000004094 surface-active agent Substances 0.000 description 22
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 19
- 229940042585 tocopherol acetate Drugs 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 18
- 239000011521 glass Substances 0.000 description 18
- 229920003023 plastic Polymers 0.000 description 18
- 239000004033 plastic Substances 0.000 description 18
- 239000003755 preservative agent Substances 0.000 description 18
- 239000011780 sodium chloride Substances 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 16
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 16
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 16
- 230000007423 decrease Effects 0.000 description 16
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 16
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 15
- 229940001447 lactate Drugs 0.000 description 15
- 238000005259 measurement Methods 0.000 description 15
- 159000000000 sodium salts Chemical class 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 150000003863 ammonium salts Chemical class 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 14
- 239000006196 drop Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 230000002335 preservative effect Effects 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 239000004698 Polyethylene Substances 0.000 description 13
- 229920000573 polyethylene Polymers 0.000 description 13
- 229960003471 retinol Drugs 0.000 description 13
- 235000020944 retinol Nutrition 0.000 description 13
- 239000011607 retinol Substances 0.000 description 13
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 12
- 206010006784 Burning sensation Diseases 0.000 description 12
- 241000251730 Chondrichthyes Species 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 12
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 12
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 12
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 12
- 239000000654 additive Substances 0.000 description 12
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 12
- 229910052751 metal Inorganic materials 0.000 description 12
- 239000002184 metal Substances 0.000 description 12
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 12
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical group [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 11
- 229910021538 borax Inorganic materials 0.000 description 11
- 238000004040 coloring Methods 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 150000002148 esters Chemical class 0.000 description 11
- 230000007794 irritation Effects 0.000 description 11
- UWKAYLJWKGQEPM-UHFFFAOYSA-N linalool acetate Natural products CC(C)=CCCC(C)(C=C)OC(C)=O UWKAYLJWKGQEPM-UHFFFAOYSA-N 0.000 description 11
- 150000007530 organic bases Chemical class 0.000 description 11
- 235000010339 sodium tetraborate Nutrition 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 229920001214 Polysorbate 60 Polymers 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- 230000006872 improvement Effects 0.000 description 10
- 150000007529 inorganic bases Chemical class 0.000 description 10
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 10
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 10
- UWKAYLJWKGQEPM-LBPRGKRZSA-N linalyl acetate Chemical compound CC(C)=CCC[C@](C)(C=C)OC(C)=O UWKAYLJWKGQEPM-LBPRGKRZSA-N 0.000 description 10
- OSZNNLWOYWAHSS-UHFFFAOYSA-M neostigmine methyl sulfate Chemical compound COS([O-])(=O)=O.CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 OSZNNLWOYWAHSS-UHFFFAOYSA-M 0.000 description 10
- 229960002253 neostigmine methylsulfate Drugs 0.000 description 10
- 229920003207 poly(ethylene-2,6-naphthalate) Polymers 0.000 description 10
- 239000011112 polyethylene naphthalate Substances 0.000 description 10
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 9
- 239000004743 Polypropylene Substances 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 9
- 159000000007 calcium salts Chemical class 0.000 description 9
- 230000003833 cell viability Effects 0.000 description 9
- IKALZAKZWHFNIC-JIZZDEOASA-L dipotassium;(2s)-2-aminobutanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CC([O-])=O IKALZAKZWHFNIC-JIZZDEOASA-L 0.000 description 9
- 150000003840 hydrochlorides Chemical class 0.000 description 9
- 239000000017 hydrogel Substances 0.000 description 9
- 229910052749 magnesium Inorganic materials 0.000 description 9
- 239000011777 magnesium Substances 0.000 description 9
- 238000000569 multi-angle light scattering Methods 0.000 description 9
- 239000002736 nonionic surfactant Substances 0.000 description 9
- 239000008363 phosphate buffer Substances 0.000 description 9
- 229920001155 polypropylene Polymers 0.000 description 9
- 229920001296 polysiloxane Polymers 0.000 description 9
- 159000000001 potassium salts Chemical class 0.000 description 9
- 239000008213 purified water Substances 0.000 description 9
- 229910052708 sodium Inorganic materials 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 229940083542 sodium Drugs 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- BJORNXNYWNIWEY-UHFFFAOYSA-N tetrahydrozoline hydrochloride Chemical compound Cl.N1CCN=C1C1C2=CC=CC=C2CCC1 BJORNXNYWNIWEY-UHFFFAOYSA-N 0.000 description 9
- 229940021790 tetrahydrozoline hydrochloride Drugs 0.000 description 9
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 9
- 239000006172 buffering agent Substances 0.000 description 8
- 238000011049 filling Methods 0.000 description 8
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- 229940091250 magnesium supplement Drugs 0.000 description 8
- 229930014626 natural product Natural products 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 8
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 8
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 8
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 8
- 239000004328 sodium tetraborate Substances 0.000 description 8
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 8
- 229960001763 zinc sulfate Drugs 0.000 description 8
- 229910000368 zinc sulfate Inorganic materials 0.000 description 8
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 7
- 206010013774 Dry eye Diseases 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- 239000008351 acetate buffer Substances 0.000 description 7
- 229920001400 block copolymer Polymers 0.000 description 7
- 229910002091 carbon monoxide Inorganic materials 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 229920001707 polybutylene terephthalate Polymers 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 229960000342 retinol acetate Drugs 0.000 description 7
- 235000019173 retinyl acetate Nutrition 0.000 description 7
- 239000011770 retinyl acetate Substances 0.000 description 7
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 7
- 229930003799 tocopherol Natural products 0.000 description 7
- 239000011732 tocopherol Substances 0.000 description 7
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 6
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 6
- DRGAZIDRYFYHIJ-UHFFFAOYSA-N 2,2':6',2''-terpyridine Chemical compound N1=CC=CC=C1C1=CC=CC(C=2N=CC=CC=2)=N1 DRGAZIDRYFYHIJ-UHFFFAOYSA-N 0.000 description 6
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
- URDCARMUOSMFFI-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(2-hydroxyethyl)amino]acetic acid Chemical compound OCCN(CC(O)=O)CCN(CC(O)=O)CC(O)=O URDCARMUOSMFFI-UHFFFAOYSA-N 0.000 description 6
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 6
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 6
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 6
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 229920002683 Glycosaminoglycan Polymers 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 6
- DJDFFEBSKJCGHC-UHFFFAOYSA-N Naphazoline Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 DJDFFEBSKJCGHC-UHFFFAOYSA-N 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 229920002413 Polyhexanide Polymers 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 150000001340 alkali metals Chemical class 0.000 description 6
- 150000001342 alkaline earth metals Chemical class 0.000 description 6
- 150000008051 alkyl sulfates Chemical class 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 239000002280 amphoteric surfactant Substances 0.000 description 6
- 239000003945 anionic surfactant Substances 0.000 description 6
- 239000000607 artificial tear Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 229960000686 benzalkonium chloride Drugs 0.000 description 6
- 229960001950 benzethonium chloride Drugs 0.000 description 6
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 6
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 6
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 6
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229960005069 calcium Drugs 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 6
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 6
- 239000003093 cationic surfactant Substances 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 6
- YKZPPPNXRZHVGX-PXYKVGKMSA-L dipotassium;(2s)-2-aminobutanedioate;hydron;hydrate Chemical compound [H+].[H+].O.[K+].[K+].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O YKZPPPNXRZHVGX-PXYKVGKMSA-L 0.000 description 6
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 6
- 229960001484 edetic acid Drugs 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- IFQUWYZCAGRUJN-UHFFFAOYSA-N ethylenediaminediacetic acid Chemical compound OC(=O)CNCCNCC(O)=O IFQUWYZCAGRUJN-UHFFFAOYSA-N 0.000 description 6
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 6
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- CZVXBFUKBZRMKR-UHFFFAOYSA-N lavandulol Chemical compound CC(C)=CCC(CO)C(C)=C CZVXBFUKBZRMKR-UHFFFAOYSA-N 0.000 description 6
- 159000000003 magnesium salts Chemical class 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 150000002739 metals Chemical class 0.000 description 6
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 6
- 235000019799 monosodium phosphate Nutrition 0.000 description 6
- 229940023490 ophthalmic product Drugs 0.000 description 6
- 229960003330 pentetic acid Drugs 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 229940124531 pharmaceutical excipient Drugs 0.000 description 6
- 235000021317 phosphate Nutrition 0.000 description 6
- 229920001992 poloxamer 407 Polymers 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 6
- 229960003975 potassium Drugs 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- 239000011591 potassium Substances 0.000 description 6
- 229940068988 potassium aspartate Drugs 0.000 description 6
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 6
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 6
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 6
- 235000010344 sodium nitrate Nutrition 0.000 description 6
- 239000004317 sodium nitrate Substances 0.000 description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 229910001220 stainless steel Inorganic materials 0.000 description 6
- 239000010935 stainless steel Substances 0.000 description 6
- 239000012086 standard solution Substances 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 6
- 229960003080 taurine Drugs 0.000 description 6
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 6
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 5
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 5
- 101150035093 AMPD gene Proteins 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 5
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 5
- 239000005792 Geraniol Substances 0.000 description 5
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 5
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 102000016943 Muramidase Human genes 0.000 description 5
- 108010014251 Muramidase Proteins 0.000 description 5
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
- 230000001133 acceleration Effects 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 5
- 230000005779 cell damage Effects 0.000 description 5
- 208000037887 cell injury Diseases 0.000 description 5
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 5
- 239000007979 citrate buffer Substances 0.000 description 5
- 210000000744 eyelid Anatomy 0.000 description 5
- 229940113087 geraniol Drugs 0.000 description 5
- 235000001510 limonene Nutrition 0.000 description 5
- 229940087305 limonene Drugs 0.000 description 5
- 229930007744 linalool Natural products 0.000 description 5
- 235000010335 lysozyme Nutrition 0.000 description 5
- 239000004325 lysozyme Substances 0.000 description 5
- 229960000274 lysozyme Drugs 0.000 description 5
- RXMQCXCANMAVIO-CEOVSRFSSA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical compound [H+].[H+].[Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O RXMQCXCANMAVIO-CEOVSRFSSA-L 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- 235000019477 peppermint oil Nutrition 0.000 description 5
- 229920001451 polypropylene glycol Polymers 0.000 description 5
- 235000011056 potassium acetate Nutrition 0.000 description 5
- 239000001632 sodium acetate Substances 0.000 description 5
- 235000017281 sodium acetate Nutrition 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 235000017550 sodium carbonate Nutrition 0.000 description 5
- 239000008362 succinate buffer Substances 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 229960001295 tocopherol Drugs 0.000 description 5
- 235000010384 tocopherol Nutrition 0.000 description 5
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 description 5
- 239000008158 vegetable oil Substances 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 4
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 4
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 4
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000001856 Ethyl cellulose Substances 0.000 description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 4
- 229920002971 Heparan sulfate Polymers 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 4
- 235000006679 Mentha X verticillata Nutrition 0.000 description 4
- 235000002899 Mentha suaveolens Nutrition 0.000 description 4
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 4
- CNIIGCLFLJGOGP-UHFFFAOYSA-N SJ000285664 Natural products C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000000809 air pollutant Substances 0.000 description 4
- 231100001243 air pollutant Toxicity 0.000 description 4
- 150000005215 alkyl ethers Chemical class 0.000 description 4
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 208000003464 asthenopia Diseases 0.000 description 4
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 235000019325 ethyl cellulose Nutrition 0.000 description 4
- 229920001249 ethyl cellulose Polymers 0.000 description 4
- 210000000720 eyelash Anatomy 0.000 description 4
- 229940093915 gynecological organic acid Drugs 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 4
- 150000002462 imidazolines Chemical class 0.000 description 4
- 238000004573 interface analysis Methods 0.000 description 4
- 229950000120 iproheptine Drugs 0.000 description 4
- 229960001120 levocabastine Drugs 0.000 description 4
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 description 4
- 229940040452 linolenate Drugs 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-M linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC([O-])=O DTOSIQBPPRVQHS-PDBXOOCHSA-M 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 229960005016 naphazoline Drugs 0.000 description 4
- 150000002823 nitrates Chemical class 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 4
- 229960004811 pemirolast potassium Drugs 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- NMMVKSMGBDRONO-UHFFFAOYSA-N potassium;9-methyl-3-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound [K+].CC1=CC=CN(C2=O)C1=NC=C2C1=NN=N[N-]1 NMMVKSMGBDRONO-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- KZQSXALQTHVPDQ-UHFFFAOYSA-M sodium;butanedioate;hydron Chemical compound [Na+].OC(=O)CCC([O-])=O KZQSXALQTHVPDQ-UHFFFAOYSA-M 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 239000001384 succinic acid Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229940095064 tartrate Drugs 0.000 description 4
- 229960000984 tocofersolan Drugs 0.000 description 4
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 4
- 239000011731 tocotrienol Substances 0.000 description 4
- 229930003802 tocotrienol Natural products 0.000 description 4
- 235000019148 tocotrienols Nutrition 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 229960000281 trometamol Drugs 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 150000003712 vitamin E derivatives Chemical class 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 4
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 4
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 3
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 3
- 229930182837 (R)-adrenaline Natural products 0.000 description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 3
- CZVXBFUKBZRMKR-JTQLQIEISA-N (R)-lavandulol Natural products CC(C)=CC[C@@H](CO)C(C)=C CZVXBFUKBZRMKR-JTQLQIEISA-N 0.000 description 3
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 3
- CRBBOOXGHMTWOC-NPDDRXJXSA-N 1,4-Anhydro-6-O-dodecanoyl-2,3-bis-O-(2-hydroxyethyl)-D-glucitol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](OCCO)[C@H]1OCCO CRBBOOXGHMTWOC-NPDDRXJXSA-N 0.000 description 3
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 3
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 3
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 3
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 3
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 3
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 3
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 3
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 3
- HMFKFHLTUCJZJO-UHFFFAOYSA-N 2-{2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy}ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCC(OCCO)C1OCC(OCCO)C1OCCO HMFKFHLTUCJZJO-UHFFFAOYSA-N 0.000 description 3
- ABSTXSZPGHDTAF-UHFFFAOYSA-N 4-amino-pentanoic acid Chemical compound CC(N)CCC(O)=O ABSTXSZPGHDTAF-UHFFFAOYSA-N 0.000 description 3
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 239000005973 Carvone Substances 0.000 description 3
- 208000034628 Celiac artery compression syndrome Diseases 0.000 description 3
- 241000238366 Cephalopoda Species 0.000 description 3
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- 241000723346 Cinnamomum camphora Species 0.000 description 3
- 208000028006 Corneal injury Diseases 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 3
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 3
- 239000005770 Eugenol Substances 0.000 description 3
- XLRHXNIVIZZOON-WFUPGROFSA-L Flavin adenine dinucleotide disodium Chemical compound [Na+].[Na+].C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP([O-])(=O)OP([O-])(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 XLRHXNIVIZZOON-WFUPGROFSA-L 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- 229920000569 Gum karaya Polymers 0.000 description 3
- YHGJHDJZIOYZIR-URPSFYETSA-N Helenien Chemical compound CC1(C)C[C@H](OC(=O)CCCCCCCCCCCCCCC)CC(C)=C1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@@H]1C(C)(C)C[C@@H](OC(=O)CCCCCCCCCCCCCCC)C=C1C YHGJHDJZIOYZIR-URPSFYETSA-N 0.000 description 3
- YHGJHDJZIOYZIR-KFTCWRDFSA-N Helenien Natural products O=C(O[C@H]1C=C(C)[C@H](/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=2C(C)(C)C[C@H](OC(=O)CCCCCCCCCCCCCCC)CC=2C)\C)/C)\C)/C)C(C)(C)C1)CCCCCCCCCCCCCCC YHGJHDJZIOYZIR-KFTCWRDFSA-N 0.000 description 3
- 229920001499 Heparinoid Polymers 0.000 description 3
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 3
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- ACEWLPOYLGNNHV-UHFFFAOYSA-N Ibuprofen piconol Chemical compound C1=CC(CC(C)C)=CC=C1C(C)C(=O)OCC1=CC=CC=N1 ACEWLPOYLGNNHV-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- DTGKSKDOIYIVQL-MRTMQBJTSA-N Isoborneol Natural products C1C[C@@]2(C)[C@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-MRTMQBJTSA-N 0.000 description 3
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 3
- 229930064664 L-arginine Natural products 0.000 description 3
- 235000014852 L-arginine Nutrition 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000237852 Mollusca Species 0.000 description 3
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 3
- GLZPCOQZEFWAFX-JXMROGBWSA-N Nerol Natural products CC(C)=CCC\C(C)=C\CO GLZPCOQZEFWAFX-JXMROGBWSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- YYVFXSYQSOZCOQ-UHFFFAOYSA-N Oxyquinoline sulfate Chemical compound [O-]S([O-])(=O)=O.C1=C[NH+]=C2C(O)=CC=CC2=C1.C1=C[NH+]=C2C(O)=CC=CC2=C1 YYVFXSYQSOZCOQ-UHFFFAOYSA-N 0.000 description 3
- 239000004264 Petrolatum Substances 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 239000004642 Polyimide Substances 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 229920001219 Polysorbate 40 Polymers 0.000 description 3
- 229920002642 Polysorbate 65 Polymers 0.000 description 3
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 3
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- 239000004288 Sodium dehydroacetate Substances 0.000 description 3
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 241000934878 Sterculia Species 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 3
- 239000005844 Thymol Substances 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 3
- JDLSRXWHEBFHNC-UHFFFAOYSA-N Ufenamate Chemical compound CCCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 JDLSRXWHEBFHNC-UHFFFAOYSA-N 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 3
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 3
- FZQSLXQPHPOTHG-UHFFFAOYSA-N [K+].[K+].O1B([O-])OB2OB([O-])OB1O2 Chemical compound [K+].[K+].O1B([O-])OB2OB([O-])OB1O2 FZQSLXQPHPOTHG-UHFFFAOYSA-N 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- VWQZJJZGISNFOE-UHFFFAOYSA-N acitazanolast Chemical compound OC(=O)C(=O)NC1=CC=CC(C2=NNN=N2)=C1 VWQZJJZGISNFOE-UHFFFAOYSA-N 0.000 description 3
- 229950001122 acitazanolast Drugs 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- LFVVNPBBFUSSHL-UHFFFAOYSA-N alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 description 3
- 229950010221 alexidine Drugs 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- YHGJHDJZIOYZIR-UHFFFAOYSA-N all-trans-lutein dipalmitate Natural products CC1(C)CC(OC(=O)CCCCCCCCCCCCCCC)CC(C)=C1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1C(C)(C)CC(OC(=O)CCCCCCCCCCCCCCC)C=C1C YHGJHDJZIOYZIR-UHFFFAOYSA-N 0.000 description 3
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 3
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 3
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 description 3
- 229960002684 aminocaproic acid Drugs 0.000 description 3
- SGRYPYWGNKJSDL-UHFFFAOYSA-N amlexanox Chemical compound NC1=C(C(O)=O)C=C2C(=O)C3=CC(C(C)C)=CC=C3OC2=N1 SGRYPYWGNKJSDL-UHFFFAOYSA-N 0.000 description 3
- 229960003731 amlexanox Drugs 0.000 description 3
- 229940011037 anethole Drugs 0.000 description 3
- 239000010775 animal oil Substances 0.000 description 3
- 239000000043 antiallergic agent Substances 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 3
- 229940092705 beclomethasone Drugs 0.000 description 3
- 229960005149 bendazac Drugs 0.000 description 3
- BYFMCKSPFYVMOU-UHFFFAOYSA-N bendazac Chemical compound C12=CC=CC=C2C(OCC(=O)O)=NN1CC1=CC=CC=C1 BYFMCKSPFYVMOU-UHFFFAOYSA-N 0.000 description 3
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 3
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 3
- BBWBEZAMXFGUGK-UHFFFAOYSA-N bis(dodecylsulfanyl)-methylarsane Chemical compound CCCCCCCCCCCCS[As](C)SCCCCCCCCCCCC BBWBEZAMXFGUGK-UHFFFAOYSA-N 0.000 description 3
- 238000009530 blood pressure measurement Methods 0.000 description 3
- 229940116229 borneol Drugs 0.000 description 3
- 229960000962 bufexamac Drugs 0.000 description 3
- MXJWRABVEGLYDG-UHFFFAOYSA-N bufexamac Chemical compound CCCCOC1=CC=C(CC(=O)NO)C=C1 MXJWRABVEGLYDG-UHFFFAOYSA-N 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 3
- 239000000920 calcium hydroxide Substances 0.000 description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 3
- 229960002079 calcium pantothenate Drugs 0.000 description 3
- JHECKPXUCKQCSH-UHFFFAOYSA-L calcium;disodium;2-[2-[bis(carboxylatomethyl)azaniumyl]ethyl-(carboxylatomethyl)azaniumyl]acetate;hydrate Chemical compound O.[Na+].[Na+].[Ca+2].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O JHECKPXUCKQCSH-UHFFFAOYSA-L 0.000 description 3
- 229930006739 camphene Natural products 0.000 description 3
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 3
- 229930008380 camphor Natural products 0.000 description 3
- 229960000846 camphor Drugs 0.000 description 3
- 239000010624 camphor oil Substances 0.000 description 3
- 229960000411 camphor oil Drugs 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 3
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 3
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 3
- 239000000544 cholinesterase inhibitor Substances 0.000 description 3
- 229940006423 chondroitin sulfate sodium Drugs 0.000 description 3
- 229960005233 cineole Drugs 0.000 description 3
- 239000010630 cinnamon oil Substances 0.000 description 3
- 235000000484 citronellol Nutrition 0.000 description 3
- 239000001926 citrus aurantium l. subsp. bergamia wright et arn. oil Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000012459 cleaning agent Substances 0.000 description 3
- 239000002826 coolant Substances 0.000 description 3
- 229940109248 cromoglycate Drugs 0.000 description 3
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 3
- 229960002104 cyanocobalamin Drugs 0.000 description 3
- 235000000639 cyanocobalamin Nutrition 0.000 description 3
- 239000011666 cyanocobalamin Substances 0.000 description 3
- 229930007927 cymene Natural products 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- SQIFACVGCPWBQZ-UHFFFAOYSA-N delta-terpineol Natural products CC(C)(O)C1CCC(=C)CC1 SQIFACVGCPWBQZ-UHFFFAOYSA-N 0.000 description 3
- 239000000645 desinfectant Substances 0.000 description 3
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 3
- 229940043276 diisopropanolamine Drugs 0.000 description 3
- 229960000520 diphenhydramine Drugs 0.000 description 3
- 229940095629 edetate calcium disodium Drugs 0.000 description 3
- 229940124274 edetate disodium Drugs 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 229960005139 epinephrine Drugs 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 3
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 3
- OUDSFQBUEBFSPS-UHFFFAOYSA-N ethylenediaminetriacetic acid Chemical compound OC(=O)CNCCN(CC(O)=O)CC(O)=O OUDSFQBUEBFSPS-UHFFFAOYSA-N 0.000 description 3
- 239000010642 eucalyptus oil Substances 0.000 description 3
- 229940044949 eucalyptus oil Drugs 0.000 description 3
- 229960002217 eugenol Drugs 0.000 description 3
- 229960000192 felbinac Drugs 0.000 description 3
- 239000010643 fennel seed oil Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229960000676 flunisolide Drugs 0.000 description 3
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 description 3
- 229960001469 fluticasone furoate Drugs 0.000 description 3
- 229960000289 fluticasone propionate Drugs 0.000 description 3
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 239000002554 heparinoid Substances 0.000 description 3
- 229940025770 heparinoids Drugs 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 229920013818 hydroxypropyl guar gum Polymers 0.000 description 3
- 229960002491 ibudilast Drugs 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- 229950005954 ibuprofen piconol Drugs 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- NKGYBXHAQAKSSG-UHFFFAOYSA-N iproheptine Chemical compound CC(C)CCCC(C)NC(C)C NKGYBXHAQAKSSG-UHFFFAOYSA-N 0.000 description 3
- 235000010494 karaya gum Nutrition 0.000 description 3
- 239000000231 karaya gum Substances 0.000 description 3
- 229940039371 karaya gum Drugs 0.000 description 3
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 3
- 229960000991 ketoprofen Drugs 0.000 description 3
- 229960004958 ketotifen Drugs 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 235000011147 magnesium chloride Nutrition 0.000 description 3
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 3
- 239000000347 magnesium hydroxide Substances 0.000 description 3
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000001683 mentha spicata herb oil Substances 0.000 description 3
- 229930007503 menthone Natural products 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 229960001047 methyl salicylate Drugs 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 229960002744 mometasone furoate Drugs 0.000 description 3
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 3
- DUNCVNHORHNONW-UHFFFAOYSA-N myrcenol Chemical compound CC(C)(O)CCCC(=C)C=C DUNCVNHORHNONW-UHFFFAOYSA-N 0.000 description 3
- 229930008383 myrcenol Natural products 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 3
- 239000000820 nonprescription drug Substances 0.000 description 3
- UQDVHJGNIFVBLG-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O UQDVHJGNIFVBLG-UHFFFAOYSA-N 0.000 description 3
- OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 229960004114 olopatadine Drugs 0.000 description 3
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 description 3
- 229960001257 oxyquinoline sulfate Drugs 0.000 description 3
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 229940066842 petrolatum Drugs 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 229960002702 piroxicam Drugs 0.000 description 3
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 3
- 229940044476 poloxamer 407 Drugs 0.000 description 3
- 229920001230 polyarylate Polymers 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 229940093158 polyhexanide Drugs 0.000 description 3
- 229920001721 polyimide Polymers 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 3
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 3
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 3
- 229940068977 polysorbate 20 Drugs 0.000 description 3
- 229940101027 polysorbate 40 Drugs 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 229940099511 polysorbate 65 Drugs 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 235000010241 potassium sorbate Nutrition 0.000 description 3
- 239000004302 potassium sorbate Substances 0.000 description 3
- 229940069338 potassium sorbate Drugs 0.000 description 3
- JVUYWILPYBCNNG-UHFFFAOYSA-N potassium;oxido(oxo)borane Chemical compound [K+].[O-]B=O JVUYWILPYBCNNG-UHFFFAOYSA-N 0.000 description 3
- 229960003101 pranoprofen Drugs 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 3
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 239000010666 rose oil Substances 0.000 description 3
- 235000019719 rose oil Nutrition 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 235000010378 sodium ascorbate Nutrition 0.000 description 3
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 3
- 229960005055 sodium ascorbate Drugs 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 229960003885 sodium benzoate Drugs 0.000 description 3
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 3
- 229940079839 sodium dehydroacetate Drugs 0.000 description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 description 3
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 3
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000010199 sorbic acid Nutrition 0.000 description 3
- 239000004334 sorbic acid Substances 0.000 description 3
- 229940075582 sorbic acid Drugs 0.000 description 3
- 235000011069 sorbitan monooleate Nutrition 0.000 description 3
- 239000001593 sorbitan monooleate Substances 0.000 description 3
- 229940035049 sorbitan monooleate Drugs 0.000 description 3
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 3
- 239000001570 sorbitan monopalmitate Substances 0.000 description 3
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 3
- 229950011392 sorbitan stearate Drugs 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 235000019721 spearmint oil Nutrition 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- 229960000654 sulfafurazole Drugs 0.000 description 3
- 229960005404 sulfamethoxazole Drugs 0.000 description 3
- YZMCKZRAOLZXAZ-UHFFFAOYSA-N sulfisomidine Chemical compound CC1=NC(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 YZMCKZRAOLZXAZ-UHFFFAOYSA-N 0.000 description 3
- 229960001975 sulfisomidine Drugs 0.000 description 3
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 3
- 229940116411 terpineol Drugs 0.000 description 3
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 229960000790 thymol Drugs 0.000 description 3
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 3
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 3
- 229960005342 tranilast Drugs 0.000 description 3
- WYXIGTJNYDDFFH-UHFFFAOYSA-Q triazanium;borate Chemical compound [NH4+].[NH4+].[NH4+].[O-]B([O-])[O-] WYXIGTJNYDDFFH-UHFFFAOYSA-Q 0.000 description 3
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 3
- 229960004791 tropicamide Drugs 0.000 description 3
- 229950010121 ufenamate Drugs 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 238000009736 wetting Methods 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- 229910052724 xenon Inorganic materials 0.000 description 3
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- 239000011576 zinc lactate Substances 0.000 description 3
- 235000000193 zinc lactate Nutrition 0.000 description 3
- 229940050168 zinc lactate Drugs 0.000 description 3
- 239000011787 zinc oxide Substances 0.000 description 3
- 235000014692 zinc oxide Nutrition 0.000 description 3
- RZLVQBNCHSJZPX-UHFFFAOYSA-L zinc sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O RZLVQBNCHSJZPX-UHFFFAOYSA-L 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- NOOLISFMXDJSKH-AEJSXWLSSA-N (+)-menthol Chemical compound CC(C)[C@H]1CC[C@H](C)C[C@@H]1O NOOLISFMXDJSKH-AEJSXWLSSA-N 0.000 description 2
- FMCGSUUBYTWNDP-ONGXEEELSA-N (1R,2S)-2-(dimethylamino)-1-phenyl-1-propanol Chemical compound CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 FMCGSUUBYTWNDP-ONGXEEELSA-N 0.000 description 2
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 2
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 2
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 2
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 2
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 2
- FMCGSUUBYTWNDP-UHFFFAOYSA-N N-Methylephedrine Natural products CN(C)C(C)C(O)C1=CC=CC=C1 FMCGSUUBYTWNDP-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 2
- SFRPDSKECHTFQA-ONOWFSFQSA-N [(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] propanoate Chemical compound CCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SFRPDSKECHTFQA-ONOWFSFQSA-N 0.000 description 2
- XQAXGZLFSSPBMK-UHFFFAOYSA-M [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride;trihydrate Chemical compound O.O.O.[Cl-].C1=CC(=[N+](C)C)C=C2SC3=CC(N(C)C)=CC=C3N=C21 XQAXGZLFSSPBMK-UHFFFAOYSA-M 0.000 description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 description 2
- 229910000318 alkali metal phosphate Inorganic materials 0.000 description 2
- 229910000316 alkaline earth metal phosphate Inorganic materials 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- ZGISOPBIAXHOTQ-OUGXGHBNSA-N all-trans-retinyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C ZGISOPBIAXHOTQ-OUGXGHBNSA-N 0.000 description 2
- FXKDHZXYYBPLHI-TUTABMRPSA-N all-trans-retinyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FXKDHZXYYBPLHI-TUTABMRPSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 235000012501 ammonium carbonate Nutrition 0.000 description 2
- 229960002028 atropine sulfate Drugs 0.000 description 2
- KKEMWYNNTBRYMR-UHFFFAOYSA-N azulene-1-sulfonic acid Chemical compound C1=CC=CC=C2C(S(=O)(=O)O)=CC=C21 KKEMWYNNTBRYMR-UHFFFAOYSA-N 0.000 description 2
- 150000001545 azulenes Chemical class 0.000 description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 2
- 229940093265 berberine Drugs 0.000 description 2
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 2
- 229940066595 beta tocopherol Drugs 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 2
- 229960003655 bromfenac Drugs 0.000 description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 2
- 235000011092 calcium acetate Nutrition 0.000 description 2
- 239000001639 calcium acetate Substances 0.000 description 2
- 229960005147 calcium acetate Drugs 0.000 description 2
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 2
- 239000001354 calcium citrate Substances 0.000 description 2
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 239000001527 calcium lactate Substances 0.000 description 2
- 235000011086 calcium lactate Nutrition 0.000 description 2
- 229960002401 calcium lactate Drugs 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical class O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 229920003064 carboxyethyl cellulose Polymers 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 229930007050 cineol Natural products 0.000 description 2
- 229940043350 citral Drugs 0.000 description 2
- 229940001468 citrate Drugs 0.000 description 2
- 229940010007 cobalamins Drugs 0.000 description 2
- 150000001867 cobalamins Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- 235000010389 delta-tocopherol Nutrition 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 239000002526 disodium citrate Substances 0.000 description 2
- 235000019262 disodium citrate Nutrition 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 2
- 230000008641 drought stress Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229960002179 ephedrine Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 2
- 235000010382 gamma-tocopherol Nutrition 0.000 description 2
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 2
- 229960002389 glycol salicylate Drugs 0.000 description 2
- 229960002350 guaiazulen Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 229960001983 magnesium aspartate Drugs 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 235000014380 magnesium carbonate Nutrition 0.000 description 2
- ONSCBWDZUUNMMK-UBKPKTQASA-L magnesium;3-[[(2r)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoate Chemical compound [Mg+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O ONSCBWDZUUNMMK-UBKPKTQASA-L 0.000 description 2
- 229960001929 meloxicam Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 2
- 235000007672 methylcobalamin Nutrition 0.000 description 2
- 239000011585 methylcobalamin Substances 0.000 description 2
- 229960002221 methylephedrine Drugs 0.000 description 2
- 229960000907 methylthioninium chloride Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 235000019691 monocalcium phosphate Nutrition 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 description 2
- 239000002524 monosodium citrate Substances 0.000 description 2
- 235000018342 monosodium citrate Nutrition 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 229960001528 oxymetazoline Drugs 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 description 2
- 229960002139 pilocarpine hydrochloride Drugs 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- VUOLWBPDWWANLX-FJXQXJEOSA-M potassium 3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoate Chemical compound [K+].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O VUOLWBPDWWANLX-FJXQXJEOSA-M 0.000 description 2
- 229960004109 potassium acetate Drugs 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 2
- PHZLMBHDXVLRIX-UHFFFAOYSA-M potassium lactate Chemical compound [K+].CC(O)C([O-])=O PHZLMBHDXVLRIX-UHFFFAOYSA-M 0.000 description 2
- 235000011085 potassium lactate Nutrition 0.000 description 2
- 239000001521 potassium lactate Substances 0.000 description 2
- 229960001304 potassium lactate Drugs 0.000 description 2
- 229960003581 pyridoxal Drugs 0.000 description 2
- 235000008164 pyridoxal Nutrition 0.000 description 2
- 239000011674 pyridoxal Substances 0.000 description 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 2
- 229960001327 pyridoxal phosphate Drugs 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
- 229960000371 rofecoxib Drugs 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- GQTHJBOWLPZUOI-FJXQXJEOSA-M sodium D-pantothenate Chemical compound [Na+].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GQTHJBOWLPZUOI-FJXQXJEOSA-M 0.000 description 2
- 229960004249 sodium acetate Drugs 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 229940068459 sodium pantothenate Drugs 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000019149 tocopherols Nutrition 0.000 description 2
- 229940068778 tocotrienols Drugs 0.000 description 2
- 229960000401 tranexamic acid Drugs 0.000 description 2
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 235000013337 tricalcium citrate Nutrition 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 2
- 235000019801 trisodium phosphate Nutrition 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 150000002266 vitamin A derivatives Chemical class 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- 229960001939 zinc chloride Drugs 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- 239000011590 β-tocopherol Substances 0.000 description 2
- 235000007680 β-tocopherol Nutrition 0.000 description 2
- 239000002478 γ-tocopherol Substances 0.000 description 2
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 2
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 2
- 239000002446 δ-tocopherol Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- HOHIAEPXOHCCGW-UHFFFAOYSA-N 2-aminoethanesulfonic acid Chemical compound NCCS(O)(=O)=O.NCCS(O)(=O)=O HOHIAEPXOHCCGW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 1
- OPSXJNAGCGVGOG-DKWTVANSSA-L Calcium L-aspartate Chemical compound [Ca+2].[O-]C(=O)[C@@H](N)CC([O-])=O OPSXJNAGCGVGOG-DKWTVANSSA-L 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 1
- PVNIQBQSYATKKL-UHFFFAOYSA-N Glycerol trihexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QYEORIIWGAAORG-UHFFFAOYSA-N Iproheptine hydrochloride Chemical compound [Cl-].CC(C)CCCC(C)[NH2+]C(C)C QYEORIIWGAAORG-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- HVRLZEKDTUEKQH-NOILCQHBSA-N Olopatadine hydrochloride Chemical compound Cl.C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 HVRLZEKDTUEKQH-NOILCQHBSA-N 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- NTCYWJCEOILKNG-ROLPUNSJSA-N [(1r,2s)-1-hydroxy-1-phenylpropan-2-yl]-dimethylazanium;chloride Chemical compound Cl.CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 NTCYWJCEOILKNG-ROLPUNSJSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- FYBWCLKVKGHJKS-UHFFFAOYSA-L berberine sesquihydrate sulfate Chemical compound O.O.O.[O-]S([O-])(=O)=O.C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2.C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 FYBWCLKVKGHJKS-UHFFFAOYSA-L 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 229940073563 dl- methylephedrine hydrochloride Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 1
- 229960003072 epinephrine hydrochloride Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 1
- 229960003630 ketotifen fumarate Drugs 0.000 description 1
- NFFJLMKHRCXLJO-DKWTVANSSA-L magnesium;(2s)-2-aminobutanedioate Chemical compound [Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O NFFJLMKHRCXLJO-DKWTVANSSA-L 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 229960004760 naphazoline hydrochloride Drugs 0.000 description 1
- 229960004186 naphazoline nitrate Drugs 0.000 description 1
- 229960003139 olopatadine hydrochloride Drugs 0.000 description 1
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 1
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229940111263 potassium magnesium aspartate Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- GEYJUFBPCGDENK-UHFFFAOYSA-M sodium;3,8-dimethyl-5-propan-2-ylazulene-1-sulfonate Chemical compound [Na+].CC(C)C1=CC=C(C)C2=C(S([O-])(=O)=O)C=C(C)C2=C1 GEYJUFBPCGDENK-UHFFFAOYSA-M 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Definitions
- the first invention relates to an ophthalmic composition.
- Dry eyes are caused by the use of air conditioners, reduced blinking due to long hours of computer work, and the wearing of contact lenses. with symptoms.
- the symptoms are alleviated by, for example, frequent instillation of artificial tears, but little is known about ophthalmic preparations for preventing dry eyes.
- Chondroitin sulfate or its salt is a type of acidic mucopolysaccharide, and is used in ophthalmic preparations for the purpose of promoting energy metabolism, promoting metabolism and cell respiration to relieve eye fatigue, and replenishing tear components. are blended (for example, Patent Literature 1).
- a first object of the present invention is to provide an ophthalmic composition capable of suppressing dryness of the eyes.
- the present inventors unexpectedly discovered that sodium chondroitin sulfate, which has a specific weight-average molecular weight, remarkably suppresses corneal damage due to dryness of the eyes, has a high affinity for contact lenses, and suppresses dryness of contact lenses. found to do.
- the first invention provides, for example, the following inventions.
- An ophthalmic composition for suppressing dryness of the eyes containing at least one selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 40,000 to 70,000 and salts thereof.
- An ophthalmic composition for suppressing dryness of contact lenses containing at least one selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 40,000 to 70,000 and salts thereof.
- At least one selected from the group consisting of anti-inflammatory agents, vitamins A, vitamins B, vitamins E, aminoethylsulfonic acid and its salts, aspartic acid and its salts, neostigmine and its salts, and cellulosic polymer compounds The ophthalmic composition according to [1] or [2], further comprising a seed.
- the first invention also provides, for example, the following inventions.
- an ophthalmic composition capable of suppressing eye dryness. Further, according to the first aspect of the present invention, it is possible to provide an ophthalmic composition capable of suppressing dryness of contact lenses.
- FIG. 4 is a graph showing the results of Test Example 1.
- the content unit “%” means “w/v%” and is synonymous with “g/100 mL”.
- the ophthalmic composition according to the present embodiment contains at least one selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 40,000 to 70,000 and salts thereof (also simply referred to as "component (A)"). contains.
- Chondroitin sulfate and its salts are not particularly limited as long as they are pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- chondroitin sulfate salts include alkali metal salts and alkaline earth metal salts.
- alkali metal salts include sodium salts and potassium salts.
- alkaline earth metal salts include magnesium salts and calcium salts.
- Chondroitin sulfate and its salts are preferably chondroitin sulfate and alkali metal salts of chondroitin sulfate, more preferably chondroitin sulfate and sodium chondroitin sulfate, and still more preferably sodium chondroitin sulfate.
- Chondroitin sulfate and its salts may be natural products or synthetic products, but are generally natural products of animals (preferably mammals, fish, mollusks, etc.; more preferably bovine, shark, squid, A chondroitin sulfate derived from a ray, etc.) and a salt thereof are preferably used, a chondroitin sulfate derived from a shark and/or a ray and a salt thereof are more preferably used, and a chondroitin sulfate and a salt thereof derived from a shark are more preferably used. .
- chondroitin sulfate and its salts can also be used. Chondroitin sulfate and its salt may be used alone or in combination of two or more.
- chondroitin sulfate and its salts include chondroitin sulfate and its salts having a weight-average molecular weight of 40,000 to 70,000 defined herein and chondroitin sulfate and its salts having a weight-average molecular weight outside the range defined herein. can be used in combination with For example, sodium chondroitin sulfate with a weight average molecular weight of 56,000 and sodium chondroitin sulfate with a weight average molecular weight of 25,000 can be used in combination.
- chondroitin sulfate having a weight average molecular weight of 40,000 to 70,000 and a salt thereof defined herein and chondroitin sulfate having a weight average molecular weight outside the range defined herein and a salt thereof may be contained as raw materials.
- the "weight average molecular weight” can be determined by using gel permeation chromatography in which a multi-angle light scattering detector (MALS detector) and a differential refractive index detector (RI detector) are connected online. . Specifically, the following conditions are presented. ⁇ Standard sample preparation> 10 mL of 0.1 M sodium nitrate aqueous solution was added to 5 mg of chondroitin sulfate or its salt, and the mixture was gently stirred at room temperature to dissolve completely.
- MALS detector multi-angle light scattering detector
- RI detector differential refractive index detector
- Apparatus Gel permeation chromatograph - multi-angle light scatterometer Detector: Differential refractive index detector (Optilab rEX manufactured by Wyatt Technology) Multi-angle light scattering detector (DAWN HELEOS manufactured by Wyatt Technology) Column: 2 Shodex OHpak SB-806M HQ ( ⁇ 7.8 mm ⁇ 30 cm, manufactured by Showa Denko) Solvent: 0.1 M sodium nitrate aqueous solution Flow rate: 0.7 mL/min Column temperature: 23°C Detector temperature: 23°C Injection volume: 0.2 mL Data processing: Wyatt Technology data processing system (ASTRA)
- the weight average molecular weight of chondroitin sulfate and its salt calculated by the above method is not particularly limited as long as it is in the range of 40,000 to 70,000.
- Examples of the lower limit of the weight average molecular weight include 41000 or more, 42000 or more, 43000 or more, 44000 or more, 45000 or more, 46000 or more, 47000 or more, 48000 or more, 49000 or more, and 50000 or more.
- Examples of the upper limit of the weight average molecular weight include 69000 or less, 68000 or less, 67000 or less, 66000 or less, 65000 or less, 64000 or less, 63000 or less, 62000 or less, 61000 or less, and 60000 or less.
- the weight average molecular weight ranges are 41,000 to 69,000, 42,000 to 68,000, 43,000 to 67,000, 44,000 to 66,000, 45,000 to 65,000, 46,000 to 64,000, 47,000 to 63,000, 48,000 to 62,000, 49,000 to 61,000, and 500.
- 00 to 60000 are examples be done.
- the content of component (A) in the ophthalmic composition according to the present embodiment is not particularly limited, and is appropriately set according to the type and content of other compounding components, the application and formulation form of the ophthalmic composition, and the like.
- the content of component (A) is usually 0.001 to 5 w/v%, for example, 0.005%, based on the total amount of the ophthalmic composition, from the viewpoint of exhibiting the effects of the first present invention more remarkably.
- ⁇ 5 w/v%, more preferably 0.008 to 4 w/v%, even more preferably 0.01 to 3 w/v%, and 0.05 to 2 w/v% 0.1 to 1 w/v % is particularly preferred, and 0.3 to 1 w/v % is most preferred.
- the ophthalmic composition according to the present embodiment further comprises anti-inflammatory agents, vitamins A, vitamins B, vitamins E, aminoethylsulfonic acid and salts thereof, aspartic acid and salts thereof, neostigmine and salts thereof, and cellulose-based high It may further contain at least one selected from the group consisting of molecular compounds (also referred to simply as "component (B)").
- component (B) molecular compounds
- the ophthalmic composition containing the (A) component and the (B) component according to the present embodiment as confirmed in the test examples described later, the liquid in the pipe during filling into the container or during liquid delivery
- the effect of suppressing the residue, the effect of increasing the preservative effect, the effect of making it easier to blink regardless of the viscosity when the formulation is put in the eyes (even if it is a high viscosity formulation), and the viscosity when the formulation is put in the eyes Effect of suppressing discomfort when blinking (even for high-viscosity formulations), effect of suppressing viscosity change due to daylight, effect of suppressing precipitation of ingredients (white residue), and prevention of coloring of formulations due to daylight Inhibition effect, effect in inhibiting coloration of preparation by ultraviolet rays, effect in inhibiting change in appearance (transparency) by heat, effect in increasing cell viability, external stimulation (blinking, contact lens origin (when wearing/removing, wearing) ), eye rubbing, foreign matter contamination (pollen, air pollutants, eyelashes,
- Anti-inflammatory agents are compounds and salts thereof that have anti-inflammatory or anti-inflammatory activity.
- the anti-inflammatory agent is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- anti-inflammatory agents include epsilon-aminocaproic acid, allantoin, berberine, azulenes (azulene, azulene sulfonic acid, camaazulene, guaiazulene, etc.), glycyrrhizic acid, zinc salts, lysozyme, lysozyme chloride, celecoxib, rofecoxib, indomethacin, diclofenac, bromfenac, piroxicam, meloxicam, methyl salicylate, glycol salicylate, tranexamic acid, ibuprofen, ibuprofen piconol, bufexamac, butyl flufenamate, bendazac, ketoprofen, felbinac, pranoprofen, and salts thereof.
- allantoin, glycyrrhizic acid and its salts, and zinc salts are preferred, and allantoin, glycyrrhizic acid and its salts are more preferred.
- glycyrrhizic acid and its salts alkali metal salts or ammonium salts of glycyrrhizic acid are preferred, dipotassium glycyrrhizinate and monoammonium glycyrrhizinate are more preferred, and dipotassium glycyrrhizinate is even more preferred.
- the zinc salt is preferably zinc sulfate or zinc lactate, more preferably zinc sulfate.
- the zinc salt may be a hydrate (for example, zinc sulfate heptahydrate).
- Anti-inflammatory agents can also be used. Anti-inflammatory agents may be used singly or in combination of two or more.
- the content of the anti-inflammatory agent in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the use of the composition, the formulation form, and the like.
- the content of the anti-inflammatory agent is 0.0001 to 10 w/v% based on the total amount of the ophthalmic composition, from the viewpoint of exhibiting the effect of the first present invention more remarkably. preferably 0.001 to 5 w/v%, more preferably 0.005 to 3 w/v%, even more preferably 0.01 to 1 w/v% , 0.03 to 0.5 w/v %.
- the total content of anti-inflammatory agents may be 0.25 w/v%.
- the content ratio of the anti-inflammatory agent to the component (A) in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the type and content of other compounding ingredients, the application and formulation form of the ophthalmic composition, and the like.
- the content ratio of the anti-inflammatory agent to the component (A) is, from the viewpoint of further enhancing the effect of the first present invention, for example, the total content of the component (A) contained in the ophthalmic composition according to the present embodiment is 1 mass.
- the total content of the anti-inflammatory agent is preferably 0.0002 to 1000 parts by mass, more preferably 0.001 to 500 parts by mass, and 0.01 to 100 parts by mass.
- the total content of the anti-inflammatory agent may be 0.5 parts by mass with respect to 1 part by mass of the total content of the component (A).
- Vitamin A is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable. Specific examples of vitamin A include retinol, retinal, retinoic acid, derivatives thereof, and salts thereof.
- vitamin A derivatives include esters with monovalent carboxylic acids such as retinol palmitate, retinol acetate, retinol butyrate, retinol propionate, retinol octylate, retinol laurate, retinol oleate and retinol linolenate. mentioned.
- vitamin A salts include organic acid salts [e.g., monocarboxylates (acetate, trifluoroacetate, butyrate, palmitate, stearate, etc.), polyvalent carboxylates (fumaric acid salt, maleate, succinate, malonate, etc.), oxycarboxylate (lactate, tartrate, citrate, etc.), organic sulfonate (methanesulfonate, toluenesulfonate, tosylate salts, etc.)], inorganic acid salts (e.g., hydrochlorides, sulfates, nitrates, hydrobromides, phosphates, etc.), salts with organic bases (e.g., methylamine, triethylamine, triethanolamine, morpholine , piperazine, pyrrolidine, tripyridine, salts with organic amines such as picoline, etc.), salts with inorganic bases [e.g., ammonium salts
- vitamin A derivatives of retinol are preferable, esters of retinol and monovalent carboxylic acid are more preferable, retinol palmitate and retinol acetate are more preferable, and retinol palmitate is even more preferable.
- vitamin A synthetic products may be used, or extracts obtained from natural products (eg, vitamin A oil, etc.) may be used.
- Vitamin A oil is a fatty oil obtained from animal tissue containing retinol, a concentrate thereof, or a mixture thereof with vegetable oil added as appropriate. Commercially available vitamin A can also be used. Vitamin A may be used individually by 1 type, or may be used in combination of 2 or more type.
- the content of vitamin A in the ophthalmic composition according to the present embodiment is preferably 0.1 to 300,000 IU/100 mL based on the total amount of the ophthalmic composition. , More preferably 50,000 to 300,000 IU / 100 mL, more preferably 10,000 to 100,000 IU / 100 mL, and even more preferably 30,000 to 55,000 IU / 100 mL , more preferably 35,000 to 55,000 IU/100 mL, and particularly preferably 45,000 to 55,000 IU/100 mL.
- IU means the international unit determined by the method described in the Japanese Pharmacopoeia 17th Edition Vitamin A Determination Method. For example, in each article of the Japanese Pharmacopoeia 17th Edition, it is stated that retinol acetate contains 2.5 million units or more of vitamin A per 1g, and retinol palmitate contains 1.5 million units or more of vitamin A per 1g. ing.
- the content ratio of vitamin A to component (A) in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the type and content of other compounding ingredients, the application and formulation form of the ophthalmic composition, and the like.
- the content ratio of vitamin A relative to the component (A) is, from the viewpoint of further enhancing the effects of the first present invention, for example, the total content of the component (A) contained in the ophthalmic composition according to the present embodiment is 1 mass.
- the total content of vitamin A is preferably 10,000 to 3,000,000 IU/g, more preferably 10,000 to 1,000,000 IU/g, and 35,000 to It is more preferably 550,000 IU/g, and even more preferably 4.5 to 550,000 IU/g.
- [Vitamin B] B vitamins are not particularly limited as long as they are pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- B vitamins include flavin adenine dinucleotide and salts thereof (flavin adenine dinucleotide sodium, etc.), cobalamins (cyanocobalamin, methylcobalamin, etc.), pantothenic acid and salts thereof (e.g., sodium pantothenate, potassium pantothenate) , calcium pantothenate, magnesium pantothenate, etc.), panthenol, pyridoxine or salts thereof (pyridoxine hydrochloride, etc.), pyridoxal and salts thereof (pyridoxal phosphate, etc.).
- As the B vitamins, panthenol, pyridoxine or salts thereof are preferred.
- B vitamins can also be used. B vitamins may be used singly or in combination of two or more.
- the content of the B vitamins in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the use of the composition, the formulation form, and the like.
- the total content of B vitamins is 0.0001 to 5 w/v% based on the total amount of the ophthalmic composition, from the viewpoint of exhibiting the effects of the first present invention more remarkably. It is preferably 0.0005 to 1 w/v%, more preferably 0.001 to 1 w/v%, further preferably 0.005 to 0.5 w/v%. More preferably, 0.01 to 0.1 w/v% is particularly preferred.
- the content ratio of the B vitamins to the component (A) in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the type and content of other compounding ingredients, the application and formulation form of the ophthalmic composition, and the like. From the viewpoint of further enhancing the effect of the first present invention, the content ratio of the B vitamins to the component (A) is, for example, 1 mass of the total content of the component (A) contained in the ophthalmic composition according to the present embodiment.
- the total content of B vitamins is preferably 0.00002 to 1000 parts by mass, more preferably 0.0001 to 500 parts by mass, and 0.001 to 100 parts by mass. is more preferably 0.005 to 50 parts by mass, even more preferably 0.01 to 30 parts by mass, and particularly preferably 0.05 to 1 part by mass.
- Vitamin E is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable. Specific examples of vitamin E include tocopherol, tocotrienol, derivatives thereof, and salts thereof. Tocopherols and tocotrienols may be ⁇ -, ⁇ -, ⁇ -, or ⁇ -, and may be d- or dl-forms.
- vitamin E derivatives include esters with organic acids such as tocopherol acetate, tocopherol succinate, tocopherol nicotinate, and tocopherol linolenate.
- vitamin E salts examples include organic acid salts (lactate, acetate, butyrate, trifluoroacetate, fumarate, maleate, tartrate, citrate, succinate, malonate, , methanesulfonate, toluenesulfonate, tosylate, palmitate, stearate, etc.), inorganic acid salts (e.g., hydrochloride, sulfate, nitrate, hydrobromide, phosphate, etc.) , salts with organic bases (e.g., salts with organic amines such as methylamine, triethylamine, triethanolamine, morpholine, piperazine, pyrrolidine, amino acids, tripyridine, picoline, etc.), salts with inorganic bases (e.g., ammonium salts, alkali metals such as sodium and potassium; alkaline earth metals such as calcium and magnesium; salts with metals such as aluminum;
- organic acid salts e.g
- vitamin E examples include d- ⁇ -tocopherol, dl- ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol, vitamin E acetate (e.g. tocopherol acetate), vitamin E nicotinate, vitamin E succinate Acid esters and vitamin E linolenic acid esters are preferred, and tocopherol acetate (eg, d- ⁇ -tocopherol acetate, dl- ⁇ -tocopherol acetate, etc.) is more preferred.
- Vitamin E may be either natural or synthetic. Commercially available vitamin E can also be used. Vitamin E may be used individually by 1 type, or may be used in combination of 2 or more type.
- the content of vitamin E in the ophthalmic composition according to the present embodiment is preferably 0.0001 to 0.5 w/v% based on the total amount of the ophthalmic composition. , More preferably 0.001 to 0.1 w/v%, even more preferably 0.005 to 0.05 w/v%, further preferably 0.01 to 0.05 w/v% more preferred.
- the content ratio of vitamin E to component (A) in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the type and content of other compounding ingredients, the application and formulation form of the ophthalmic composition, and the like.
- the content ratio of vitamin E relative to the component (A) is, from the viewpoint of further enhancing the effect of the first present invention, for example, the total content of the component (A) contained in the ophthalmic composition according to the present embodiment is 1 mass.
- the total content of vitamin E is preferably 0.0001 to 50 parts by mass, more preferably 0.001 to 20 parts by mass, and 0.005 to 10 parts by mass. is more preferable, 0.01 to 5 parts by mass is even more preferable, and 0.01 to 0.5 parts by mass is particularly preferable.
- Aminoethylsulfonic acid and its salt Aminoethylsulfonic acid (taurine) and salts thereof are not particularly limited as long as they are pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- salts of aminoethylsulfonic acid include salts with organic bases (e.g., salts with organic amines such as methylamine, triethylamine, triethanolamine, morpholine, piperazine, pyrrolidine, tripyridine, and picoline), and inorganic bases.
- Salts [for example, salts with metals such as ammonium salts, alkali metals (sodium, potassium, etc.), alkaline earth metals (calcium, magnesium, etc.), aluminum] can be mentioned.
- Aminoethylsulfonic acid is preferred as aminoethylsulfonic acid and its salt.
- aminoethylsulfonic acid and its salts can also be used.
- Aminoethylsulfonic acid and its salt may be used individually by 1 type, or may be used in combination of 2 or more type.
- the content of aminoethylsulfonic acid and its salts in the ophthalmic composition according to the present embodiment is based on the total amount of the ophthalmic composition, and the total content of aminoethylsulfonic acid and its salts is 0.001 to 10 w/v. %, more preferably 0.01 to 5 w/v%, even more preferably 0.05 to 3 w/v%, further preferably 0.1 to 2 w/v%. more preferred.
- the content ratio of the aminoethylsulfonic acid and its salt to the component (A) in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the type of ingredients, aminoethylsulfonic acid and its salt, the type and content of other compounding ingredients, the application and formulation form of the ophthalmic composition, and the like.
- the content ratio of aminoethylsulfonic acid and its salt to component (A) is, from the viewpoint of further enhancing the effect of the first present invention,
- the total content of aminoethylsulfonic acid and its salt is preferably 0.001 to 1000 parts by mass, more preferably 0.01 to 200 parts by mass, based on 1 part by mass of the content. It is more preferably from 0.05 to 100 parts by mass, even more preferably from 0.1 to 20 parts by mass, and particularly preferably from 0.1 to 10 parts by mass.
- Aspartic acid and its salt Aspartic acid is a compound known as an acidic amino acid, also called 2-aminobutanedioic acid. Aspartic acid and salts thereof are not particularly limited as long as they are pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable. Aspartic acid may be in the L-, D-, or DL-form, preferably the L-form.
- Salts of aspartic acid include, for example, salts with inorganic bases (e.g., ammonium salts; salts with alkali metals (sodium, potassium, etc.), alkaline earth metals (calcium, magnesium, etc.), metals such as aluminum, etc.),
- inorganic bases e.g., ammonium salts; salts with alkali metals (sodium, potassium, etc.), alkaline earth metals (calcium, magnesium, etc.), metals such as aluminum, etc.
- organic bases for example, salts with organic amines such as methylamine, triethylamine, triethanolamine, morpholine, piperazine, pyrrolidine, tripyridine, picoline, etc.
- salts of aspartic acid with an inorganic base are preferred, alkali metal salts and alkaline earth metal salts of aspartic acid are more preferred, and potassium aspartate, magnesium aspartate and magnesium/potassium aspartate are further preferred. preferable.
- Aspartic acid and its salts can also be used. Aspartic acid and salts thereof may be used singly or in combination of two or more.
- the content of aspartic acid and its salt in the ophthalmic composition according to the present embodiment is not particularly limited, and is appropriately set according to the type and content of other compounding ingredients, formulation form, and the like.
- the content of aspartic acid or a salt thereof for example, the total content of aspartic acid or a salt thereof is preferably 0.001 to 10 w/v% based on the total amount of the ophthalmic composition, and 0.001 to 10% w/v. It is more preferably 01 to 5 w/v%, still more preferably 0.05 to 3 w/v%, even more preferably 0.1 to 2 w/v%.
- the content ratio of the aspartic acid and its salt to the component (A) in the ophthalmic composition according to the present embodiment is not particularly limited. and the type of salt thereof, the type and content of other compounding ingredients, the application and formulation form of the ophthalmic composition, and the like.
- the content ratio of aspartic acid and its salt to component (A) is, from the viewpoint of further enhancing the effects of the first present invention, for example, the total content of component (A) contained in the ophthalmic composition according to the present embodiment.
- the total content of aspartic acid and its salts is preferably 0.001 to 1000 parts by mass, more preferably 0.01 to 300 parts by mass, and more preferably 0.05 to 200 parts by mass with respect to 1 part by mass. It is more preferably 0.1 to 50 parts by mass, particularly preferably 0.1 to 20 parts by mass.
- Neostigmine and its salt are not particularly limited as long as they are pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- Salts of neostigmine include, for example, neostigmine methyl sulfate. As neostigmine and its salt, neostigmine methyl sulfate is preferred.
- Neostigmine and its salts can also be used. Neostigmine and salts thereof may be used singly or in combination of two or more.
- the content of neostigmine and salts thereof in the ophthalmic composition according to the present embodiment is 0.0001 to 0.05 w/v% based on the total amount of the ophthalmic composition. is preferably 0.0005 to 0.01 w/v%, more preferably 0.0008 to 0.008 w/v%, and 0.001 to 0.005 w/v% is more preferred.
- the content ratio of the neostigmine and its salt to the component (A) in the ophthalmic composition according to the present embodiment is not particularly limited. type, type and content of other compounding ingredients, application and formulation form of the ophthalmic composition, and the like.
- the content ratio of neostigmine and its salt to the component (A) is, from the viewpoint of further enhancing the effect of the first present invention, for example, the total content of the component (A) contained in the ophthalmic composition according to the present embodiment is 1
- the total content of neostigmine and its salts is preferably 0.0001 to 5 parts by mass, more preferably 0.0001 to 1 part by mass, and 0.0005 to 0.8 parts by mass. It is more preferably 0.001 to 0.5 parts by mass, particularly preferably 0.001 to 0.05 parts by mass.
- the cellulose-based polymer compound is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- Cellulose-based polymer compounds include, for example, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose (hypromellose), carboxymethylcellulose, carboxyethylcellulose, and salts thereof.
- hydroxyethyl cellulose, hydroxypropylmethyl cellulose and salts thereof are preferable, and hydroxypropylmethyl cellulose and salts thereof are more preferable.
- Such salts include, for example, salts with organic bases (amine salts, basic ammonium salts such as arginine, etc.), salts with inorganic bases (alkali metal salts such as ammonium salts, sodium salts, potassium salts, calcium salts, alkaline earth metal salts such as magnesium salts, aluminum salts, etc.), among which sodium salts, potassium salts and calcium salts are more preferred, and sodium salts are particularly preferred.
- a commercially available one can also be used as the cellulose-based polymer compound.
- a cellulose polymer compound may be used individually by 1 type, or may be used in combination of 2 or more type.
- the content of the cellulose-based polymer compound in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the type and content, the application and formulation form of the ophthalmic composition, and the like.
- the total content of the cellulose-based polymer compound is 0.0001 to 10w based on the total amount of the ophthalmic composition, from the viewpoint of exhibiting the effect of the first invention more remarkably.
- /v% more preferably 0.001 to 5 w/v%, even more preferably 0.005 to 3 w/v%, and 0.01 to 2 w/v% is even more preferred.
- the content ratio of the cellulose-based polymer compound to the component (A) in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the type of polymer compound, the type and content of other compounding ingredients, the application and formulation form of the ophthalmic composition, and the like.
- the content ratio of the cellulose-based polymer compound to the component (A) is, for example, the total content of the component (A) contained in the ophthalmic composition according to the present embodiment, from the viewpoint of further enhancing the effects of the first present invention.
- the total content of the cellulose-based polymer compound is preferably 0.0001 to 500 parts by mass, more preferably 0.001 to 100 parts by mass, and 0.005 to 50 parts by mass with respect to 1 part by mass. It is more preferably 0.01 to 30 parts by mass, and even more preferably 0.01 to 30 parts by mass.
- the ophthalmic composition according to the present embodiment may further contain (C) a surfactant (also referred to as “component (C)").
- a surfactant also referred to as "component (C)"
- component (C) a surfactant
- the effect of the first aspect of the present invention is exhibited more remarkably.
- surfactants are not particularly limited as long as they are pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable, nonionic surfactants, amphoteric surfactants, anionic surfactants , cationic surfactants.
- nonionic surfactants include POE (20) sorbitan monolaurate (polysorbate 20), POE (20) sorbitan monopalmitate (polysorbate 40), POE (20) sorbitan monostearate (polysorbate 60), POE sorbitan fatty acid esters such as POE (20) sorbitan stearate (polysorbate 65), POE (20) sorbitan monooleate (polysorbate 80); POE (40) hydrogenated castor oil (polyoxyethylene hydrogenated castor oil 40), POE ( 60) POE hydrogenated castor oil such as hydrogenated castor oil (polyoxyethylene hydrogenated castor oil 60); POE (3) hydrogenated castor oil (polyoxyethylene castor oil 3), POE (10) castor oil (polyoxyethylene castor oil 10 ), POE castor oil such as POE (35) castor oil (polyoxyethylene castor oil 35); POE alkyl ether such as POE (9) lauryl ether; POE-POP al
- amphoteric surfactants include alkyldiaminoethylglycine or salts thereof (eg, hydrochlorides, etc.).
- anionic surfactants include alkylbenzenesulfonates, alkylsulfates, polyoxyethylene alkylsulfates, aliphatic ⁇ -sulfomethyl esters, ⁇ -olefinsulfonic acids, and the like.
- cationic surfactants examples include cetylpyridinium chloride, benzalkonium chloride, and benzethonium chloride.
- nonionic surfactants are preferred, and POE sorbitan fatty acid esters, POE hydrogenated castor oil, POE castor oil, and POE/POP block copolymers are more preferred.
- Commercially available surfactants can also be used.
- Surfactants may be used alone or in combination of two or more.
- the content of component (C) in the ophthalmic composition according to the present embodiment is not particularly limited, and is appropriately set according to the type of component (C), the application of the ophthalmic composition, the form of formulation, and the like.
- the content of the component (C) from the viewpoint of exhibiting the effect of the first present invention more remarkably, for example, the total content of the component (C) is 0.001 to 0.001 based on the total amount of the ophthalmic composition. It is preferably 3 w/v%, more preferably 0.005 to 2 w/v%, even more preferably 0.01 to 1 w/v%, and 0.05 to 1 w/v%. is particularly preferred.
- the content ratio of component (C) to component (A) is not particularly limited. It is appropriately set according to the use, formulation form, etc. of the ophthalmic composition.
- the content ratio of component (C) to component (A) is, from the viewpoint of further enhancing the effect of the first present invention, for example, the total content of component (A) contained in the ophthalmic composition according to the present embodiment.
- the total content of component (C) is more preferably 0.001 to 30 parts by mass, more preferably 0.005 to 20 parts by mass, and 0.01 It is more preferably 10 parts by mass, and particularly preferably 0.01 to 2 parts by mass.
- the ophthalmic composition according to the present embodiment preferably further contains (D) a buffering agent (also referred to as "(D) component").
- a buffering agent also referred to as "(D) component”
- the buffering agent is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- Buffers include, for example, inorganic buffers that are buffers derived from inorganic acids, and organic buffers that are buffers derived from organic acids or organic bases.
- inorganic buffers include borate buffers, phosphate buffers, carbonate buffers, and the like.
- Boric acid buffers include boric acid or salts thereof (alkali metal borates, alkaline earth metal borates, etc.).
- Phosphate buffers include phosphoric acid and salts thereof (alkali metal phosphate, alkaline earth metal phosphate, etc.).
- Carbonic acid buffers include carbonic acid or salts thereof (alkali metal carbonates, alkaline earth metal carbonates, etc.). Borate, phosphate, or carbonate hydrates may also be used as the borate buffer, phosphate buffer, or carbonate buffer.
- More specific examples include boric acid or a salt thereof (sodium borate, potassium tetraborate, potassium metaborate, ammonium borate, borax, etc.) as a borate buffer; Salts (disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, trisodium phosphate, tripotassium phosphate, calcium monohydrogen phosphate, calcium dihydrogen phosphate, etc.); Alternatively, salts thereof (sodium hydrogen carbonate, sodium carbonate, ammonium carbonate, potassium carbonate, calcium carbonate, potassium hydrogen carbonate, magnesium carbonate, etc.) can be exemplified.
- organic buffers examples include citrate buffers, acetate buffers, lactate buffers, succinate buffers, Tris buffers, AMPD buffers, and the like.
- Citric acid buffers include citric acid or salts thereof (alkali metal citrate, alkaline earth metal citrate, etc.).
- the acetate buffer includes acetic acid or salts thereof (alkali metal acetate, alkaline earth metal acetate, etc.).
- Lactic acid buffers include lactic acid or salts thereof (alkali metal lactate, alkaline earth metal lactate, etc.).
- Succinic acid buffers include succinic acid or salts thereof (alkali metal succinate, etc.).
- citrate buffer hydrates of citrate, acetate, lactate, or succinate may be used as the citrate buffer, acetate buffer, lactate buffer, or succinate buffer. More specific examples include citric acid or a salt thereof (sodium citrate, potassium citrate, calcium citrate, sodium dihydrogen citrate, disodium citrate, etc.) as a citric acid buffer; acetic acid as an acetic acid buffer or salts thereof (ammonium acetate, sodium acetate, potassium acetate, calcium acetate, etc.); lactic acid or salts thereof (sodium lactate, potassium lactate, calcium lactate, etc.) as a lactic acid buffer; monosodium succinate, disodium succinate, etc.).
- Tris buffers include, for example, trometamol or salts thereof (trometamol hydrochloride, etc.).
- AMPD buffers include, for example, 2-amino-2-methyl-1,3-propanediol or salts thereof.
- buffering agents include borate buffers (e.g., a combination of boric acid and borax), phosphate buffers (e.g., a combination of disodium hydrogen phosphate and sodium dihydrogen phosphate), Tris buffers (e.g., , trometamol) are preferred, borate buffers are more preferred, boric acid and its salts are more preferred, and a combination of boric acid and borax is even more preferred.
- borate buffers e.g., a combination of boric acid and borax
- phosphate buffers e.g., a combination of disodium hydrogen phosphate and sodium dihydrogen phosphate
- Tris buffers e.g., trometamol
- borate buffers are more preferred
- boric acid and its salts are more preferred
- a combination of boric acid and borax is even more preferred.
- a buffering agent may be used individually by 1 type, or may be used in combination of 2 or more types.
- the content of component (D) in the ophthalmic composition according to the present embodiment is not particularly limited, and depends on the type of component (D), the type and content of other ingredients, the application and formulation form of the ophthalmic composition, and the like. is set as appropriate.
- the content of the component (D) from the viewpoint of exhibiting the effect of the first present invention more remarkably, for example, the total content of the component (D) based on the total amount of the ophthalmic composition is from 0.01 to 0.01. It is preferably 10 w/v%, more preferably 0.05 to 5 w/v%, even more preferably 0.1 to 3 w/v%.
- the content ratio of component (D) to component (A) in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the use, formulation form, etc. of the ophthalmic composition.
- the content ratio of component (D) to component (A) is, from the viewpoint of further enhancing the effects of the first present invention, for example, the total content of component (A) contained in the ophthalmic composition according to the present embodiment.
- the total content of component (D) is preferably 0.01 to 100 parts by mass, more preferably 0.05 to 50 parts by mass, and 0.1 to 30 parts by mass, relative to 1 part by mass. Part is more preferred.
- the pH of the ophthalmic composition according to this embodiment is not particularly limited as long as it is within a pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable range.
- the pH of the ophthalmic composition according to this embodiment may be, for example, 4.0 to 9.5, preferably 4.0 to 9.0, and more preferably 4.5 to 9.0. is more preferable, more preferably 4.5 to 8.5, even more preferably 5.0 to 8.5, particularly preferably 5.0 to 8.0, 5.3 ⁇ 7.5 is more particularly preferred, and 5.3 to 7.0 is most preferred.
- the ophthalmic composition according to the present embodiment can be adjusted to have an osmotic pressure ratio within a range acceptable to living organisms, if necessary.
- An appropriate osmotic pressure ratio can be appropriately set according to the application, formulation form, method of use, etc. of the ophthalmic composition, and can be, for example, 0.4 to 5.0, and 0.6 to 3.0. , more preferably 0.8 to 2.2, even more preferably 0.8 to 2.0.
- the osmotic pressure ratio is the ratio of the osmotic pressure of the sample to 286 mOsm (osmotic pressure of 0.9 w/v% sodium chloride aqueous solution) based on the 17th revision of the Japanese Pharmacopoeia, and the osmotic pressure is the osmotic pressure measurement method described in the Japanese Pharmacopoeia. (freezing point depression method).
- the standard solution for osmotic pressure ratio measurement (0.9 w/v% sodium chloride aqueous solution) was obtained by drying sodium chloride (Japanese Pharmacopoeia standard reagent) at 500 to 650 ° C. for 40 to 50 minutes and then placing it in a desiccator (silica gel).
- the viscosity of the ophthalmic composition according to this embodiment is not particularly limited as long as it is within a pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable range.
- the viscosity of the ophthalmic composition according to the present embodiment for example, the viscosity at 20 ° C.
- a rotational viscometer (TV-20 type viscometer, manufactured by Toki Sangyo Co., Ltd., rotor; 1 ° 34' ⁇ R24) is 1 It is preferably from 1 to 10,000 mPa s, more preferably from 1 to 8,000 mPa s, still more preferably from 1 to 1,000 mPa s, even more preferably from 1 to 100 mPa s, and from 1 to 20 mPa.
- ⁇ s is particularly preferred, and 1.5 to 10 mPa ⁇ s is most preferred.
- the ophthalmic composition according to the present embodiment contains, in addition to the above components, an appropriate amount of a combination of components selected from various pharmacologically active components and physiologically active components within a range that does not impair the effects of the first present invention.
- You may have The ingredients are not particularly limited, and examples thereof include active ingredients in ophthalmic drugs described in the 2017 edition of the Standards for Manufacturing and Marketing Approval of Over-the-Counter Drugs (supervised by the Japanese Society of Regulatory Science). Specific examples of components used in ophthalmic drugs include the following components.
- Antiallergic agents for example, cromoglycate sodium, tranilast, pemirolast potassium, acitazanolast, amlexanox, ibudilast and the like.
- Antihistamines e.g. diphenhydramine or salts thereof (e.g. diphenhydramine hydrochloride), iproheptine or salts thereof (e.g. iproheptine hydrochloride), chlorpheniramine or salts thereof (e.g. chlorpheniramine maleate), levocabastine or salts thereof (e.g. hydrochloric acid) levocabastine), ketotifen or a salt thereof (eg, ketotifen fumarate), pemirolast potassium, olopatadine or a salt thereof (eg, olopatadine hydrochloride), and the like.
- diphenhydramine or salts thereof e.g. diphenhydramine hydrochloride
- iproheptine or salts thereof e.g. iproheptine hydrochloride
- chlorpheniramine or salts thereof e.g. chlorpheniramine maleate
- levocabastine or salts thereof e.g.
- Steroid agents for example, fluticasone propionate, fluticasone furoate, mometasone furoate, beclomethasone propionate, flunisolide and the like.
- Decongestants for example, tetrahydrozoline hydrochloride, tetrahydrozoline nitrate, naphazoline hydrochloride, naphazoline nitrate, epinephrine, epinephrine hydrochloride, ephedrine hydrochloride, phenylephrine hydrochloride, dl-methylephedrine hydrochloride and the like.
- Ocular muscle modulating drug For example, a cholinesterase inhibitor having an active center similar to that of acetylcholine, specifically tropicamide, helenien, atropine sulfate, pilocarpine hydrochloride and the like.
- Vitamins For example, ascorbic acid, sodium ascorbate and the like.
- Amino acids such as L-arginine, glutamic acid, glycine, alanine, lysine, ⁇ -aminobutyric acid, ⁇ -aminovaleric acid, trimethylglycine and salts thereof.
- Astringent For example, zinc white and the like.
- Others For example, sulfamethoxazole, sulfisoxazole, sulfisomidine and salts thereof and the like.
- additives are appropriately selected in accordance with conventional methods according to the application and formulation form, as long as the effects of the first present invention are not impaired. Alternatively, more than that may be used in combination and contained in an appropriate amount. Examples of such additives include various additives described in Pharmaceutical Excipient Encyclopedia 2016 (edited by Japan Pharmaceutical Excipients Association). Typical ingredients include the following additives.
- Carrier For example, an aqueous solvent such as water or hydrous ethanol.
- Chelating agents for example, ethylenediaminediacetic acid (EDDA), ethylenediaminetriacetic acid, ethylenediaminetetraacetic acid (EDTA), N-(2-hydroxyethyl)ethylenediaminetriacetic acid (HEDTA), diethylenetriaminepentaacetic acid (DTPA) and the like.
- Base For example, octyldodecanol, titanium oxide, potassium bromide, Plastibase and the like.
- pH adjuster for example, hydrochloric acid, acetic acid, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, triethanolamine, monoethanolamine, diisopropanolamine and the like.
- Perfumes or cooling agents e.g. menthol, menthone, camphor, borneol, geraniol, cineol, citronellol, carvone, anethole, eugenol, limonene, linalool, linalyl acetate, thymol, cymene, terpineol, pinene, camphene, isoborneol, fenchen , nerol, myrcene, myrcenol, linalool acetate, lavandulol, eucalyptus oil, bergamot oil, peppermint oil, cool mint oil, spearmint oil, peppermint oil, fennel oil, cinnamon oil, rose oil, camphor oil, etc.
- Thickeners polyvinyl pyrrolidone, polyvinyl alcohol and other polyvinyl polymer compounds; carboxyvinyl polymer; guar gum; hydroxypropyl guar gum; gum arabic; karaya gum; xanthan gum; substances, heparin, heparin sulfate, heparan sulfate, heparinoids, mucopolysaccharides such as hyaluronic acid and its salts (sodium salts, etc.); starch; chitin and its derivatives; chitosan and its derivatives; carrageenan; Stabilizers: for example, edetic acid, edetate salts (edetate disodium, edetate calcium disodium, edetate trisodium, edetate tetrasodium), sodium formaldehyde sulfoxylate (Rongalite),
- Preservatives for example, alkylpolyaminoethylglycine quaternary ammonium salts (e.g., benzalkonium chloride, benzethonium chloride, etc.), chlorhexidine gluconate, polydronium chloride, zinc chloride, sodium benzoate, ethanol, chlorobutanol, sorbic acid, Potassium sorbate, sodium dehydroacetate, methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, butyl parahydroxybenzoate, oxyquinoline sulfate, phenethyl alcohol, benzyl alcohol, biguanide compounds (specifically, polyhexanide hydrochloride (poly hexamethylenebiguanide), Alexidine, etc.), Glokyl (trade name, manufactured by Rhodia), etc.
- alkylpolyaminoethylglycine quaternary ammonium salts e.g.,
- Tonicity agents e.g. potassium chloride, calcium chloride, sodium chloride, magnesium chloride, potassium acetate, sodium acetate, sodium bicarbonate, sodium carbonate, sodium thiosulfate, magnesium sulfate, glycerin, propylene glycol, sodium bisulfite, sodium sulfite etc.
- Sugar alcohols For example, xylitol, sorbitol, mannitol, glycerin and the like. These may be d-, l- or dl-isomers.
- Oils For example, vegetable oils such as sesame oil, castor oil, soybean oil and olive oil; animal oils such as squalane; mineral oils such as liquid paraffin and petrolatum.
- the ophthalmic composition according to this embodiment contains at least one selected from the group consisting of geraniol, linalyl acetate, limonene, citral and linalool in an amount of 0.5% from the viewpoint that the effects of the first invention can be exhibited remarkably. It is preferable not to contain 01% or more, more preferably not to contain.
- the content of water is, for example, based on the total amount of the ophthalmic composition, from the viewpoint of exhibiting the effects of the first present invention more remarkably.
- the content is preferably 80 w/v% or more and less than 100 w/v%, more preferably 85 w/v% or more and 99.5 w/v% or less, and 90 w/v% or more and 99.2 w/v% More preferably:
- the water used in the ophthalmic composition according to this embodiment may be pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- examples of such water include distilled water, ordinary water, purified water, sterile purified water, water for injection, and distilled water for injection. Their definitions are based on the 17th revision of the Japanese Pharmacopoeia.
- the ophthalmic composition according to the present embodiment can be prepared by adding and mixing a desired amount of component (A) and, if necessary, other components such as component (B) to a desired concentration.
- it can be prepared by dissolving or dispersing these components in purified water, adjusting to a predetermined pH and osmotic pressure, and sterilizing by filtration sterilization or the like.
- the ophthalmic composition according to this embodiment can take various formulation forms depending on the purpose.
- Formulations include, for example, liquids, gels, semi-solids (ointments, etc.) and the like.
- the ophthalmic composition according to the present embodiment includes, for example, eye drops (also referred to as eye drops or eye drops. Eye drops include eye drops that can be dropped while wearing contact lenses), artificial tears, and eye washes. (Also referred to as eye wash or eye wash. Eye wash includes eye wash that can be washed while wearing contact lenses.), contact lens composition [contact lens wetting solution, contact lens care composition (contact lens disinfectant, contact lens preservative, contact lens cleaning agent, contact lens cleaning and preserving agent), contact lens packaging solution, etc.].
- contact lens includes hard contact lenses and soft contact lenses (both ionic and non-ionic, including both silicone hydrogel contact lenses and non-silicone hydrogel contact lenses).
- the ophthalmic composition according to the present embodiment exhibits the effect of suppressing dryness of the eyes, it can be suitably used as an ophthalmic composition for suppressing dryness of the eyes. Therefore, as an embodiment of the first present invention, an ophthalmic composition for suppressing dryness of the eyes containing at least one selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 40,000 to 70,000 and salts thereof. goods are provided.
- the "effect of suppressing dryness of the eyes" in the present specification is not due to the action of promoting tear secretion, but due to the action of reducing eye cell damage due to dryness, the action of improving affinity with contact lenses, etc. it is conceivable that.
- a method for suppressing dryness of the eyes using at least one selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 40,000 to 70,000 and salts thereof. provided. Furthermore, as one embodiment of the first present invention, it is selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 40,000 to 70,000 and salts thereof for the production of an ophthalmic composition for suppressing dryness of the eyes. At least one use is provided.
- the ophthalmic composition according to this embodiment can suppress dryness of eyes and contact lenses. Therefore, various symptoms caused by these symptoms can be improved. That is, the ophthalmic composition according to the present embodiment suppresses dryness of the eyes and contact lenses, thereby reducing friction, watery eyes, eye fatigue, bloodshot eyes, and blurred vision when blinking due to dryness of the eyes and contact lenses. , decreased visual function, inflammation, itching, gritty sensation in the eyes, foreign body sensation, pain, photophobia, eye discomfort (e.g., discomfort when wearing hard or soft contact lenses), eyes due to dry stress It can reduce symptoms such as surface damage, eye surface damage due to light or other rays, dullness of the eyelids (heavy eyelids), inability to continue watching with concentration.
- the ophthalmic composition according to the present embodiment has a high affinity for contact lenses and exhibits an effect of suppressing dryness of contact lenses, it can be suitably used as an ophthalmic composition for suppressing dryness of contact lenses.
- the contact lens is preferably a soft contact lens, and more preferably a silicone hydrogel contact lens, from the viewpoint of exhibiting the effect of the first invention more remarkably.
- a method for suppressing dryness of contact lenses using at least one selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 40,000 to 70,000 and salts thereof. is provided. Furthermore, as an embodiment of the first present invention, selected from the group consisting of chondroitin sulfate and salts thereof having a weight average molecular weight of 40,000 to 70,000 for the production of an ophthalmic composition for suppressing dryness of contact lenses At least one use is provided.
- the ophthalmic composition according to the present embodiment is preferably an eye drop (including an eye drop that can be instilled while wearing contact lenses) because the effect of the first present invention can be exhibited more remarkably.
- the ophthalmic composition according to the present embodiment is an eye drop
- the usage and dosage are not particularly limited as long as they are effective and have few side effects.
- a method of using 1 to 3 drops, 1 to 2 drops, or 2 to 3 drops at a time, 2 to 4 times, or 5 to 6 times a day can be exemplified.
- the ophthalmic composition according to this embodiment is provided in an arbitrary container.
- the container for containing the ophthalmic composition according to this embodiment is not particularly limited, and may be made of glass or plastic, for example. It is preferably made of plastic. Examples of plastics include polyethylene terephthalate (PET), polyarylate, polyethylene naphthalate, polycarbonate, polyethylene, polypropylene, polyimide, copolymers of these monomers, and mixtures of two or more thereof.
- PET polyethylene terephthalate
- the container for storing the ophthalmic composition is preferably polyethylene terephthalate from the viewpoint of further enhancing the effects of the first present invention.
- the container containing the ophthalmic composition according to the present embodiment may be a transparent container in which the inside of the container is visible, or an opaque container in which the inside of the container is difficult to be seen.
- a transparent container is preferred.
- the "transparent container” includes both a colorless transparent container and a colored transparent container.
- a nozzle may be attached to the container containing the ophthalmic composition according to the present embodiment.
- the material of the nozzle is not particularly limited, and may be, for example, glass or plastic. It is preferably made of plastic. Examples of plastics include polybutylene terephthalate, polyethylene, polypropylene, polyethylene terephthalate, polyethylene naphthalate, copolymers of monomers constituting these, and mixtures of two or more of these.
- the material of the nozzle is preferably polypropylene, polyethylene, polyethylene terephthalate, polybutylene terephthalate, or polyethylene naphthalate, more preferably polyethylene, from the viewpoint of further enhancing the effects of the first invention.
- the container containing the ophthalmic composition according to the present embodiment may be of a multi-dose type that contains multiple doses, or may be of a unit dose type that contains a single dose.
- the ophthalmic composition according to the present embodiment is preferably filled in a container having an internal volume of 4 to 30 mL, more preferably filled in a container having an internal volume of 5 to 20 mL. More preferably, it is packed in a container of 6 to 16 mL, and even more preferably packed in a container with an internal volume of 10 to 15 mL. Also, it may be filled in a container with an internal volume of 0.1 to 3 mL, or may be filled in a container with an internal volume of 0.2 to 1 mL.
- the first invention will be specifically described below based on test examples, but the first invention is not limited to these.
- the sodium chondroitin sulfate used in the test examples below is as follows, and the sodium chondroitin sulfate having a weight-average molecular weight of about 56,000 is derived from sharks. Chondroitin sulfate sodium weight average molecular weight about 56000: Seikagaku Corporation; grade NK Weight average molecular weight about 28000: Seikagaku Corporation; grade ND-K Weight average molecular weight about 25000: Maruha Nichiro Co., Ltd.;
- Test Example 1 Drought stress test using rabbits] Sodium chondroitin sulfate with a weight average molecular weight of about 25,000 (Maruha Nichiro Co., Ltd.; external regulation sodium chondroitin sulfate) or sodium chondroitin sulfate with a weight average molecular weight of about 56,000 (Seikagaku Corporation) was added to physiological saline (Otsuka Pharmaceutical Factory Co., Ltd.). Company; Grade NK) was dissolved to 0.5 w/v% or 3 w/v%, respectively, to prepare each test substance.
- sodium chondroitin sulfate with a weight-average molecular weight of about 56,000 has significantly lower absorbance than sodium chondroitin sulfate with a weight-average molecular weight of about 25,000 (**p ⁇ 0.01, Tukey-type multiple comparison test). was confirmed to suppress corneal damage due to dry eyes.
- Test Example 2 Contact lens wettability test
- Each ophthalmic composition was prepared according to a conventional method with the composition shown in Table 1 and used as a test solution. The unit of each component in Table 1 is w/v %.
- sodium chondroitin sulfate has a weight average molecular weight of about 28000 (Seikagaku Corporation; grade ND-K) and about 56000 (Seikagaku Corporation; grade ND-K). Grade NK) was used.
- Phosphate buffered saline sodium chloride 0.60%, sodium hydrogen phosphate (12-hydrate) 0.60%, sodium dihydrogen phosphate (2 hydrate) 0.05%, pH 7.4 ⁇ 0.1
- One contact lens (Acuvue Oasis (Johnson & Johnson Co., Ltd.)) was immersed in each well and allowed to stand at room temperature for 4 hours or longer.
- 4 mL of phosphate-buffered saline and each test solution were dispensed into a 12-well plate. Moisture on the contact lens was lightly wiped off with lint-free paper, immersed in the contact lens, and allowed to stand for 15 minutes.
- phosphate buffered saline 100 mL of phosphate buffered saline was dispensed into the beaker.
- the soaked contact lenses were rinsed lightly with phosphate-buffered saline and dried using lint-free paper.
- a contact lens is placed on a slide glass, and a contact angle measurement device (solid-liquid interface analysis system DropMaster 500 (Kyowa Interface Science Co., Ltd.)) is used to measure the contact angle at 0.10 seconds after dropping 3 ⁇ l of phosphate buffered saline. It was measured. Table 1 shows the results. In addition, it can be evaluated that the lower the contact angle, the better the wettability of the contact lens, and the higher the affinity for the contact lens.
- Test solution 2 containing sodium chondroitin sulfate with a weight-average molecular weight of about 28,000 showed almost the same contact angle as test solution 1 containing no sodium chondroitin sulfate.
- test solution 3 containing sodium chondroitin sulfate with a weight average molecular weight of about 56,000 has a significantly smaller contact angle and wettability than test solution 2 containing sodium chondroitin sulfate with a weight average molecular weight of about 28,000. It was confirmed that the affinity for contact lenses was high.
- test solution 3-1 having the same composition as test solution 3 except that the content of sodium chondroitin sulfate (weight average molecular weight of about 56000) in test solution 3 was 1 w/v%, and palmitin was added to test solution 3-1.
- test solution 3-2 containing 50,000 units/100 mL of acid retinol, 0.35 w/v% of polyoxyethylene hydrogenated castor oil 60, and 0.2 w/v% of polyoxyethylene castor oil 10, Test Example 2 and When the contact angle (°) was measured in the same manner, it was 67.4° for test solution 3-1 and 44.2° for test solution 3-2.
- the contact lens After lightly wiping off the moisture of the contact lens with lint-free paper, the contact lens is immersed in a 12-well plate into which 4 mL each of phosphate-buffered saline and each test solution described in Table 1 above is dispensed, and immersed at room temperature for 24 hours. left undisturbed. Lightly wipe off the moisture from the contact lens with lint-free paper, and immerse it in a 12-well plate in which 2 mL each of 2 mL of a comparative undiluted solution of cobalt (II) chloride color (Wako Pure Chemical Industries, vendor code: 031-19041) is dispensed. and shaken at room temperature and 200 rpm for 5 minutes.
- II cobalt
- test solution 1 without sodium chondroitin sulfate and in test solution 2 with sodium chondroitin sulfate with a weight average molecular weight of about 28,000 a slight coloration was observed after 15 minutes, whereas a slight coloration was observed after 15 minutes.
- test solution 3 containing sodium chondroitin sulfate no coloration was observed after 15 minutes and slight coloration was observed after 30 minutes. Therefore, it was confirmed that sodium chondroitin sulfate with a weight-average molecular weight of about 56,000 suppresses contact lens drying compared to sodium chondroitin sulfate with a weight-average molecular weight of about 28,000.
- Test Example 4 Contact lens wettability test
- Each ophthalmic composition was prepared according to a conventional method with the composition shown in Table 3 and used as a test solution. The unit of each component in Table 3 is w/v % unless specified in the table.
- retinol palmitate of 1,740,000 IU/g was used.
- a droplet about 1 ⁇ L of each prepared ophthalmic composition was applied.
- test solutions 6 to 10 and 13 to 15 were significantly smaller than that of test solution 4, and the wettability was significantly improved.
- test solutions 11 and 12 had significantly smaller contact angles than test solution 5, and the wettability was significantly improved. That is, sodium chondroitin sulfate with a weight average molecular weight of about 56,000 and neostigmine methyl sulfate, allantoin, dipotassium glycyrrhizinate, pyridoxine hydrochloride, and bread were compared to a test solution containing only sodium chondroitin sulfate, with a weight average molecular weight of about 56,000.
- Each ophthalmic composition was prepared according to a conventional method with the composition shown in Table 4 and used as a test solution.
- the unit of each component in Table 4 is w/v%.
- a droplet (about 1 ⁇ L) of each prepared ophthalmic composition was dropped on a stainless metal plate (ferrule cap Type CLF-B), and an automatic contact angle meter (solid-liquid interface analysis system Drop Master, DM-A501 (Kyowa Interface Science Co., Ltd.) company)) was used to measure the contact angle (static contact angle) to the metal 0.1 seconds after dropping.
- the contact angle of each ophthalmic composition was measured three times, and the average value was calculated as the contact angle of each ophthalmic composition. Table 4 shows the results.
- test solution 15 was significantly increased compared to test solution 4. That is, compared with the test solution containing only sodium chondroitin sulfate with a weight average molecular weight of about 56,000, the test solution containing sodium chondroitin sulfate with a weight average molecular weight of about 56,000 and hydroxypropyl methylcellulose has an affinity for stainless steel tubes. Remarkably low was confirmed. Since the filling tube in the production line is made of metal such as stainless steel, it is possible to reduce droplets adhering to the tip of the filling tube when the ophthalmic composition is filled into the container, resulting in a uniform filling volume. you know it will be easier.
- Each ophthalmic composition was prepared according to a conventional method with the composition shown in Table 5 and used as a test solution.
- the unit of each component in Table 5 is w/v% unless specified in the table.
- Staphylococcus aureus ATCC6538 was inoculated onto the surface of soybean-casein digest slants and cultured at 33° C. for 24 hours.
- the cultured cells were aseptically collected with a platinum loop and suspended in an appropriate amount of sterilized physiological saline to prepare a bacterial suspension containing about 1 ⁇ 10 7 CFU/mL viable cells. The number of viable bacteria in the suspension was separately cultured and measured.
- each prepared ophthalmic composition was filled in a 15 mL conical tube (CORNING) made of PET.
- CORNING conical tube
- Each of these ophthalmic compositions was inoculated with a Staphylococcus aureus bacterial solution (suspended in physiological saline) so that the viable cell count (final concentration) was about 10 5 CFU/mL, and stirred well to obtain a sample. . Samples containing bacteria were stored at 23°C for 3 days in the dark.
- Each ophthalmic composition was prepared according to a conventional method with the composition shown in Table 6, and used as a test solution.
- the unit of each component in Table 6 is w/v% unless specified in the table.
- the viscosity of each prepared ophthalmic composition (600 ⁇ L) was measured at 34° C. using a cone-plate measuring jig (CP50-1, d: 0.102 mm) with a rheometer (MCR302 (manufactured by AntonPaar)). Viscosity versus shear rate was measured.
- the viscosity reduction rate of test solution 12 or 13 relative to test solution 4 or 5 was calculated according to the following formula.
- the decrease in viscosity means that the viscosity decreases when stress is applied, and the shear rate of 10000 (1/s) is assumed to be the blink rate.
- the change in viscosity of the formulation in the eye during blinking can be evaluated.
- a reduction in the viscosity at the time of blinking means that it is easy to blink, and it is difficult to feel discomfort at the time of blinking.
- Viscosity reduction rate (%) (1-viscosity of test solution 12 or 13/viscosity of corresponding test solution) x 100 Note that the corresponding test solution is test solution 5 for test solution 12 and test solution 4 for test solution 13 . Table 6 shows the results.
- test solutions 12 and 13 containing retinol palmitate or potassium L-aspartate had significantly lower viscosities.
- the viscosity measured with a rotational viscometer after preparation of test solution 4 using sodium chondroitin sulfate with a weight average molecular weight of about 56,000 is the weight of sodium chondroitin sulfate with a weight average molecular weight of about 56,000 in test solution 4 It has been confirmed by the inventors that the viscosity was higher than that of test solutions of the same composition except that sodium chondroitin sulfate with an average molecular weight of about 28,000 was used.
- the ophthalmic composition has a high viscosity when instilled into the eye, problems such as difficulty in blinking and a tendency to feel discomfort may occur. Therefore, it can be said that if the viscosity at a high shear rate is low, it is easy to blink after instillation, and it is difficult to feel discomfort. Therefore, an ophthalmic composition containing sodium chondroitin sulfate with a weight average molecular weight of about 56,000 and retinol palmitate or potassium L-aspartate is compared to an ophthalmic composition containing only sodium chondroitin sulfate with a weight average molecular weight of about 56,000. It was confirmed that it was easy to blink after instillation and it was difficult to feel discomfort.
- each ophthalmic composition was prepared according to a conventional method with the composition shown in Table 7 and used as a test solution. The unit of each component in Table 7 is w/v% unless specified in the table. 10 mL of each ophthalmic composition was filled in a 10 mL capacity glass headspace vial (GL Sciences Inc.) and tested with a photostability tester (LT-120A-WCD (manufactured by Nagano Sciences)) using a D65 fluorescent lamp as the light source. , at a room temperature of 25° C., irradiation was performed at an illuminance of 4000 lx/h until an integrated illuminance of 1,200,000 lx.
- Each ophthalmic composition (600 ⁇ L) before and after irradiation was subjected to shearing at 34° C. using a cone-plate measuring jig (CP50-1, d: 0.102 mm) with a rheometer (MCR302 (AntonPaar)). Viscosity was measured against speed (1-10000 (1/s)). Using the viscosity (mPa ⁇ s) at a shear rate of 1000 (1/s), the viscosity stability before and after the test was evaluated according to the following formula. Table 7 shows the results. Incidentally, the smaller the value of the viscosity change rate, the less the viscosity change caused by light, indicating that the ophthalmic composition maintains the same physical properties.
- Viscosity change rate (%) ⁇ (Viscosity of each ophthalmic composition before light irradiation - Viscosity of each ophthalmic composition after light irradiation)/Viscosity of each ophthalmic composition before light irradiation ⁇ x 100
- Each ophthalmic composition was prepared according to a conventional method with the composition shown in Table 8 and used as a test solution.
- the unit of each component in Table 8 is w/v %.
- 1 mL of each ophthalmic composition was added to a 24-well plate (Corning), stored at 60° C. for 2 days in a dry heat dryer (Ikeda Rika), and then visually observed for precipitation in each well in the plate. Observation was made, and the occurrence of precipitates was evaluated according to the following evaluation criteria. Table 8 shows the results.
- test solution 18 containing sodium chondroitin sulfate and potassium aspartate with a weight-average molecular weight of about 28,000 precipitation occurred significantly in test solution 13 containing sodium chondroitin sulfate and potassium aspartate with a weight-average molecular weight of about 56,000. suppressed by
- Each ophthalmic composition was prepared according to a conventional method with the composition shown in Table 9, and used as a test solution.
- the unit of each component in Table 9 is w/v% unless specified in the table.
- 10 mL of each ophthalmic composition was filled in a glass headspace vial with a capacity of 10 mL, and a photostability tester (LT-120A-WCD (manufactured by Nagano Science)) was used at room temperature of 25 ° C. with a D65 fluorescent lamp as a light source. Irradiation was performed at an illuminance of 4,000 lx/h until the integrated illuminance reached 1,200,000 lx.
- Each ophthalmic composition was prepared according to a conventional method with the composition shown in Table 10 and used as a test solution.
- the unit of each component in Table 10 is w/v % unless specified in the table.
- 10 mL of each ophthalmic composition was filled in a glass bottle (10 mL) and irradiated at 35° C. for 96 hours at an ultraviolet light illuminance of 765 (W/m 2 ) using SUNTESTER XLS+ (manufactured by Toyo Seiki Co., Ltd., 1700 W xenon air-cooled lamp light source). .
- each ophthalmic composition was sufficiently thermostated at 25° C., and the color difference change (b * value) of each ophthalmic composition before and after UV irradiation was measured using a spectrophotometer (CM3500d: manufactured by Konica Minolta). Then, the change in the appearance (color) of the ophthalmic composition before and after UV irradiation (degree of change in color difference; ⁇ b * value) was calculated according to Formula 1 below, and the rate of decrease in color difference change was calculated according to Formula 2 below. Table 9 shows the results. Note that the smaller the ⁇ b * value, the more suppressed the change (coloring) in the appearance (color) of the ophthalmic composition.
- test solutions 9 and 12 containing were smaller in color difference change ( ⁇ b * ) due to ultraviolet irradiation, and that coloration due to ultraviolet irradiation was suppressed.
- Each ophthalmic composition was prepared according to a conventional method with the composition shown in Table 11 and used as a test solution. The unit of each component in Table 11 is w/v% unless specified in the table. 10 mL of each ophthalmic composition was filled in a 10 mL capacity glass headspace vial and left to stand for 3 weeks in a 60° C. thermostatic chamber (thermal acceleration test). After that, each ophthalmic composition was sufficiently thermostated at 25° C., and the color difference change (L * value) of each ophthalmic composition before and after the thermal acceleration test was measured using a spectrophotometer (CM3500d: manufactured by Konica Minolta).
- CM3500d manufactured by Konica Minolta
- Each ophthalmic composition was prepared according to a conventional method with the composition shown in Table 12 and used as a test solution.
- the unit of each component in Table 12 is w/v% unless specified in the table.
- 100 ⁇ L of human corneal epithelial cell line HCE-T cells were seeded in each well at a concentration of 1 ⁇ 10 cells/mL in a 96-well plate (Corning), and the concentration was 37° C., 90% humidity, and 5% CO 2 . Cultured until confluent in a set CO2 incubator.
- DMEM/F12 ThermoFisher
- FCS DS Pharma
- DMSO Wired Chemical Industries
- recombinant human EGF R & D
- insulin solution The one to which human (SIGMA) was added so as to be 5 ⁇ g/mL was used.
- SIGMA human EGF
- test solution 12 the same test was performed with the same formulation as test solution 12 except that the concentration of retinol palmitate was 50,000 units/100 mL. can be obtained.
- Each ophthalmic composition was prepared according to a conventional method with the composition shown in Table 13 and used as a test solution.
- the unit of each component in Table 13 is w/v %.
- 500 ⁇ L of human corneal epithelial cell line HCE-T cells were seeded in each well at a concentration of 1 ⁇ 10 5 cells/mL in a 24-well plate (Corning), and the concentration was set at 37° C. and 5% CO 2 . Cultured in a CO2 incubator.
- DMEM/F12 ThermoFisher
- FCS DS Pharma
- DMSO Wired Chemical Industries
- recombinant human EGF R & D
- insulin solution The one to which human (SIGMA) was added so as to be 5 ⁇ g/mL was used.
- SIGMA human EGF
- test solution 4 containing sodium chondroitin sulfate with a weight average molecular weight of about 56,000 had a higher cell viability than the test solution 16 containing sodium chondroitin sulfate with a weight average molecular weight of about 28,000.
- test solutions 4, 7, and 8 to 10 containing sodium chondroitin sulfate having a weight average molecular weight of about 56,000 allantoin, dipotassium glycyrrhizinate, pyridoxine hydrochloride, or panthenol have remarkable cell viability. was confirmed to be high.
- Test Example 15 Measurement test of the amount of residual liquid in the eyedropper bottle
- Each ophthalmic composition was prepared according to a conventional method with the composition shown in Table 14 and used as a test solution. The unit of each component in Table 14 is w/v%.
- a 10 mL PET eye dropper bottle was tared and filled with 5 mL of each ophthalmic composition.
- the weight of each ophthalmic composition filled in each ophthalmic composition is measured, and according to the following formulas 1 and 2, the residual liquid amount (g) and the improvement rate of the residual liquid amount to the residual liquid amount of the test solution 22 (%) was calculated.
- test solutions 6 and 14 containing neostigmine methyl sulfate or taurine in test solution 4 and in test solutions 11 and 12 containing d- ⁇ -tocopherol acetate or retinol palmitate in test solution 5
- the residual liquid volume was It was confirmed that the ophthalmic composition in the eyedropper bottle was easily used up.
- Eye drops are prepared by a conventional method with the formulations shown in Tables 15 to 19 below.
- the unit of each component amount in Tables 15 to 19 below is w/v% unless specified in the table.
- the second invention relates to an ophthalmic composition.
- Chondroitin sulfate or its salt is a type of acidic mucopolysaccharide, and is used in ophthalmic preparations for the purpose of promoting energy metabolism, promoting metabolism and cell respiration to relieve eye fatigue, and replenishing tear components. are blended (for example, Patent Document 2-1).
- Patent Literature [Patent Document 2-1] JP 2011-148791 A
- a second object of the present invention is to provide a stable ophthalmic composition that contains chondroitin sulfate or a salt thereof having a specific weight-average molecular weight and is suppressed in viscosity change due to light.
- the present inventors have unexpectedly found that an ophthalmic composition containing sodium chondroitin sulfate having a weight-average molecular weight of 40,000 to 70,000 and a specific component suppresses changes in viscosity caused by light.
- the second invention provides, for example, the following inventions.
- Chondroitin sulfate having a weight average molecular weight of 40,000 to 70,000 and at least one selected from the group consisting of salts thereof, antihistamines, zinc salts, decongestants, hydroxyethyl cellulose and salts thereof, and polyvinyl-based polymer compounds. and at least one selected from the group consisting of:
- the antihistamine is at least one selected from the group consisting of chlorpheniramine and its salts
- the decongestant is at least one selected from the group consisting of tetrahydrozoline and its salts
- the polyvinyl polymer compound is polyvinylpyrrolidone.
- the ophthalmic composition according to [1].
- the content unit “%” means “w/v%” and is synonymous with “g/100 mL”.
- the ophthalmic composition according to the present embodiment includes at least one selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 40,000 to 70,000 and salts thereof (also simply referred to as “component (A)”). , antihistamines, zinc salts, decongestants, hydroxyethyl cellulose and its salts, and at least one selected from the group consisting of polyvinyl polymer compounds (also simply referred to as "(B) component”).
- the ophthalmic composition according to the present embodiment has the effect of suppressing viscosity change due to light, and suppresses liquid residue in the piping when filling the container or when delivering the liquid.
- effect effect of increasing preservative effect, effect of making it easier to blink regardless of the viscosity when the formulation is put in the eyes (even if it is a high viscosity formulation), regardless of the viscosity when the formulation is put in the eyes ( Effect of suppressing discomfort when blinking, effect of suppressing coloring of the formulation due to ultraviolet rays, effect of increasing cell viability, and external stimuli (blinking, contact lens derived (when wearing and removing) It has the effect of suppressing eye cell damage caused by irritation caused by (medium), eye rubbing, foreign matter contamination (pollen, air pollutants, eyelashes, eye makeup-related foreign matter, other foreign matter, etc.).
- Chondroitin sulfate and salts thereof are not particularly limited as long as they are pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- chondroitin sulfate salts include alkali metal salts and alkaline earth metal salts.
- alkali metal salts include sodium salts and potassium salts.
- alkaline earth metal salts include magnesium salts and calcium salts.
- Chondroitin sulfate and its salts are preferably chondroitin sulfate and alkali metal salts of chondroitin sulfate, more preferably chondroitin sulfate and sodium chondroitin sulfate, and still more preferably sodium chondroitin sulfate.
- Chondroitin sulfate and its salts may be natural products or synthetic products, but are generally natural products of animals (preferably mammals, fish, mollusks, etc.; more preferably bovine, shark, squid, A chondroitin sulfate derived from a ray, etc.) and a salt thereof are preferably used, a chondroitin sulfate derived from a shark and/or a ray and a salt thereof are more preferably used, and a chondroitin sulfate and a salt thereof derived from a shark are more preferably used. .
- chondroitin sulfate and its salts can also be used. Chondroitin sulfate and its salt may be used alone or in combination of two or more.
- chondroitin sulfate and its salts include chondroitin sulfate and its salts having a weight-average molecular weight of 40,000 to 70,000 defined herein and chondroitin sulfate and its salts having a weight-average molecular weight outside the range defined herein. can be used in combination with For example, sodium chondroitin sulfate with a weight average molecular weight of 56,000 and sodium chondroitin sulfate with a weight average molecular weight of 25,000 can be used in combination.
- chondroitin sulfate having a weight average molecular weight of 40,000 to 70,000 and a salt thereof defined herein and chondroitin sulfate having a weight average molecular weight outside the range defined herein and a salt thereof may be contained as raw materials.
- the "weight average molecular weight” can be determined by using gel permeation chromatography in which a multi-angle light scattering detector (MALS detector) and a differential refractive index detector (RI detector) are connected online. . Specifically, the following conditions are presented. ⁇ Standard sample preparation> 10 mL of 0.1 M sodium nitrate aqueous solution was added to 5 mg of chondroitin sulfate or its salt, and the mixture was gently stirred at room temperature to dissolve completely.
- MALS detector multi-angle light scattering detector
- RI detector differential refractive index detector
- Apparatus Gel permeation chromatograph - multi-angle light scatterometer Detector: Differential refractive index detector (Optilab rEX manufactured by Wyatt Technology) Multi-angle light scattering detector (DAWN HELEOS manufactured by Wyatt Technology) Column: 2 Shodex OHpak SB-806M HQ ( ⁇ 7.8 mm ⁇ 30 cm, manufactured by Showa Denko) Solvent: 0.1 M sodium nitrate aqueous solution Flow rate: 0.7 mL/min Column temperature: 23°C Detector temperature: 23°C Injection volume: 0.2 mL Data processing: Wyatt Technology data processing system (ASTRA)
- the weight average molecular weight of chondroitin sulfate and its salt calculated by the above method is not particularly limited as long as it is in the range of 40,000 to 70,000.
- Examples of the lower limit of the weight average molecular weight include 41000 or more, 42000 or more, 43000 or more, 44000 or more, 45000 or more, 46000 or more, 47000 or more, 48000 or more, 49000 or more, and 50000 or more.
- Examples of the upper limit of the weight average molecular weight include 69000 or less, 68000 or less, 67000 or less, 66000 or less, 65000 or less, 64000 or less, 63000 or less, 62000 or less, 61000 or less, and 60000 or less.
- the weight average molecular weight ranges are 41,000 to 69,000, 42,000 to 68,000, 43,000 to 67,000, 44,000 to 66,000, 45,000 to 65,000, 46,000 to 64,000, 47,000 to 63,000, 48,000 to 62,000, 49,000 to 61,000, and 500.
- 00 to 60000 are examples be done.
- the content of component (A) in the ophthalmic composition according to the present embodiment is not particularly limited, and is appropriately set according to the type and content of other compounding components, the application and formulation form of the ophthalmic composition, and the like.
- the content of component (A) is usually 0.001 to 5 w/v%, for example, 0.005%, based on the total amount of the ophthalmic composition, from the viewpoint of exhibiting the effect of the second aspect of the present invention more remarkably.
- ⁇ 5 w/v% more preferably 0.008 to 4 w/v%, even more preferably 0.01 to 3 w/v%, and 0.05 to 2 w/v% It is even more preferable to be 0.1 to 1 w/v%, particularly preferably 0.3 to 1 w/v%.
- Antihistamines are compounds and salts thereof that have antihistamine action. Antihistamines are not particularly limited as long as they are pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- antihistamines include chlorpheniramine, iproheptine, diphenhydramine, ketotifen, olopatadine, levocabastine, and salts thereof.
- chlorpheniramine and its salts are preferred, and chlorpheniramine maleate is more preferred.
- a commercially available antihistamine can also be used.
- One type of antihistamine may be used alone, or two or more types may be used in combination.
- the content of the antihistamine in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the form and the like.
- the content of the antihistamine is preferably 0.001 to 1 w/v% based on the total amount of the ophthalmic composition, from the viewpoint of exhibiting the effect of the second aspect of the present invention more remarkably. , More preferably 0.003 to 0.5 w / v%, more preferably 0.005 to 0.1 w / v%, further preferably 0.01 to 0.05 w / v% More preferably, 0.02 to 0.04 w/v% (eg, 0.03 w/v%) is particularly preferred.
- the content ratio of the antihistamine to the component (A) in the ophthalmic composition according to the present embodiment is not particularly limited. and content, the application and formulation form of the ophthalmic composition, and the like.
- the content ratio of the antihistamine to the component (A) is, for example, 1 part by mass of the total content of the component (A) contained in the ophthalmic composition according to the present embodiment.
- the total content of antihistamines is preferably 0.0002 to 20 parts by mass, more preferably 0.001 to 10 parts by mass, even more preferably 0.01 to 1 part by mass. .
- the zinc salt is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- the zinc salt is preferably zinc sulfate, zinc lactate or zinc chloride, more preferably zinc sulfate.
- the zinc salt may be a hydrate (for example, zinc sulfate heptahydrate).
- Zinc salts may be used singly or in combination of two or more.
- the content of the zinc salt in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the application, dosage form, and the like.
- the content of the zinc salt is usually 0.00001 to 10 w/v% based on the total amount of the ophthalmic composition, from the viewpoint of exhibiting the effect of the second aspect of the present invention more remarkably. , preferably 0.0001 to 10 w / v%, more preferably 0.001 to 5 w / v%, even more preferably 0.005 to 3 w / v%, 0.01 to 1 w /v % is even more preferred, and 0.03 to 0.5 w/v % is particularly preferred.
- the total zinc salt content may be 0.25 w/v%.
- the content ratio of the zinc salt to the component (A) in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the type and content of the component, the application and formulation form of the ophthalmic composition, and the like. From the viewpoint of further enhancing the effect of the second aspect of the present invention, the content ratio of the zinc salt to the component (A) is, for example, 1 part by mass of the total content of the component (A) contained in the ophthalmic composition according to the present embodiment.
- the total content of the zinc salt is preferably 0.0002 to 1000 parts by mass, more preferably 0.001 to 500 parts by mass, and 0.01 to 100 parts by mass.
- the total content of zinc salts may be 0.5 parts by mass with respect to 1 part by mass of the total content of component (A).
- a decongestant is a compound or its salt that has the effect of decongesting the eye.
- the decongestant is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- decongestants include imidazoline compounds such as tetrahydrozoline, naphazoline, oxymetazoline and salts thereof (e.g., hydrochlorides, nitrates); epinephrine, ephedrine, methylephedrine, phenylephrine and salts thereof (e.g., hydrochlorides); ).
- imidazoline compounds and salts thereof are preferred, tetrahydrozoline, naphazoline and salts thereof are more preferred, tetrahydrozoline and salts thereof are still more preferred, and tetrahydrozoline hydrochloride (tetrahydrozoline hydrochloride) is particularly preferred.
- a commercially available decongestant can also be used.
- the decongestants may be used singly or in combination of two or more.
- the content of the decongestant in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the use of the composition, the formulation form, and the like.
- the content of the decongestant is 0.0001 to 1 w/v% based on the total amount of the ophthalmic composition, from the viewpoint of exhibiting the effect of the second aspect of the present invention more remarkably. is preferably 0.0005 to 0.5 w/v%, more preferably 0.001 to 0.1 w/v%, and 0.002 to 0.1 w/v% It is even more preferred to have
- the content ratio of the decongestant to the component (A) in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the type and content of other compounding ingredients, the application and formulation form of the ophthalmic composition, and the like.
- the content ratio of the decongestant to the component (A) is, from the viewpoint of further enhancing the effect of the second aspect of the present invention, for example, the total content of the component (A) contained in the ophthalmic composition according to the present embodiment is 1 mass.
- the total content of the decongestant is preferably 0.0001 to 50 parts by weight, more preferably 0.0005 to 20 parts by weight, and 0.001 to 10 parts by weight. is more preferable, and 0.003 to 5 parts by mass is even more preferable.
- Hydroxyethyl cellulose and its salts are not particularly limited as long as they are pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- the salts of hydroxyethylcellulose include, for example, salts with organic bases (amine salts, basic ammonium salts such as arginine, etc.), salts with inorganic bases (alkali metal salts such as ammonium salts, sodium salts, potassium salts, etc., calcium salts, alkaline earth metal salts such as magnesium salts, aluminum salts, etc.), among which sodium salts, potassium salts and calcium salts are more preferred, and sodium salts are particularly preferred.
- organic bases amine salts, basic ammonium salts such as arginine, etc.
- salts with inorganic bases alkali metal salts such as ammonium salts, sodium salts, potassium salts, etc., calcium salts, alkaline earth metal salts such as magnesium salts, aluminum salts, etc.
- sodium salts, potassium salts and calcium salts are more preferred, and sodium salts are particularly preferred.
- Hydroxyethyl cellulose and salts thereof may be used singly or in combination of two or more.
- the content of hydroxyethyl cellulose and its salts in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the type and content, the application and formulation form of the ophthalmic composition, and the like.
- the content of hydroxyethyl cellulose and its salts is 0.0001 to 10 w/w based on the total amount of the ophthalmic composition, from the viewpoint of exhibiting the effect of the second present invention more remarkably.
- v% more preferably 0.001 to 5 w/v%, even more preferably 0.005 to 3 w/v%, and preferably 0.01 to 1 w/v% Even more preferred.
- the content ratio of the hydroxyethyl cellulose and its salt to the component (A) in the ophthalmic composition according to the present embodiment is not particularly limited. and the type of salt thereof, the type and content of other compounding ingredients, the application and formulation form of the ophthalmic composition, and the like.
- the content ratio of hydroxyethyl cellulose and its salt to component (A) is, from the viewpoint of further enhancing the effect of the second present invention, for example, the total content of component (A) contained in the ophthalmic composition according to the present embodiment.
- the total content of hydroxyethyl cellulose and its salt is preferably 0.0001 to 500 parts by mass, more preferably 0.001 to 100 parts by mass, and 0.005 to 50 parts by mass with respect to 1 part by mass. It is more preferably 0.01 to 30 parts by mass, and even more preferably 0.01 to 30 parts by mass.
- the polyvinyl polymer compound is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- polyvinyl-based polymer compounds examples include polyvinyl alcohol (fully or partially saponified), polyvinylpyrrolidone, and carboxyvinyl polymer.
- the polyvinyl polymer that can be used in the second aspect of the present invention is not limited in its molecular weight. One million or so can be used.
- the K value (viscosity characteristic value) of polyvinylpyrrolidone is not particularly limited, but one of about 10 to 150 can be preferably used.
- polyvinylpyrrolidone is preferable, polyvinylpyrrolidone K25, polyvinylpyrrolidone K30 and polyvinylpyrrolidone K90 are more preferable, and polyvinylpyrrolidone K30 and polyvinylpyrrolidone K90 are more preferable, from the viewpoint of further enhancing the effect of the second invention.
- Polyvinyl-based polymer compounds can also be used. Polyvinyl polymer compounds may be used singly or in combination of two or more.
- the content of the polyvinyl-based polymer compound in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the type and content, the application and formulation form of the ophthalmic composition, and the like. From the viewpoint of exhibiting the effect of the second aspect of the present invention more remarkably, the content of the polyvinyl polymer compound is 0.0001 to 10w based on the total amount of the ophthalmic composition. /v%, more preferably 0.001 to 8 w/v%, even more preferably 0.005 to 5 w/v%, and 0.01 to 3 w/v% is even more preferred, and 0.01 to 2 w/v% is particularly preferred.
- the content ratio of the polyvinyl-based polymer compound to the component (A) in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the type of polymer compound, the type and content of other compounding ingredients, the application and formulation form of the ophthalmic composition, and the like.
- the content ratio of the polyvinyl-based polymer compound to the component (A) is, for example, the total content of the component (A) contained in the ophthalmic composition according to the present embodiment, from the viewpoint of further enhancing the effect of the second aspect of the present invention.
- the total content of the polyvinyl polymer compound is preferably 0.0001 to 1000 parts by mass, more preferably 0.001 to 500 parts by mass, and 0.005 to 100 parts by mass. It is more preferably 0.01 to 50 parts by mass, and even more preferably 0.01 to 50 parts by mass.
- the ophthalmic composition according to the present embodiment may further contain (C) a surfactant (also referred to as "component (C)").
- a surfactant also referred to as "component (C)"
- component (C) a surfactant
- the effect of the second aspect of the present invention is exhibited more remarkably.
- surfactants are not particularly limited as long as they are pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable, nonionic surfactants, amphoteric surfactants, anionic surfactants , cationic surfactants.
- nonionic surfactants include POE (20) sorbitan monolaurate (polysorbate 20), POE (20) sorbitan monopalmitate (polysorbate 40), POE (20) sorbitan monostearate (polysorbate 60), POE sorbitan fatty acid esters such as POE (20) sorbitan stearate (polysorbate 65), POE (20) sorbitan monooleate (polysorbate 80); POE (40) hydrogenated castor oil (polyoxyethylene hydrogenated castor oil 40), POE ( 60) POE hydrogenated castor oil such as hydrogenated castor oil (polyoxyethylene hydrogenated castor oil 60); POE (3) hydrogenated castor oil (polyoxyethylene castor oil 3), POE (10) castor oil (polyoxyethylene castor oil 10 ), POE castor oil such as POE (35) castor oil (polyoxyethylene castor oil 35); POE alkyl ether such as POE (9) lauryl ether; POE-POP al
- amphoteric surfactants include alkyldiaminoethylglycine or salts thereof (eg, hydrochlorides, etc.).
- anionic surfactants include alkylbenzenesulfonates, alkylsulfates, polyoxyethylene alkylsulfates, aliphatic ⁇ -sulfomethyl esters, ⁇ -olefinsulfonic acids, and the like.
- cationic surfactants examples include cetylpyridinium chloride, benzalkonium chloride, and benzethonium chloride.
- nonionic surfactants are preferred, and POE sorbitan fatty acid esters, POE hydrogenated castor oil, POE castor oil, and POE/POP block copolymers are more preferred.
- Commercially available surfactants can also be used.
- Surfactants may be used alone or in combination of two or more.
- the content of component (C) in the ophthalmic composition according to the present embodiment is not particularly limited, and is appropriately set according to the type of component (C), the application of the ophthalmic composition, the form of formulation, and the like.
- the content of component (C) from the viewpoint of exhibiting the effect of the second aspect of the present invention more remarkably, for example, the total content of component (C) is 0.001 to 0.001 based on the total amount of the ophthalmic composition. It is preferably 3 w/v%, more preferably 0.005 to 2 w/v%, even more preferably 0.01 to 1 w/v%, and 0.05 to 1 w/v%. is particularly preferred.
- the content ratio of component (C) to component (A) is not particularly limited. It is appropriately set according to the use, formulation form, etc. of the ophthalmic composition.
- the content ratio of component (C) to component (A) is, for example, the total content of component (A) contained in the ophthalmic composition according to the present embodiment, from the viewpoint of further enhancing the effect of the second aspect of the present invention.
- the total content of component (C) is more preferably 0.001 to 30 parts by mass, more preferably 0.005 to 20 parts by mass, and 0.01 It is more preferably 10 parts by mass, and particularly preferably 0.01 to 2 parts by mass.
- the ophthalmic composition according to the present embodiment preferably further contains (D) a buffering agent (also referred to as "(D) component").
- a buffering agent also referred to as "(D) component”
- the buffering agent is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- Buffers include, for example, inorganic buffers that are buffers derived from inorganic acids, and organic buffers that are buffers derived from organic acids or organic bases.
- inorganic buffers include borate buffers, phosphate buffers, carbonate buffers, and the like.
- Boric acid buffers include boric acid or salts thereof (alkali metal borates, alkaline earth metal borates, etc.).
- Phosphate buffers include phosphoric acid and salts thereof (alkali metal phosphate, alkaline earth metal phosphate, etc.).
- Carbonic acid buffers include carbonic acid or salts thereof (alkali metal carbonates, alkaline earth metal carbonates, etc.). Borate, phosphate, or carbonate hydrates may also be used as the borate buffer, phosphate buffer, or carbonate buffer.
- More specific examples include boric acid or a salt thereof (sodium borate, potassium tetraborate, potassium metaborate, ammonium borate, borax, etc.) as a borate buffer; Salts (disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, trisodium phosphate, tripotassium phosphate, calcium monohydrogen phosphate, calcium dihydrogen phosphate, etc.); Alternatively, salts thereof (sodium hydrogen carbonate, sodium carbonate, ammonium carbonate, potassium carbonate, calcium carbonate, potassium hydrogen carbonate, magnesium carbonate, etc.) can be exemplified.
- organic buffers examples include citrate buffers, acetate buffers, lactate buffers, succinate buffers, Tris buffers, AMPD buffers, and the like.
- Citric acid buffers include citric acid or salts thereof (alkali metal citrate, alkaline earth metal citrate, etc.).
- the acetate buffer includes acetic acid or salts thereof (alkali metal acetate, alkaline earth metal acetate, etc.).
- Lactic acid buffers include lactic acid or salts thereof (alkali metal lactate, alkaline earth metal lactate, etc.).
- Succinic acid buffers include succinic acid or salts thereof (alkali metal succinate, etc.).
- citrate buffer hydrates of citrate, acetate, lactate, or succinate may be used as the citrate buffer, acetate buffer, lactate buffer, or succinate buffer. More specific examples include citric acid or a salt thereof (sodium citrate, potassium citrate, calcium citrate, sodium dihydrogen citrate, disodium citrate, etc.) as a citric acid buffer; acetic acid as an acetic acid buffer or salts thereof (ammonium acetate, sodium acetate, potassium acetate, calcium acetate, etc.); lactic acid or salts thereof (sodium lactate, potassium lactate, calcium lactate, etc.) as a lactic acid buffer; monosodium succinate, disodium succinate, etc.).
- Tris buffers include, for example, trometamol or salts thereof (trometamol hydrochloride, etc.).
- AMPD buffers include, for example, 2-amino-2-methyl-1,3-propanediol or salts thereof.
- buffering agents include borate buffers (e.g., a combination of boric acid and borax), phosphate buffers (e.g., a combination of disodium hydrogen phosphate and sodium dihydrogen phosphate), Tris buffers (e.g., , trometamol) are preferred, borate buffers are more preferred, boric acid and its salts are more preferred, and a combination of boric acid and borax is even more preferred.
- borate buffers e.g., a combination of boric acid and borax
- phosphate buffers e.g., a combination of disodium hydrogen phosphate and sodium dihydrogen phosphate
- Tris buffers e.g., trometamol
- borate buffers are more preferred
- boric acid and its salts are more preferred
- a combination of boric acid and borax is even more preferred.
- a buffering agent may be used individually by 1 type, or may be used in combination of 2 or more types.
- the content of component (D) in the ophthalmic composition according to the present embodiment is not particularly limited, and depends on the type of component (D), the type and content of other ingredients, the application and formulation form of the ophthalmic composition, and the like. is set as appropriate.
- the content of component (D) from the viewpoint of exhibiting the effect of the second aspect of the present invention more remarkably, for example, the total content of component (D) is 0.01 to 0.01 based on the total amount of the ophthalmic composition. It is preferably 10 w/v%, more preferably 0.05 to 5 w/v%, even more preferably 0.1 to 3 w/v%.
- the content ratio of component (D) to component (A) in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the use, formulation form, etc. of the ophthalmic composition.
- the content ratio of component (D) to component (A) is, for example, the total content of component (A) contained in the ophthalmic composition according to the present embodiment, from the viewpoint of further enhancing the effect of the second aspect of the present invention.
- the total content of component (D) is preferably 0.01 to 100 parts by mass, more preferably 0.05 to 50 parts by mass, and 0.1 to 30 parts by mass, relative to 1 part by mass. Part is more preferred.
- the pH of the ophthalmic composition according to this embodiment is not particularly limited as long as it is within a pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable range.
- the pH of the ophthalmic composition according to this embodiment may be, for example, 4.0 to 9.5, preferably 4.0 to 9.0, and more preferably 4.5 to 9.0. is more preferable, more preferably 4.5 to 8.5, even more preferably 5.0 to 8.5, particularly preferably 5.0 to 8.0, 5.3 ⁇ 7.5 is more particularly preferred, and 5.3 to 7.0 is most preferred.
- the ophthalmic composition according to the present embodiment can be adjusted to have an osmotic pressure ratio within a range acceptable to living organisms, if necessary.
- An appropriate osmotic pressure ratio can be appropriately set according to the application, formulation form, method of use, etc. of the ophthalmic composition, and can be, for example, 0.4 to 5.0, and 0.6 to 3.0. , more preferably 0.8 to 2.2, even more preferably 0.8 to 2.0.
- the osmotic pressure ratio is the ratio of the osmotic pressure of the sample to 286 mOsm (osmotic pressure of 0.9 w/v% sodium chloride aqueous solution) based on the 17th revision of the Japanese Pharmacopoeia, and the osmotic pressure is the osmotic pressure measurement method described in the Japanese Pharmacopoeia. (freezing point depression method).
- the standard solution for osmotic pressure ratio measurement (0.9 w/v% sodium chloride aqueous solution) was obtained by drying sodium chloride (Japanese Pharmacopoeia standard reagent) at 500 to 650 ° C. for 40 to 50 minutes and then placing it in a desiccator (silica gel).
- the viscosity of the ophthalmic composition according to this embodiment is not particularly limited as long as it is within a pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable range.
- the viscosity of the ophthalmic composition according to the present embodiment for example, the viscosity at 20 ° C.
- a rotational viscometer (TV-20 type viscometer, manufactured by Toki Sangyo Co., Ltd., rotor; 1 ° 34' ⁇ R24) is 1 It is preferably from 1 to 10,000 mPa s, more preferably from 1 to 8,000 mPa s, still more preferably from 1 to 1,000 mPa s, even more preferably from 1 to 100 mPa s, and from 1 to 20 mPa.
- ⁇ s is particularly preferred, and 1.5 to 10 mPa ⁇ s is most preferred.
- the ophthalmic composition according to the present embodiment contains, in addition to the above components, an appropriate amount of a combination of components selected from various pharmacologically active components and physiologically active components within a range that does not impair the effects of the second aspect of the present invention.
- You may have The ingredients are not particularly limited, and examples thereof include active ingredients in ophthalmic drugs described in the 2017 edition of the Standards for Manufacturing and Marketing Approval of Over-the-Counter Drugs (supervised by the Japanese Society of Regulatory Science). Specific examples of components used in ophthalmic drugs include the following components.
- Antiallergic agents for example, cromoglycate sodium, tranilast, pemirolast potassium, acitazanolast, amlexanox, ibudilast and the like.
- Steroid agents for example, fluticasone propionate, fluticasone furoate, mometasone furoate, beclomethasone propionate, flunisolide and the like.
- Ocular muscle modulating drug For example, cholinesterase inhibitors having an active center similar to that of acetylcholine, specifically neostigmine methylsulfate, tropicamide, helenien, atropine sulfate, pilocarpine hydrochloride and the like.
- Anti-inflammatory agents for example, methyl salicylate, glycol salicylate, allantoin, tranexamic acid, lysozyme, lysozyme chloride, indomethacin, pranoprofen, ibuprofen, ibuprofen piconol, ketoprofen, felbinac, bendazac, piroxicam, bufexamac, butyl flufenamate, epsilon- aminocaproic acid, berberine chloride, berberine sulfate, sodium azulene sulfonate, glycyrrhizic acid or a salt thereof (eg, dipotassium glycyrrhizinate, monoammonium glycyrrhizinate) and the like.
- methyl salicylate for example, methyl salicylate, glycol salicylate, allantoin, tranexamic acid, lysozyme, ly
- Vitamins for example, retinol acetate, retinol palmitate, tocopherol acetate, flavin adenine dinucleotide sodium, cyanocobalamin, pyridoxine hydrochloride, panthenol, calcium pantothenate, ascorbic acid, sodium ascorbate and the like.
- Amino acids for example, L-arginine, glutamic acid, glycine, alanine, lysine, ⁇ -aminobutyric acid, ⁇ -aminovaleric acid, trimethylglycine, taurine, aspartic acid and salts thereof.
- Astringent For example, zinc white and the like.
- Others For example, sulfamethoxazole, sulfisoxazole, sulfisomidine and salts thereof and the like.
- additives are appropriately selected in accordance with conventional methods according to the use and formulation form, as long as the effects of the second present invention are not impaired. Alternatively, more than that may be used in combination and contained in an appropriate amount. Examples of such additives include various additives described in Pharmaceutical Excipient Encyclopedia 2016 (edited by Japan Pharmaceutical Excipients Association). Typical ingredients include the following additives.
- Carrier For example, an aqueous solvent such as water or hydrous ethanol.
- Chelating agents for example, ethylenediaminediacetic acid (EDDA), ethylenediaminetriacetic acid, ethylenediaminetetraacetic acid (EDTA), N-(2-hydroxyethyl)ethylenediaminetriacetic acid (HEDTA), diethylenetriaminepentaacetic acid (DTPA) and the like.
- Base For example, octyldodecanol, titanium oxide, potassium bromide, Plastibase and the like.
- pH adjuster for example, hydrochloric acid, acetic acid, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, triethanolamine, monoethanolamine, diisopropanolamine and the like.
- Perfumes or cooling agents e.g. menthol, menthone, camphor, borneol, geraniol, cineol, citronellol, carvone, anethole, eugenol, limonene, linalool, linalyl acetate, thymol, cymene, terpineol, pinene, camphene, isoborneol, fenchen , nerol, myrcene, myrcenol, linalool acetate, lavandulol, eucalyptus oil, bergamot oil, peppermint oil, cool mint oil, spearmint oil, peppermint oil, fennel oil, cinnamon oil, rose oil, camphor oil, etc.
- Thickeners cellulosic polymer compounds such as methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose; guar gum; hydroxypropylguar gum; gum arabic; karaya gum; xanthan gum; Heparin-like substances, heparin, heparin sulfate, heparan sulfate, heparinoids, hyaluronic acid and mucopolysaccharides thereof (such as sodium salts); starch; chitin and its derivatives; chitosan and its derivatives; carrageenan; Stabilizers: for example, edetic acid, edetate salts (edetate disodium, edetate calcium disodium, edetate trisodium, edetate tetrasodium), sodium formaldehyde sulfoxylate (Rongalite), aluminum mono
- Preservatives e.g. quaternary ammonium salts of alkylpolyaminoethylglycines (e.g. benzalkonium chloride, benzethonium chloride, etc.), chlorhexidine gluconate, polydronium chloride, sodium benzoate, ethanol, chlorobutanol, sorbic acid, potassium sorbate , sodium dehydroacetate, methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, butyl parahydroxybenzoate, oxyquinoline sulfate, phenethyl alcohol, benzyl alcohol, biguanide compounds (specifically, polyhexanide hydrochloride (polyhexamethylene biguanide ), Alexidine, etc.), Glokill (trade name of Rhodia), etc.
- alkylpolyaminoethylglycines e.g. benzalkonium chloride, benzethonium
- Tonicity agents e.g. potassium chloride, calcium chloride, sodium chloride, magnesium chloride, potassium acetate, sodium acetate, sodium bicarbonate, sodium carbonate, sodium thiosulfate, magnesium sulfate, glycerin, propylene glycol, sodium bisulfite, sodium sulfite etc.
- Sugar alcohols For example, xylitol, sorbitol, mannitol, glycerin and the like. These may be d-, l- or dl-isomers.
- Oils For example, vegetable oils such as sesame oil, castor oil, soybean oil and olive oil; animal oils such as squalane; mineral oils such as liquid paraffin and petrolatum.
- the ophthalmic composition according to this embodiment contains at least one selected from the group consisting of geraniol, linalyl acetate, limonene, citral and linalool in an amount of 0.2% from the viewpoint that the effects of the second aspect of the present invention can be exhibited remarkably. It is preferable not to contain 01% or more, and it is preferable not to contain.
- the content of water is, for example, based on the total amount of the ophthalmic composition, from the viewpoint of exhibiting the effect of the second present invention more remarkably.
- the content is preferably 80 w/v% or more and less than 100 w/v%, more preferably 85 w/v% or more and 99.5 w/v% or less, and 90 w/v% or more and 99.2 w/v% More preferably:
- the water used in the ophthalmic composition according to this embodiment may be pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- examples of such water include distilled water, ordinary water, purified water, sterile purified water, water for injection, and distilled water for injection. Their definitions are based on the 17th revision of the Japanese Pharmacopoeia.
- the ophthalmic composition according to the present embodiment can be prepared by adding and mixing desired amounts of component (A), component (B), and, if necessary, other components to a desired concentration.
- component (A), component (B), and, if necessary, other components can be prepared by dissolving or dispersing these components in purified water, adjusting to a predetermined pH and osmotic pressure, and sterilizing by filtration sterilization or the like.
- the ophthalmic composition according to this embodiment can take various formulation forms depending on the purpose.
- Formulations include, for example, liquids, gels, semi-solids (ointments, etc.) and the like.
- the ophthalmic composition according to the present embodiment includes, for example, eye drops (also referred to as eye drops or eye drops. Eye drops include eye drops that can be dropped while wearing contact lenses), artificial tears, and eye washes. (Also referred to as eye wash or eye wash. Eye wash includes eye wash that can be washed while wearing contact lenses.), contact lens composition [contact lens wetting solution, contact lens care composition (contact lens disinfectant, contact lens preservative, contact lens cleaning agent, contact lens cleaning and preserving agent), contact lens packaging solution, etc.].
- contact lens includes hard contact lenses and soft contact lenses (both ionic and non-ionic, including both silicone hydrogel contact lenses and non-silicone hydrogel contact lenses). From the viewpoint of exhibiting the effects of the second aspect of the present invention more remarkably, an ophthalmic composition for silicone hydrogel contact lenses is preferable, and an eye drop that can be instilled while the silicone hydrogel lens is being worn is more preferable.
- the ophthalmic composition according to the present embodiment is preferably an eye drop (including an eye drop that can be instilled while wearing contact lenses) because the effect of the second aspect of the present invention can be exhibited more remarkably.
- the ophthalmic composition according to the present embodiment is an eye drop
- the usage and dosage are not particularly limited as long as they are effective and have few side effects.
- a method of using 1 to 3 drops, 1 to 2 drops, or 2 to 3 drops at a time, 2 to 4 times, or 5 to 6 times a day can be exemplified.
- the ophthalmic composition according to this embodiment is provided in an arbitrary container.
- the container for containing the ophthalmic composition according to this embodiment is not particularly limited, and may be made of glass or plastic, for example. It is preferably made of plastic. Examples of plastics include polyethylene terephthalate (PET), polyarylate, polyethylene naphthalate, polycarbonate, polyethylene, polypropylene, polyimide, copolymers of these monomers, and mixtures of two or more thereof. Preferred is polyethylene terephthalate.
- PET polyethylene terephthalate
- the container containing the ophthalmic composition according to the present embodiment may be a transparent container in which the inside of the container is visible, or an opaque container in which the inside of the container is difficult to be seen. A transparent container is preferred.
- the "transparent container” includes both a colorless transparent container and a colored transparent container.
- a nozzle may be attached to the container containing the ophthalmic composition according to the present embodiment.
- the material of the nozzle is not particularly limited, and may be, for example, glass or plastic. It is preferably made of plastic. Examples of plastics include polybutylene terephthalate, polyethylene, polypropylene, polyethylene terephthalate, polyethylene naphthalate, copolymers of monomers constituting these, and mixtures of two or more of these.
- the material of the nozzle is preferably polypropylene, polyethylene, polyethylene terephthalate, polybutylene terephthalate, or polyethylene naphthalate, more preferably polyethylene, from the viewpoint of further enhancing the effect of the second aspect of the present invention.
- the container containing the ophthalmic composition according to the present embodiment may be of a multi-dose type that contains multiple doses, or may be of a unit dose type that contains a single dose.
- the ophthalmic composition according to the present embodiment is preferably filled in a container having an internal volume of 4 to 30 mL, more preferably filled in a container having an internal volume of 5 to 20 mL. More preferably, it is packed in a container of 6 to 16 mL, and even more preferably packed in a container with an internal volume of 10 to 15 mL. Also, it may be filled in a container with an internal volume of 0.1 to 3 mL, or may be filled in a container with an internal volume of 0.2 to 1 mL.
- the second invention will be specifically described below based on test examples, but the second invention is not limited to these.
- the sodium chondroitin sulfate used in the test examples below is as follows, and the sodium chondroitin sulfate having a weight average molecular weight of 56,000 is derived from sharks. Chondroitin sulfate sodium weight average molecular weight about 56000: Seikagaku Corporation; grade NK Weight average molecular weight about 28000: Seikagaku Corporation; grade ND-K Weight average molecular weight about 25000: Maruha Nichiro Co., Ltd.;
- Each ophthalmic composition was prepared according to a conventional method with the composition shown in Table 20 and used as a test solution.
- the unit of each component in Table 20 is w/v %.
- 10 mL of each ophthalmic composition was filled in a 10 mL capacity glass headspace vial (GL Sciences Inc.) and tested with a photostability tester (LT-120A-WCD (manufactured by Nagano Sciences)) using a D65 fluorescent lamp as a light source. , at a room temperature of 25° C., irradiation was performed at an illuminance of 4000 lx/h until an integrated illuminance of 1,200,000 lx.
- Each ophthalmic composition (600 ⁇ L) before and after irradiation was subjected to shearing at 34° C. using a cone-plate measuring jig (CP50-1, d: 0.102 mm) with a rheometer (MCR302 (AntonPaar)). Viscosity was measured against speed (1-10000 (1/s)). Using the viscosity (mPa ⁇ s) at a shear rate of 1000 (1/s), the viscosity stability before and after the test was evaluated according to the following formula. Table 20 shows the results.
- Viscosity change rate (%) ⁇ (Viscosity of each ophthalmic composition before light irradiation - Viscosity of each ophthalmic composition after light irradiation)/Viscosity of each ophthalmic composition before light irradiation ⁇ x 100
- Examples 1-6 containing sodium chondroitin sulfate having a weight average molecular weight of about 56000, tetrahydrozoline hydrochloride, zinc sulfate hydrate, chlorpheniramine maleate, hydroxyethylcellulose, polyvinylpyrrolidone K30 or polyvinylpyrrolidone K90, respectively.
- the rate of change in viscosity was significantly reduced, and that the stability of the ophthalmic composition under light irradiation was improved.
- a similar tendency was obtained when the viscosity was measured at a shear rate of 100 (1/s).
- Each ophthalmic composition was prepared according to a conventional method with the composition shown in Table 21 and used as a test solution.
- the unit of each component in Table 21 is w/v %.
- a droplet (about 1 ⁇ L) of each prepared ophthalmic composition was dropped on a stainless metal plate (ferrule cap Type CLF-B), and an automatic contact angle meter (solid-liquid interface analysis system Drop Master, DM-A501 (Kyowa Interface Science Co., Ltd.) company)) was used to measure the contact angle (static contact angle) to the metal 0.1 seconds after dropping.
- the contact angle of each ophthalmic composition was measured three times, and the average value was calculated as the contact angle of each ophthalmic composition. The results are shown in Table 21.
- the contact angles of the test solutions of Examples 4 and 5 were significantly increased compared to the test solution of Reference Example 2. That is, compared with the test solution containing only sodium chondroitin sulfate with a weight average molecular weight of about 56,000, the test solution containing sodium chondroitin sulfate with a weight average molecular weight of about 56,000 and hydroxyethyl cellulose or polyvinylpyrrolidone has an affinity for stainless steel tubes. It was confirmed that the resilience was remarkably low. Since the filling tube in the production line is made of metal such as stainless steel, it is possible to reduce droplets adhering to the tip of the filling tube when the ophthalmic composition is filled into the container, resulting in a uniform filling amount. you know it will be easier.
- Each ophthalmic composition was prepared according to a conventional method with the composition shown in Table 22 and used as a test solution.
- the unit of each component in Table 22 is w/v %.
- Staphylococcus aureus ATCC6538 was inoculated onto the surface of soybean-casein digest slants and cultured at 33° C. for 24 hours.
- the cultured cells were aseptically collected with a platinum loop and suspended in an appropriate amount of sterilized physiological saline to prepare a bacterial suspension containing about 1 ⁇ 10 7 CFU/mL viable cells. The number of viable bacteria in the suspension was separately cultured and measured.
- each prepared ophthalmic composition was filled in a 15 mL conical tube (CORNING) made of PET.
- CORNING conical tube
- Each of these ophthalmic compositions was inoculated with a Staphylococcus aureus bacterial solution (suspended in physiological saline) so that the viable cell count (final concentration) was about 10 5 CFU/mL, and stirred well to obtain a sample. . Samples containing bacteria were stored at 23°C for 3 days in the dark.
- Reference Example 1 has low preservative efficacy, but Examples 2 and 6 have improved preservative efficacy. That is, Example 2 containing sodium chondroitin sulfate with a weight average molecular weight of about 56,000 and zinc sulfate hydrate or polyvinylpyrrolidone compared to the test solution of Reference Example 1 containing sodium chondroitin sulfate with a weight average molecular weight of about 28,000. It was confirmed that the preservative efficacy was further improved in the test solutions of and 6.
- Each ophthalmic composition was prepared according to a conventional method with the composition shown in Table 23 and used as a test solution.
- the unit of each component in Table 21 is w/v %.
- the viscosity of each prepared ophthalmic composition (600 ⁇ L) was measured at 34° C. using a cone-plate measuring jig (CP50-1, d: 0.102 mm) with a rheometer (MCR302 (manufactured by AntonPaar)). Viscosity versus shear rate was measured.
- Viscosity reduction rate (%) (1-viscosity of Example 2/viscosity of Reference Example 2) x 100 The results are shown in Table 23.
- Example 2 containing zinc sulfate hydrate was significantly lower than that of Reference Example 2.
- the viscosity measured using a rotational viscometer after preparation of Reference Example 2 using sodium chondroitin sulfate with a weight average molecular weight of about 56,000 is The present inventors have confirmed that the viscosity was higher than that of a test solution of the same composition except that sodium chondroitin sulfate having a weight average molecular weight of about 28,000 was used. If the ophthalmic composition has a high viscosity when instilled into the eye, problems such as difficulty in blinking and a tendency to feel discomfort may occur.
- an ophthalmic composition containing sodium chondroitin sulfate with a weight-average molecular weight of about 56,000 and zinc sulfate hydrate has a higher effect after instillation than an ophthalmic composition containing only sodium chondroitin sulfate with a weight-average molecular weight of about 56,000. It was confirmed that it was easy to blink and it was difficult to feel discomfort.
- Each ophthalmic composition was prepared according to a conventional method with the composition shown in Table 24 and used as a test solution.
- the unit of each component in Table 24 is w/v %.
- 10 mL of each ophthalmic composition was filled in a glass bottle (10 mL) and irradiated at 35° C. for 96 hours at an ultraviolet light illuminance of 765 (W/m 2 ) using SUNTESTER XLS+ (manufactured by Toyo Seiki Co., Ltd., 1700 W xenon air-cooled lamp light source). .
- each ophthalmic composition was sufficiently thermostated at 25° C., and the color difference change (b * value) of each ophthalmic composition before and after UV irradiation was measured using a spectrophotometer (CM3500d: manufactured by Konica Minolta). Then, the change in appearance of the ophthalmic composition before and after UV irradiation (degree of change in color difference; ⁇ b * value) was calculated according to Formula 1 below, and the rate of decrease in change in color difference was calculated according to Formula 2 below. The results are shown in Table 24. Note that the smaller the ⁇ b * value, the more suppressed the change (coloring) in the appearance (color) of the ophthalmic composition.
- Example 1 containing sodium chondroitin sulfate and tetrahydrozoline hydrochloride having a weight-average molecular weight of about 28,000 is affected by ultraviolet irradiation. It was confirmed that the degree of change in color difference ( ⁇ b * ) was small, and the coloring of the preparation due to ultraviolet irradiation was suppressed.
- Each ophthalmic composition was prepared according to a conventional method with the composition shown in Table 25 and used as a test solution.
- the unit of each component in Table 25 is w/v%.
- 500 ⁇ L of human corneal epithelial cell line HCE-T cells were seeded in each well at a concentration of 1 ⁇ 10 5 cells/mL in a 24-well plate (Corning), and the concentration was set at 37° C. and 5% CO 2 . Cultured in a CO2 incubator.
- DMEM/F12 ThermoFisher
- FCS DS Pharma
- DMSO Wired Chemical Industries
- recombinant human EGF R & D
- insulin solution The one to which human (SIGMA) was added so as to be 5 ⁇ g/mL was used.
- SIGMA human EGF
- Example 4 containing sodium chondroitin sulfate with a weight-average molecular weight of about 56,000 and hydroxyethyl cellulose was confirmed to have a remarkably high cell viability. . Therefore, when an ophthalmic composition containing sodium chondroitin sulfate having a weight-average molecular weight of about 56,000 and hydroxyethyl cellulose is instilled into the eye, external irritation is applied to the eye (for example, rubbing the eye with a hand, blinking, contact lenses, etc.).
- Eye drops are prepared by a conventional method with the formulations shown in Tables 26 to 29 below.
- the unit of each component amount in Tables 26 to 29 below is w/v % except for those specified in the table.
- the third invention relates to an ophthalmic composition.
- Chondroitin sulfate or its salt is a type of acidic mucopolysaccharide, and is used in ophthalmic preparations for the purpose of promoting energy metabolism, promoting metabolism and cell respiration to relieve eye fatigue, and replenishing tear components. (eg, Patent Document 3-1).
- Patent Literature [Patent Document 3-1] JP 2011-148791 A
- a third object of the present invention is to provide a novel ophthalmic composition containing chondroitin sulfate or a salt thereof.
- ophthalmic compositions containing menthol in sodium chondroitin sulfate which has a weight average molecular weight of about 56,000, may cause unpleasant irritation and a burning sensation in the eyes. It was unexpectedly found that these were significantly suppressed in the composition.
- the third invention provides, for example, the following inventions.
- An ophthalmic composition comprising at least one selected from the group consisting of chondroitin sulfate having a weight-average molecular weight of 40,000 to 70,000 and salts thereof, and menthol.
- the ophthalmic composition according to [1] further containing at least one selected from the group consisting of boric acid and salts thereof.
- the content unit “%” means “w/v%” and is synonymous with “g/100 mL”.
- the ophthalmic composition according to the present embodiment includes at least one selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 40,000 to 70,000 and salts thereof (also simply referred to as “component (A)”). , and menthol (also simply referred to as “(B) component”).
- Chondroitin sulfate and salts thereof are not particularly limited as long as they are pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- chondroitin sulfate salts include alkali metal salts and alkaline earth metal salts.
- alkali metal salts include sodium salts and potassium salts.
- alkaline earth metal salts include magnesium salts and calcium salts.
- Chondroitin sulfate and its salts are preferably chondroitin sulfate and alkali metal salts of chondroitin sulfate, more preferably chondroitin sulfate and sodium chondroitin sulfate, and still more preferably sodium chondroitin sulfate.
- Chondroitin sulfate and its salts may be natural products or synthetic products, but are generally natural products of animals (preferably mammals, fish, mollusks, etc.; more preferably bovine, shark, squid, A chondroitin sulfate derived from a ray, etc.) and a salt thereof are preferably used, a chondroitin sulfate derived from a shark and/or a ray and a salt thereof are more preferably used, and a chondroitin sulfate and a salt thereof derived from a shark are more preferably used. .
- chondroitin sulfate and its salts can also be used. Chondroitin sulfate and its salt may be used alone or in combination of two or more.
- chondroitin sulfate and its salts include chondroitin sulfate and its salts having a weight-average molecular weight of 40,000 to 70,000 defined herein and chondroitin sulfate and its salts having a weight-average molecular weight outside the range defined herein. can be used in combination with For example, sodium chondroitin sulfate with a weight average molecular weight of 56,000 and sodium chondroitin sulfate with a weight average molecular weight of 25,000 can be used in combination.
- chondroitin sulfate having a weight average molecular weight of 40,000 to 70,000 and a salt thereof defined herein and chondroitin sulfate having a weight average molecular weight outside the range defined herein and a salt thereof may be contained as raw materials.
- the "weight average molecular weight” can be determined by using gel permeation chromatography in which a multi-angle light scattering detector (MALS detector) and a differential refractive index detector (RI detector) are connected online. . Specifically, the following conditions are presented. ⁇ Standard sample preparation> 10 mL of 0.1 M sodium nitrate aqueous solution was added to 5 mg of chondroitin sulfate or its salt, and the mixture was gently stirred at room temperature to dissolve completely.
- MALS detector multi-angle light scattering detector
- RI detector differential refractive index detector
- Apparatus Gel permeation chromatograph - multi-angle light scatterometer Detector: Differential refractive index detector (Optilab rEX manufactured by Wyatt Technology) Multi-angle light scattering detector (DAWN HELEOS manufactured by Wyatt Technology) Column: 2 Shodex OHpak SB-806M HQ ( ⁇ 7.8 mm ⁇ 30 cm, manufactured by Showa Denko) Solvent: 0.1 M sodium nitrate aqueous solution Flow rate: 0.7 mL/min Column temperature: 23°C Detector temperature: 23°C Injection volume: 0.2 mL Data processing: Wyatt Technology data processing system (ASTRA)
- the weight average molecular weight of chondroitin sulfate and its salt calculated by the above method is not particularly limited as long as it is in the range of 40,000 to 70,000.
- Examples of the lower limit of the weight average molecular weight include 41000 or more, 42000 or more, 43000 or more, 44000 or more, 45000 or more, 46000 or more, 47000 or more, 48000 or more, 49000 or more, and 50000 or more.
- Examples of the upper limit of the weight average molecular weight include 69000 or less, 68000 or less, 67000 or less, 66000 or less, 65000 or less, 64000 or less, 63000 or less, 62000 or less, 61000 or less, and 60000 or less.
- the weight average molecular weight ranges are 41,000 to 69,000, 42,000 to 68,000, 43,000 to 67,000, 44,000 to 66,000, 45,000 to 65,000, 46,000 to 64,000, 47,000 to 63,000, 48,000 to 62,000, 49,000 to 61,000, and 500.
- 00 to 60000 are examples be done.
- Menthol is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- Menthol may be d-, l-, or dl-menthol, and examples include l-menthol, d-menthol, and dl-menthol.
- essential oils include mint oil, cool mint oil, spearmint oil, peppermint oil and the like.
- the content of component (B) in the ophthalmic composition according to the present embodiment is not particularly limited, and is appropriately set according to the type and content of other compounding components, the application and formulation form of the ophthalmic composition, and the like.
- the content of menthol is 0.00001 to 0.5 w/v%, 0.0001 to 0.1 w/v, based on the total amount of the ophthalmic composition, from the viewpoint of exhibiting the effect of the third aspect of the present invention more remarkably. %, or 0.001 to 0.05 w/v %.
- the blending ratio of the essential oil is set so that the content of menthol in the essential oil to be blended satisfies the above blending ratio.
- the content ratio of component (B) to component (A) is not particularly limited. And it is appropriately set according to the dosage form and the like.
- the content ratio of component (B) to component (A) is, from the viewpoint of further enhancing the effect of the third aspect of the present invention, for example, the total content of component (A) contained in the ophthalmic composition according to the present embodiment is 1
- the total content of component (B) may be 0.00001 to 10 parts by mass, 0.0001 to 1 part by mass, or 0.001 to 0.1 parts by mass.
- the ophthalmic composition according to the present embodiment contains, in addition to components (A) and (B), at least one selected from the group consisting of boric acid and salts thereof (also simply referred to as "component (C)". ) may be further contained.
- component (C) the effect of the third aspect of the present invention is exhibited more remarkably.
- Component (C) is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- boric acid and salts thereof include boric acid, sodium borate, potassium tetraborate, potassium metaborate, ammonium borate, and borax.
- boric acid and its salt a combination of boric acid and borax is preferred.
- the content of component (C) in the ophthalmic composition according to the present embodiment is not particularly limited, and is appropriately set according to the type and content of other compounding components, the application and formulation form of the ophthalmic composition, and the like.
- the content of component (C) is 0.01 to 5 w/v%, 0.05 to 3 w/v%, based on the total amount of the ophthalmic composition, from the viewpoint of exhibiting the effect of the third aspect of the present invention more remarkably. , or 0.1 to 2 w/v %.
- the content ratio of component (C) to component (A) is not particularly limited. And it is appropriately set according to the dosage form and the like.
- the content ratio of component (C) to component (A) is, from the viewpoint of further enhancing the effect of the third aspect of the present invention, for example, the total content of component (A) contained in the ophthalmic composition according to the present embodiment is 1
- the total content of component (C) may be 0.001 to 50 parts by mass, 0.01 to 10 parts by mass, or 0.1 to 5 parts by mass.
- the ophthalmic composition according to the present embodiment further contains chlorobutanol (also simply referred to as “component (D)”) in addition to component (A), component (B) and, if necessary, component (C). You may By further containing the component (D) in the ophthalmic composition, the effects of the third aspect of the present invention are exhibited more remarkably.
- Component (D) is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- the content of component (D) in the ophthalmic composition according to the present embodiment is not particularly limited, and is appropriately set according to the type and content of other compounding components, the application and formulation form of the ophthalmic composition, and the like.
- the content of component (D) is 0.0005 to 1 w/v%, 0.001 to 0, based on the total amount of the ophthalmic composition, from the viewpoint of more significantly suppressing the unpleasant irritation and burning sensation caused by menthol. 0.5 w/v%, 0.005-0.3 w/v%, or 0.01-0.1 w/v%.
- the content ratio of component (D) to component (A) is not particularly limited. And it is appropriately set according to the dosage form and the like.
- the content ratio of component (D) to component (A) is, from the viewpoint of further enhancing the effect of the third aspect of the present invention, for example, the total content of component (A) contained in the ophthalmic composition according to the present embodiment is 1
- the total content of component (D) may be 0.0001 to 5 parts by mass, 0.001 to 1 part by mass, or 0.01 to 0.5 parts by mass.
- Another embodiment of the ophthalmic composition according to the third present invention comprises, in addition to components (A) and (B), It may further contain at least one selected from the group consisting of (also simply referred to as "(E) component").
- the ophthalmic composition has the effect of reducing the liquid residue in the container after use, and the viscosity when the formulation is put into the eye, as confirmed in the test examples described later. (Even if it is a high-viscosity formulation), the effect of making it easier to blink, the effect of suppressing changes in viscosity due to ultraviolet rays, and/or the effect of suppressing discomfort during blinking.
- Decongestants are compounds and salts thereof that act to decongest the eye.
- the decongestant is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- decongestants include imidazoline compounds such as tetrahydrozoline, naphazoline, oxymetazoline and salts thereof (e.g., hydrochlorides, nitrates); epinephrine, ephedrine, methylephedrine, phenylephrine and salts thereof (e.g., hydrochlorides); ).
- imidazoline compounds and salts thereof are preferred, tetrahydrozoline, naphazoline and salts thereof are more preferred, tetrahydrozoline and salts thereof are still more preferred, and tetrahydrozoline hydrochloride (tetrahydrozoline hydrochloride) is particularly preferred.
- a commercially available decongestant can also be used.
- the decongestants may be used singly or in combination of two or more.
- the content of the decongestant in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the use of the composition, the formulation form, and the like.
- the content of the decongestant is 0.0001 to 0.5 w/v%, 0.0006 to 0.1 w/v%, based on the total amount of the ophthalmic composition, from the viewpoint of exhibiting the effect of the third aspect of the present invention more remarkably. /v%, or 0.0015 to 0.05w/v%.
- component (E) When tetrahydrozoline and its salt are used as component (E), the content of component (E) is, for example, 0.01 to 0.05 w/v%, or 0.025 to 0.05%, based on the total amount of the ophthalmic composition. It may be 0.05 w/v%.
- the content ratio of the decongestant to the component (A) in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the type and content of other compounding ingredients, the application and formulation form of the ophthalmic composition, and the like.
- the content ratio of the decongestant to the component (A) is, from the viewpoint of further enhancing the effect of the third aspect of the present invention, for example, the total content of the component (A) contained in the ophthalmic composition according to the present embodiment is 1 mass.
- the total content of decongestants may be 0.0005 to 1 parts by weight, 0.0015 to 0.5 parts by weight, or 0.025 to 0.25 parts by weight.
- the ocular muscle adjusting agent is a compound or a salt thereof that has an effect of tensing or relaxing the ocular muscle (ciliary muscle) to adjust focus.
- the eye muscle modulating agent is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- ocular muscle modulating agents include cholinesterase inhibitors having an active center similar to that of acetylcholine, more specifically neostigmine, tropicamide, helenien, atropine and salts thereof (e.g., sulfate, methylsulfate, ).
- neostigmine and its salts are preferable as the eye muscle modulating agent, and neostigmine methylsulfate is more preferable.
- a commercially available eye muscle regulating agent can also be used.
- the eye muscle regulating agent may be used singly or in combination of two or more.
- the content of the ocular muscle modulating agent in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the amount, the use of the ophthalmic composition, the formulation form, and the like.
- the content of the ocular muscle modulating agent is 0.0001 to 0.05 w/v%, 0.0005 to 0.01 w/v%, or 0.001 to 0.005 w/v based on the total amount of the ophthalmic composition. %.
- the content ratio of the ocular muscle modulating agent to the (A) component in the ophthalmic composition according to the present embodiment is not particularly limited. type, type and content of other compounding ingredients, application and formulation form of the ophthalmic composition, and the like.
- the content ratio of the ocular muscle modulating agent to the component (A) is, from the viewpoint of further enhancing the effect of the third aspect of the present invention, for example, the total content of the component (A) contained in the ophthalmic composition according to the present embodiment is 1 Even if the total content of the ocular muscle modulating agent is 0.0001 to 0.5 parts by mass, 0.0005 to 0.1 parts by mass, or 0.001 to 0.05 parts by mass, good.
- Anti-inflammatory agents are compounds and salts thereof that have anti-inflammatory or anti-inflammatory activity.
- the anti-inflammatory agent is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- anti-inflammatory agents include epsilon-aminocaproic acid, allantoin, berberine, azulenes (azulene, azulene sulfonic acid, camaazulene, guaiazulene, etc.), glycyrrhizic acid, zinc salts, lysozyme, celecoxib, rofecoxib, indomethacin, diclofenac, bromfenac.
- Preferred anti-inflammatory agents are allantoin, glycyrrhizic acid and its salts, and zinc salts.
- alkali metal salts or ammonium salts of glycyrrhizic acid are preferred, dipotassium glycyrrhizinate and monoammonium glycyrrhizinate are more preferred, and dipotassium glycyrrhizinate is even more preferred.
- the zinc salt is preferably zinc sulfate or zinc lactate, more preferably zinc sulfate. Also, the zinc salt may be a hydrate (for example, zinc sulfate heptahydrate).
- Anti-inflammatory agents can also be used. Anti-inflammatory agents may be used singly or in combination of two or more.
- the content of the anti-inflammatory agent in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the use of the composition, the formulation form, and the like.
- the content of the anti-inflammatory agent is 0.001 to 1 w/v%, 0.005 to 0.6 w/v, based on the total amount of the ophthalmic composition, from the viewpoint of exhibiting the effect of the third aspect of the present invention more remarkably. %, or 0.05-0.3 w/v %.
- the content ratio of the anti-inflammatory agent to the component (A) in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the type and content of other compounding ingredients, the application and formulation form of the ophthalmic composition, and the like.
- the content ratio of the anti-inflammatory agent to the component (A) is, from the viewpoint of further enhancing the effect of the third aspect of the present invention, for example, the total content of the component (A) contained in the ophthalmic composition according to the present embodiment is 1 mass.
- the total content of the anti-inflammatory agent may be 0.001 to 10 parts by weight, 0.005 to 6 parts by weight, or 0.05 to 3 parts by weight.
- Antihistamines are compounds and salts thereof that have antihistamine action. Antihistamines are not particularly limited as long as they are pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- antihistamines include chlorpheniramine, iproheptine, diphenhydramine, ketotifen, olopatadine, levocabastine, and salts thereof.
- chlorpheniramine and its salts are preferred, and chlorpheniramine maleate is more preferred.
- a commercially available antihistamine can also be used.
- One type of antihistamine may be used alone, or two or more types may be used in combination.
- the content of the antihistamine in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the form and the like.
- the content of the antihistamine is 0.0001 to 0.05 w/v%, 0.0006 to 0.05 w/v%, based on the total amount of the ophthalmic composition, from the viewpoint of exhibiting the effect of the third aspect of the present invention more remarkably. %, 0.006-0.04 w/v %, or 0.015-0.03 w/v %.
- the content ratio of the antihistamine to the component (A) in the ophthalmic composition according to the present embodiment is not particularly limited. and content, the application and formulation form of the ophthalmic composition, and the like. From the viewpoint of further enhancing the effect of the third aspect of the present invention, the content ratio of the antihistamine to the component (A) is, for example, 1 part by mass of the total content of the component (A) contained in the ophthalmic composition according to the present embodiment. On the other hand, the total content of antihistamines is 0.0001 to 0.5 parts by weight, 0.0006 to 0.5 parts by weight, 0.006 to 0.4 parts by weight, or 0.015 to 0.3 parts by weight may be
- Vitamin A is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable. Specific examples of vitamin A include retinol, retinal, retinoic acid, derivatives thereof, and salts thereof.
- vitamin A derivatives include esters with monovalent carboxylic acids such as retinol palmitate, retinol acetate, retinol butyrate, retinol propionate, retinol octylate, retinol laurate, retinol oleate and retinol linolenate. mentioned.
- vitamin A salts include organic acid salts [e.g., monocarboxylates (acetate, trifluoroacetate, butyrate, palmitate, stearate, etc.), polyvalent carboxylates (fumaric acid salt, maleate, succinate, malonate, etc.), oxycarboxylate (lactate, tartrate, citrate, etc.), organic sulfonate (methanesulfonate, toluenesulfonate, tosylate salts, etc.)], inorganic acid salts (e.g., hydrochlorides, sulfates, nitrates, hydrobromides, phosphates, etc.), salts with organic bases (e.g., methylamine, triethylamine, triethanolamine, morpholine , piperazine, pyrrolidine, tripyridine, salts with organic amines such as picoline, etc.), salts with inorganic bases [e.g., ammonium salts
- vitamin A derivatives of retinol are preferable, esters of retinol and monovalent carboxylic acid are more preferable, retinol palmitate and retinol acetate are more preferable, and retinol palmitate is even more preferable.
- vitamin A synthetic products may be used, or extracts obtained from natural products (eg, vitamin A oil, etc.) may be used.
- Vitamin A oil is a fatty oil obtained from animal tissue containing retinol, a concentrate thereof, or a mixture thereof with vegetable oil added as appropriate. Commercially available vitamin A can also be used. Vitamin A may be used individually by 1 type, or may be used in combination of 2 or more type.
- the content of vitamin A in the ophthalmic composition according to the present embodiment is 0.1 to 100,000 IU/100 mL, based on the total amount of the ophthalmic composition. 50,000 to 75,000 IU/100 mL, or 10,000 to 50,000 IU/100 mL.
- IU means the international unit determined by the method described in the Japanese Pharmacopoeia 17th Edition Vitamin A Determination Method. For example, in each article of the Japanese Pharmacopoeia 17th Edition, it is stated that retinol acetate contains 2.5 million units or more of vitamin A per 1g, and retinol palmitate contains 1.5 million units or more of vitamin A per 1g. ing.
- the content ratio of the vitamin A to the component (A) in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the type and content of the compounding ingredients, the application and formulation form of the ophthalmic composition, and the like. From the viewpoint of further enhancing the effect of the third aspect of the present invention, the content ratio of the vitamin A relative to the component (A) is, for example, 1 mass of the total content of the component (A) contained in the ophthalmic composition according to the present embodiment. part, the total content of vitamin A may be 0.1 to 1,000,000 IU/g, 0.05 to 750,000 IU/g, or 10,000 to 500,000 IU/g .
- [Vitamin B] B vitamins are not particularly limited as long as they are pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- B vitamins include flavin adenine dinucleotide and salts thereof (flavin adenine dinucleotide sodium, etc.), cobalamins (cyanocobalamin, methylcobalamin, etc.), pantothenic acid and salts thereof (e.g., sodium pantothenate, potassium pantothenate) , calcium pantothenate, magnesium pantothenate, etc.), panthenol, pyridoxine or salts thereof (pyridoxine hydrochloride, etc.), pyridoxal and salts thereof (pyridoxal phosphate, etc.). Panthenol, pyridoxine or salts thereof are more preferred as the B vitamins.
- B vitamins can also be used. B vitamins may be used singly or in combination of two or more.
- the content of the B vitamins in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the use of the composition, the formulation form, and the like.
- the content of B vitamins is 0.0005 to 0.5 w/v%, 0.001 to 0.25 w/v%, based on the total amount of the ophthalmic composition, from the viewpoint of exhibiting the effect of the third aspect of the present invention more remarkably. /v%, or 0.01 to 0.1 w/v%.
- the content ratio of the water-soluble vitamin to the component (A) in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the type and content of the compounding ingredients, the application and formulation form of the ophthalmic composition, and the like. From the viewpoint of further enhancing the effect of the third aspect of the present invention, the content ratio of the B vitamins to the component (A) is, for example, 1 mass of the total content of the component (A) contained in the ophthalmic composition according to the present embodiment.
- the total content of B vitamins may be 0.0005 to 5 parts by mass, 0.001 to 2.5 parts by mass, or 0.01 to 1 part by mass.
- Vitamin E is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable. Specific examples of vitamin E include tocopherol, tocotrienol, derivatives thereof, and salts thereof. Tocopherols and tocotrienols may be ⁇ -, ⁇ -, ⁇ -, or ⁇ -, and may be d- or dl-forms.
- vitamin E derivatives include esters with organic acids such as tocopherol acetate, tocopherol succinate, tocopherol nicotinate, and tocopherol linolenate.
- vitamin E salts examples include organic acid salts (lactate, acetate, butyrate, trifluoroacetate, fumarate, maleate, tartrate, citrate, succinate, malonate, , methanesulfonate, toluenesulfonate, tosylate, palmitate, stearate, etc.), inorganic acid salts (e.g., hydrochloride, sulfate, nitrate, hydrobromide, phosphate, etc.) , salts with organic bases (e.g., salts with organic amines such as methylamine, triethylamine, triethanolamine, morpholine, piperazine, pyrrolidine, amino acids, tripyridine, picoline, etc.), salts with inorganic bases (e.g., ammonium salts, alkali metals such as sodium and potassium; alkaline earth metals such as calcium and magnesium; salts with metals such as aluminum;
- organic acid salts e.g
- vitamin E examples include d- ⁇ -tocopherol, dl- ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol, vitamin E acetate (e.g. tocopherol acetate), vitamin E nicotinate, vitamin E succinate Acid esters and vitamin E linolenic acid esters are preferred, and tocopherol acetate (eg, d- ⁇ -tocopherol acetate, dl- ⁇ -tocopherol acetate, etc.) is more preferred.
- Vitamin E may be either natural or synthetic. Commercially available vitamin E can also be used. Vitamin E may be used individually by 1 type, or may be used in combination of 2 or more type.
- the content of vitamin E in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the use of the composition, the formulation form, and the like.
- the content of vitamin E is 0.0001 to 0.5 w/v%, 0.0005 to 0.1 w/v%, or 0.005 to 0.05 w/v% based on the total amount of the ophthalmic composition. may be
- the content ratio of vitamin E to component (A) in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the type and content of other compounding ingredients, the application and formulation form of the ophthalmic composition, and the like. From the viewpoint of further enhancing the effect of the third aspect of the present invention, the content ratio of the vitamin E relative to the component (A) is, for example, the total content of the component (A) contained in the ophthalmic composition according to the present embodiment, which is 1 mass.
- the total content of vitamin E may be 0.0001 to 5 parts by mass, 0.0005 to 1 part by mass, or 0.005 to 0.5 parts by mass.
- Amino acids and salts thereof are not particularly limited as long as they are pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- amino acids and salts thereof include L-aspartic acid or salts thereof (e.g., potassium L-aspartate, sodium L-aspartate, magnesium L-aspartate, calcium L-aspartate, magnesium/potassium L-aspartate, (equal mixture of magnesium L-aspartate and potassium L-aspartate)), aminoethylsulfonic acid or its salts, L-arginine, glutamic acid, glycine, alanine, lysine, ⁇ -aminobutyric acid, ⁇ -aminovaleric acid , trimethylglycine and salts thereof.
- Commercially available amino acids and salts thereof can also be used.
- amino acids and salts thereof may be L-, D-, or DL-forms, and examples thereof include potassium L-aspartate, magnesium L-aspartate, and a mixture of equal amounts of magnesium and potassium L-aspartate. .
- amino acids and salts thereof aspartic acid, aminoethylsulfonic acid and salts thereof are preferred, and aminoethylsulfonic acid is particularly preferred, from the viewpoint of further enhancing the effects of the third aspect of the present invention.
- the content of the amino acid and its salt in the ophthalmic composition according to the present embodiment is, for example, It may be 0.001 to 5 w/v%, 0.01 to 3 w/v%, or 0.1 to 2 w/v% based on the total amount of the product.
- the content ratio of the amino acid and its salt to the component (A) in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the type, the type and content of other compounding ingredients, the application and formulation form of the ophthalmic composition, and the like.
- the content ratio of the amino acid and its salt to the component (A) is, from the viewpoint of further enhancing the effect of the third aspect of the present invention, for example, the total content of the component (A) contained in the ophthalmic composition according to the present embodiment is 1
- the total content of amino acids and salts thereof may be 0.001 to 50 parts by mass, 0.01 to 30 parts by mass, or 0.1 to 20 parts by mass.
- the cellulose-based polymer compound is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- Cellulose-based polymer compounds include, for example, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose (hypromellose), carboxymethylcellulose, carboxyethylcellulose, and salts thereof.
- hydroxyethyl cellulose, hydroxypropylmethyl cellulose and salts thereof are preferable, and hydroxypropylmethyl cellulose and salts thereof are more preferable.
- Such salts include, for example, salts with organic bases (amine salts, basic ammonium salts such as arginine, etc.), salts with inorganic bases (alkali metal salts such as ammonium salts, sodium salts, potassium salts, calcium salts, alkaline earth metal salts such as magnesium salts, aluminum salts, etc.), among which sodium salts, potassium salts and calcium salts are more preferred, and sodium salts are particularly preferred.
- a commercially available one can also be used as the cellulose-based polymer compound.
- a cellulose polymer compound may be used individually by 1 type, or may be used in combination of 2 or more type.
- the content of the cellulose-based polymer compound in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the type and content, the application and formulation form of the ophthalmic composition, and the like.
- the content of the cellulose-based polymer compound is 0.001 to 3 w/v%, 0.005 to 1 w/v, based on the total amount of the ophthalmic composition, from the viewpoint of exhibiting the effect of the third aspect of the present invention more remarkably. %, or 0.01-0.6 w/v %.
- the content ratio of the cellulose-based polymer compound to the component (A) in the ophthalmic composition according to the present embodiment is not particularly limited. It is appropriately set according to the type of polymer compound, the type and content of other compounding ingredients, the application and formulation form of the ophthalmic composition, and the like.
- the content ratio of the cellulose-based polymer compound to the component (A) is, for example, the total content of the component (A) contained in the ophthalmic composition according to the present embodiment, from the viewpoint of further enhancing the effect of the third aspect of the present invention.
- the total content of the cellulose polymer compound may be 0.001 to 30 parts by weight, 0.005 to 10 parts by weight, or 0.01 to 6 parts by weight with respect to 1 part by weight.
- Another embodiment of the ophthalmic composition according to the third present invention is selected from the group consisting of (A) component, (B) component, (E) component and (C) component (boric acid and salts thereof). at least one) may be further contained.
- the ophthalmic composition has the effect of reducing the liquid residue in the container after use, the effect of suppressing the viscosity change due to ultraviolet rays, and the viscosity when the formulation is put into the eye ( The effect of facilitating blinking and/or the effect of suppressing discomfort during blinking is more remarkably exhibited, even with high-viscosity formulations.
- the ophthalmic composition according to this embodiment may further contain a surfactant.
- a surfactant When the ophthalmic composition further contains a surfactant, the effects of the third aspect of the present invention are exhibited more remarkably.
- Surfactants are not particularly limited as long as they are pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable, nonionic surfactants, amphoteric surfactants, anionic surfactants , cationic surfactants.
- nonionic surfactants include POE (20) sorbitan monolaurate (polysorbate 20), POE (20) sorbitan monopalmitate (polysorbate 40), POE (20) sorbitan monostearate (polysorbate 60), POE sorbitan fatty acid esters such as POE (20) sorbitan stearate (polysorbate 65), POE (20) sorbitan monooleate (polysorbate 80); POE (40) hydrogenated castor oil (polyoxyethylene hydrogenated castor oil 40), POE ( 60) POE hydrogenated castor oil such as hydrogenated castor oil (polyoxyethylene hydrogenated castor oil 60); POE (3) hydrogenated castor oil (polyoxyethylene castor oil 3), POE (10) castor oil (polyoxyethylene castor oil 10 POE (9) POE alkyl ethers such as lauryl ether; POE (20) POP (4) POE-POP alkyl ethers such as cetyl ether; POE (196)
- amphoteric surfactants include alkyldiaminoethylglycine or salts thereof (eg, hydrochlorides, etc.).
- anionic surfactants include alkylbenzenesulfonates, alkylsulfates, polyoxyethylene alkylsulfates, aliphatic ⁇ -sulfomethyl esters, ⁇ -olefinsulfonic acids, and the like.
- cationic surfactants examples include cetylpyridinium chloride, benzalkonium chloride, and benzethonium chloride.
- nonionic surfactants are preferred, POE sorbitan fatty acid esters, POE hydrogenated castor oil, POE castor oil, POE POP block copolymers, polyethylene glycol fatty acid esters are more preferred, POE sorbitan fatty acid esters, More preferred are POE (40) hydrogenated castor oil, POE (60) hydrogenated castor oil, POE (3) castor oil, POE (10) castor oil, POE/POP block copolymers, and polyethylene glycol fatty acid esters.
- Commercially available surfactants can also be used. Surfactants may be used alone or in combination of two or more.
- the content of the surfactant in the ophthalmic composition according to the present embodiment is not particularly limited, and is appropriately set according to the type of surfactant, the application of the ophthalmic composition, the formulation form, and the like.
- the content of the surfactant is, for example, 0.001 to 3 w/v%, 0.005 to 1 w/v%, based on the total amount of the ophthalmic composition, from the viewpoint of exhibiting the effects of the third aspect of the present invention more remarkably.
- the content ratio of the surfactant to the component (A) is not particularly limited. It is appropriately set according to the use of the product, the formulation form, and the like.
- the content ratio of the surfactant to the component (A) from the viewpoint of further enhancing the effect of the third aspect of the present invention, for example, the total content of the component (A) contained in the ophthalmic composition according to the present embodiment is 1 Based on the parts by weight, the total content of the surfactant may be 0.001 to 30 parts by weight, 0.005 to 10 parts by weight, or 0.01 to 5 parts by weight.
- the pH of the ophthalmic composition according to this embodiment is not particularly limited as long as it is within a pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable range.
- the pH of the ophthalmic composition according to this embodiment may be, for example, 4.0 to 9.5, preferably 4.0 to 9.0, and more preferably 4.5 to 9.0. is more preferable, more preferably 4.5 to 8.5, even more preferably 5.0 to 8.5, particularly preferably 5.0 to 8.0, 5.3 ⁇ 7.5 is more particularly preferred, and 5.5 to 7.0 is most preferred.
- the ophthalmic composition according to the present embodiment can be adjusted to have an osmotic pressure ratio within a range acceptable to living organisms, if necessary.
- An appropriate osmotic pressure ratio can be appropriately set according to the application, formulation form, method of use, etc. of the ophthalmic composition, and can be, for example, 0.4 to 5.0, and 0.6 to 3.0. , more preferably 0.8 to 2.2, even more preferably 0.8 to 2.0.
- the osmotic pressure ratio is the ratio of the osmotic pressure of the sample to 286 mOsm (osmotic pressure of 0.9 w/v% sodium chloride aqueous solution) based on the 17th revision of the Japanese Pharmacopoeia, and the osmotic pressure is the osmotic pressure measurement method described in the Japanese Pharmacopoeia. (freezing point depression method).
- the standard solution for osmotic pressure ratio measurement (0.9 w/v% sodium chloride aqueous solution) was obtained by drying sodium chloride (Japanese Pharmacopoeia standard reagent) at 500 to 650 ° C. for 40 to 50 minutes and then placing it in a desiccator (silica gel).
- the viscosity of the ophthalmic composition according to this embodiment is not particularly limited as long as it is within a pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable range.
- the viscosity of the ophthalmic composition according to the present embodiment for example, the viscosity at 20 ° C.
- a rotational viscometer (TV-20 type viscometer, manufactured by Toki Sangyo Co., Ltd., rotor; 1 ° 34' ⁇ R24) is 1 It is preferably from 1 to 10,000 mPa s, more preferably from 1 to 8,000 mPa s, still more preferably from 1 to 1,000 mPa s, even more preferably from 1 to 100 mPa s, and from 1 to 20 mPa.
- ⁇ s is particularly preferred, and 1.5 to 10 mPa ⁇ s is most preferred.
- the ophthalmic composition according to this embodiment contains, in addition to the above components, an appropriate amount of a combination of components selected from various pharmacologically active components and physiologically active components within a range that does not impair the effects of the third aspect of the present invention.
- You may have The ingredients are not particularly limited, and examples thereof include active ingredients in ophthalmic drugs described in the 2017 edition of the Standards for Manufacturing and Marketing Approval of Over-the-Counter Drugs (supervised by the Japanese Society of Regulatory Science). Specific examples of components used in ophthalmic drugs include the following components.
- Antiallergic agents for example, cromoglycate sodium, tranilast, pemirolast potassium, acitazanolast, amlexanox, ibudilast and the like.
- Steroid agents for example, fluticasone propionate, fluticasone furoate, mometasone furoate, beclomethasone propionate, flunisolide and the like.
- Vitamins For example, ascorbic acid, sodium ascorbate and the like.
- Astringent For example, zinc white and the like.
- Others For example, sulfamethoxazole, sulfisoxazole, sulfisomidine and salts thereof and the like.
- additives are appropriately selected in accordance with conventional methods according to the use and formulation form, as long as the effects of the third present invention are not impaired. Alternatively, more than that may be used in combination and contained in an appropriate amount. Examples of such additives include various additives described in Pharmaceutical Excipient Encyclopedia 2016 (edited by Japan Pharmaceutical Excipients Association). Typical ingredients include the following additives.
- Carrier For example, an aqueous solvent such as water or hydrous ethanol.
- Chelating agents for example, ethylenediaminediacetic acid (EDDA), ethylenediaminetriacetic acid, ethylenediaminetetraacetic acid (EDTA), N-(2-hydroxyethyl)ethylenediaminetriacetic acid (HEDTA), diethylenetriaminepentaacetic acid (DTPA) and the like.
- Base For example, octyldodecanol, titanium oxide, potassium bromide, Plastibase and the like.
- pH adjuster for example, hydrochloric acid, acetic acid, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, triethanolamine, monoethanolamine, diisopropanolamine and the like.
- Thickeners other than cellulosic polymer compounds for example, guar gum; hydroxypropyl guar gum; gum arabic; karaya gum; xanthan gum; agar; Mucopolysaccharides (other than component (A)) of heparinoids, hyaluronic acid and salts thereof (sodium salts, etc.); starch; chitin and its derivatives; chitosan and its derivatives; carrageenan; Buffers other than component (C): For example, phosphate buffers, carbonate buffers, acetate buffers, lactate buffers, succinate buffers, citrate buffers, Tris buffers, AMPD buffers and the like.
- Stabilizers for example, edetic acid, edetate salts (edetate disodium, edetate calcium disodium, edetate trisodium, edetate tetrasodium), sodium formaldehyde sulfoxylate (Rongalite), aluminum monostearate, monostearate glycerin stearate, cyclodextrin, monoethanolamine, dibutylhydroxytoluene, sodium bisulfite, sodium pyrosulfite and the like.
- Preservatives e.g. quaternary ammonium salts of alkylpolyaminoethylglycines (e.g.
- benzalkonium chloride, benzethonium chloride, etc. chlorhexidine gluconate, polydronium chloride, sodium benzoate, ethanol, chlorobutanol, sorbic acid, potassium sorbate , sodium dehydroacetate, methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, butyl parahydroxybenzoate, oxyquinoline sulfate, phenethyl alcohol, benzyl alcohol, biguanide compounds (specifically, polyhexanide hydrochloride (polyhexamethylene biguanide ), Alexidine, etc.), Glokill (trade name of Rhodia), etc.
- Tonicity agents e.g.
- potassium chloride calcium chloride, sodium chloride, magnesium chloride, potassium acetate, sodium acetate, sodium bicarbonate, sodium carbonate, sodium thiosulfate, magnesium sulfate, glycerin, propylene glycol, sodium bisulfite, sodium sulfite etc.
- Sugar alcohols For example, xylitol, sorbitol, mannitol, glycerin and the like. These may be d-, l- or dl-isomers.
- Oils For example, vegetable oils such as sesame oil, castor oil, soybean oil and olive oil; animal oils such as squalane; mineral oils such as liquid paraffin and petrolatum.
- the content of water is, for example, based on the total amount of the ophthalmic composition, from the viewpoint of exhibiting the effect of the third aspect of the present invention more remarkably.
- the content is preferably 80 w/v% or more and less than 100 w/v%, more preferably 85 w/v% or more and 99.5 w/v% or less, and 90 w/v% or more and 99.2 w/v% More preferably:
- the water used in the ophthalmic composition according to this embodiment may be pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable.
- examples of such water include distilled water, ordinary water, purified water, sterile purified water, water for injection, and distilled water for injection. Their definitions are based on the 17th revision of the Japanese Pharmacopoeia.
- the ophthalmic composition according to the present embodiment can be prepared by adding and mixing desired amounts of component (A), component (B), and, if necessary, other components to a desired concentration.
- component (A), component (B), and, if necessary, other components can be prepared by dissolving or dispersing these components in purified water, adjusting to a predetermined pH and osmotic pressure, and sterilizing by filtration sterilization or the like.
- the ophthalmic composition according to this embodiment can take various formulation forms depending on the purpose.
- Formulations include, for example, liquid formulations, gel formulations, semi-solid formulations (ointments, etc.), etc. Liquid formulations are preferred from the viewpoint of exhibiting the effects of the third aspect of the present invention more remarkably.
- the ophthalmic composition according to the present embodiment includes, for example, eye drops (also referred to as eye drops or eye drops. Eye drops include eye drops that can be dropped while wearing contact lenses), artificial tears, and eye washes. (Also referred to as eye wash or eye wash. Eye wash includes eye wash that can be washed while wearing contact lenses.), contact lens composition [contact lens wetting solution, contact lens care composition (contact lens disinfectant, contact lens preservative, contact lens cleaning agent, contact lens cleaning and preserving agent), contact lens packaging solution, etc.].
- contact lens includes hard contact lenses and soft contact lenses (both ionic and non-ionic, including both silicone hydrogel contact lenses and non-silicone hydrogel contact lenses).
- the ophthalmic composition according to the present embodiment is preferably an eye drop (including an eye drop that can be instilled while wearing contact lenses), since the effect of the third aspect of the present invention can be exhibited more remarkably.
- the ophthalmic composition according to the present embodiment is an eye drop
- the usage and dosage are not particularly limited as long as they are effective and have few side effects.
- a method of using 1 to 3 drops, 1 to 2 drops, or 2 to 3 drops at a time, 2 to 4 times, or 5 to 6 times a day can be exemplified.
- the ophthalmic composition according to this embodiment is provided in an arbitrary container.
- the container for containing the ophthalmic composition according to this embodiment is not particularly limited, and may be made of glass or plastic, for example. It is preferably made of plastic. Examples of plastics include polyethylene terephthalate (PET), polyarylate, polyethylene naphthalate, polycarbonate, polyethylene, polypropylene, polyimide, copolymers of these monomers, and mixtures of two or more thereof. Preferred is polyethylene terephthalate.
- PET polyethylene terephthalate
- the container containing the ophthalmic composition according to the present embodiment may be a transparent container in which the inside of the container is visible, or an opaque container in which the inside of the container is difficult to be seen. A transparent container is preferred.
- the "transparent container” includes both a colorless transparent container and a colored transparent container.
- a nozzle may be attached to the container containing the ophthalmic composition according to the present embodiment.
- the material of the nozzle is not particularly limited, and may be, for example, glass or plastic. It is preferably made of plastic. Examples of plastics include polybutylene terephthalate, polyethylene, polypropylene, polyethylene terephthalate, polyethylene naphthalate, copolymers of monomers constituting these, and mixtures of two or more of these.
- the material of the nozzle is preferably polypropylene, polyethylene, polyethylene terephthalate, polybutylene terephthalate, or polyethylene naphthalate, more preferably polyethylene, from the viewpoint of further enhancing the effects of the third aspect of the present invention.
- the container containing the ophthalmic composition according to the present embodiment may be of a multi-dose type that contains multiple doses, or may be of a unit dose type that contains a single dose.
- the ophthalmic composition according to the present embodiment is preferably filled in a container having an internal volume of 4 to 30 mL, more preferably filled in a container having an internal volume of 5 to 20 mL. More preferably, it is packed in a container of 6 to 16 mL, and even more preferably packed in a container with an internal volume of 10 to 15 mL. Also, it may be filled in a container with an internal volume of 0.1 to 3 mL, or may be filled in a container with an internal volume of 0.2 to 1 mL.
- the third invention will be specifically described below based on test examples, but the third invention is not limited to these.
- the sodium chondroitin sulfate used in the test examples below is as follows, and the sodium chondroitin sulfate having a weight-average molecular weight of about 56,000 is derived from sharks. Chondroitin sulfate sodium weight average molecular weight about 56000: Seikagaku Corporation; grade NK Weight average molecular weight about 28000: Seikagaku Corporation; grade ND-K Weight average molecular weight about 25000: Maruha Nichiro Co., Ltd.;
- one drop of the above eye drop was applied to each of the left and right eyes of 6 subjects with naked eyes, and a 10 cm line was drawn for each of the "uncomfortable irritation” and "burning sensation” felt at the time of eye drop.
- the subjective symptom survey sheet the "unpleasant stimulus” and “burning sensation” felt by the subject were set to 0 cm when they were not felt at all, and 10 cm when they were felt very strongly.
- the degree of "burning sensation” was checked, and the length (mm) was measured as the degree of intensity of subjective symptoms, and this was used as the score for each item.
- Each item was evaluated by calculating the average score of 6 subjects. Based on the obtained values, the improvement rate of the VAS value was calculated using the following formula (I).
- the comparative example corresponding to Example 1-1 is Comparative Example 1-1
- the comparative example corresponding to Example 1-2 is Comparative Example 1-2.
- Formula (I): VAS improvement rate (%) ⁇ (VAS value of corresponding comparative example - VAS value of example) / VAS value of corresponding comparative example ⁇ x 100 The results are also shown in Table 30.
- Test Example 2 Measurement test of the amount of residual liquid in the eyedropper bottle
- Each ophthalmic composition was prepared according to a conventional method with the composition shown in Tables 31 and 32, and used as a test solution.
- the unit of each component in Tables 31 and 32 is w/v% unless otherwise specified in the table.
- a 10 mL PET eye drop bottle was tared and filled with 5 mL of each test solution.
- the weight of each eyedropper bottle after each filled test solution is drained is measured, and the remaining liquid amount (g) is calculated according to the following formula (II). ) was used to calculate the rate of improvement of the residual liquid amount relative to the residual liquid amount of the test solution 2-1.
- test solution 2-2 When sodium chondroitin sulfate having a weight-average molecular weight of about 56,000 coexists with test solution 2-1 containing menthol, the amount of residual liquid decreases, and the ophthalmic composition in the eyedropper bottle can be used up. (test solution 2-2).
- test solution 2-2 containing menthol and sodium chondroitin sulfate having a weight average molecular weight of about 56,000 was further added with neostigmine methyl sulfate, allantoin, dipotassium glycyrrhizinate, tocopherol acetate, retinol palmitate, aminoethylsulfonic acid or hydroxy It was confirmed that when ethyl cellulose coexisted, the amount of residual liquid was further reduced and the ophthalmic composition in the eye drop bottle could be used up more easily (test solutions 2-3 to 2-9).
- Each ophthalmic composition was prepared according to a conventional method with the composition shown in Tables 33 and 34, and used as a test solution.
- the unit of each component in Tables 33 and 34 is w/v % except as specified in the table.
- 10 mL of each test solution was filled in a glass bottle (10 mL) and irradiated at 35° C. for 96 hours at an ultraviolet light intensity of 765 (W/m 2 ) using SUNTESTER XLS+ (manufactured by Toyo Seiki Co., Ltd., 1700 W xenon air-cooled lamp light source).
- Viscosity reduction rate (%) ⁇ (Viscosity of each test solution before light irradiation (mPa s) - Viscosity after light irradiation of each test solution (mPa s)) / Before light irradiation of each test solution Viscosity (mPa s) ⁇ ⁇ 100
- Viscosity reduction improvement rate (%) ⁇ (viscosity reduction rate of test solution 3-2 - viscosity reduction rate of each formulation example) / viscosity reduction rate of test solution 3-2 ⁇ x 100
- Tables 33 and 34 the results are also shown in Tables 33 and 34. Incidentally, the smaller the value of the viscosity reduction rate, the smaller the change in viscosity caused by light, indicating that the ophthalmic composition maintains
- test solution 3-2 When sodium chondroitin sulfate having a weight-average molecular weight of about 56,000 was added to the test solution 3-1 containing menthol, the viscosity tended to decrease significantly (test solution 3-2). .
- test solution 3-2 in which sodium chondroitin sulfate having a weight average molecular weight of about 56,000 and menthol coexist, neostigmine methyl sulfate, allantoin, zinc sulfate, panthenol, potassium aspartate, or aminoethylsulfonic acid coexisted, respectively.
- test solutions 3-3 to 3-8 it was confirmed that the decrease in viscosity was remarkably improved, and the stability of the ophthalmic composition against ultraviolet irradiation was improved.
- Each ophthalmic composition was prepared according to a conventional method with the composition shown in Tables 35 and 36, and used as a test solution.
- the unit of each component in Tables 35 and 36 is w/v % unless otherwise specified in the table.
- the viscosity of each test solution (600 ⁇ L) after preparation was measured at 34° C. using a cone-plate measuring jig (CP50-1, d: 0.102 mm) in a rheometer (MCR302 (manufactured by AntonPaar)). Viscosity versus shear rate was measured.
- the viscosity ratio of the test solution 4-2 was calculated based on the viscosity of the test solution 4-1 being 1.
- the viscosity reduction rate (%) relative to test solution 4-2 was calculated using the following formula (VI). Note that the shear rate of 10000 (1/s) is assumed to be the blink rate.
- the viscosity at a shear rate of 10,000 (1/s) indicates the viscosity at the time of blinking, and a decrease in this value indicates that a feeling of discomfort is less likely to be felt at the time of blinking and that blinking is easier.
- Viscosity reduction rate (%) (1-viscosity of each test solution (mPa s)/viscosity of test solution 4-2 (mPa s)) x 100 The results are also shown in Tables 35 and 36.
- test solution 4-2 in which sodium chondroitin sulfate having a weight average molecular weight of about 56,000 and menthol coexist, was further added with tetrahydrozoline hydrochloride, neostigmine methyl sulfate, allantoin, dipotassium glycyrrhizinate, zinc sulfate, chlorpheniramine maleate, and bread. It was confirmed that the viscosity at a shear rate of 10,000 (1/s) significantly decreased when tenol, potassium aspartate, or aminoethylsulfonic acid coexisted.
- Eye drops and artificial tears are prepared by conventional methods according to the formulations shown in Tables 38 to 41 below.
- Tables 38 to 41 below the unit of the amount of each component is w/v%, except for those specified in the tables. ⁇ 16,28 are artificial tears.
- Formulation Examples 1 to 32 were filled in a polyethylene terephthalate container (capacity 15 mL), and Formulation Examples 1' to 32' were equipped with a nozzle made of polyethylene, and the innermost layer was equipped with a nozzle made of polybutylene terephthalate.
- Formulation Examples 1'' to 32'' were obtained by forming the innermost layer, and Formulation Examples 1'' to 32'' were obtained by attaching a nozzle made of polyethylene naphthalate to the innermost layer.
Abstract
Description
第1の本発明は、眼科組成物に関する。
[1]
重量平均分子量が4万~7万であるコンドロイチン硫酸及びその塩からなる群より選択される少なくとも1種を含有する、目の乾燥抑制用眼科組成物。
[2]
重量平均分子量が4万~7万であるコンドロイチン硫酸及びその塩からなる群より選択される少なくとも1種を含有する、コンタクトレンズの乾燥抑制用眼科組成物。
[3]
抗炎症剤、ビタミンA類、ビタミンB類、ビタミンE類、アミノエチルスルホン酸及びその塩、アスパラギン酸及びその塩、ネオスチグミン及びその塩、並びにセルロース系高分子化合物からなる群より選択される少なくとも1種を更に含有する、[1]又は[2]に記載の眼科組成物。
[2-1]
重量平均分子量が4万~7万であるコンドロイチン硫酸及びその塩からなる群より選択される少なくとも1種と、ビタミンA類並びにアミノエチルスルホン酸及びその塩からなる群より選択される少なくとも1種とを含有する、眼科組成物。
[2-2]
重量平均分子量が4万~7万であるコンドロイチン硫酸及びその塩からなる群より選択される少なくとも1種と、抗炎症剤、ビタミンA類、ビタミンB類、ビタミンE類、アミノエチルスルホン酸及びその塩、アスパラギン酸及びその塩、ネオスチグミン及びその塩、並びにセルロース系高分子化合物からなる群より選択される少なくとも1種とを含有する、眼科組成物。
<標準試料調製>
コンドロイチン硫酸又はその塩5mgに、0.1M硝酸ナトリウム水溶液10mLを加え、室温で緩やかに攪拌し、完全に溶解させたもの。
<重量平均分子量の測定条件>
装置 :ゲル浸透クロマトグラフ-多角度光散乱計
検出器 :示差屈折率検出器(Wyatt Technology製 Optilab rEX)
多角度光散乱検出器(Wyatt Technology製 DAWN HELEOS)
カラム :Shodex OHpak SB-806M HQ 2本(φ7.8mm×30cm、昭和電工製)
溶媒 :0.1M硝酸ナトリウム水溶液
流速 :0.7mL/min
カラム温度 :23℃
検出器温度 :23℃
注入量 :0.2mL
データ処理 :Wyatt Technology製データ処理システム(ASTRA)
上記の方法で算出されたコンドロイチン硫酸及びその塩の重量平均分子量は、4万~7万の範囲であれば特に制限されない。重量平均分子量の下限値としては、41000以上、42000以上、43000以上、44000以上、45000以上、46000以上、47000以上、48000以上、49000以上、及び50000以上が例示される。重量平均分子量の上限値としては、69000以下、68000以下、67000以下、66000以下、65000以下、64000以下、63000以下、62000以下、61000以下、及び60000以下が例示される。重量平均分子量の範囲としては、41000~69000、42000~68000、43000~67000、44000~66000、45000~65000、46000~64000、47000~63000、48000~62000、49000~61000、及び50000~60000が例示される。
抗炎症剤は、抗炎症作用又は消炎作用を有する化合物、及びその塩である。抗炎症剤は、医薬上、薬理学的に(製薬上)又は生理学的に許容されるものであれば、特に制限されない。
ビタミンA類は、医薬上、薬理学的に(製薬上)又は生理学的に許容されるものであれば、特に制限されない。ビタミンA類として具体的には、レチノール、レチナール、レチノイン酸及びこれらの誘導体、並びにこれらの塩が挙げられる。
ビタミンB類は、医薬上、薬理学的に(製薬上)又は生理学的に許容されるものであれば、特に制限されない。
ビタミンE類は、医薬上、薬理学的に(製薬上)又は生理学的に許容されるものであれば、特に制限されない。ビタミンE類の具体例としては、例えば、トコフェロール、トコトリエノール及びこれらの誘導体、並びにこれらの塩が挙げられる。トコフェロール及びトコトリエノールは、α-、β-、γ-、及びδ-のいずれであってもよく、またd体及びdl体のいずれであってもよい。
アミノエチルスルホン酸(タウリン)及びその塩は、医薬上、薬理学的に(製薬上)又は生理学的に許容されるものであれば、特に制限されない。
アスパラギン酸は、2-アミノブタン二酸とも称される酸性アミノ酸として公知の化合物である。アスパラギン酸及びその塩としては、医薬上、薬理学的に(製薬上)又は生理学的に許容されるものであれば、特に制限されない。アスパラギン酸は、L体、D体、DL体のいずれであってもよいが、好ましくはL体である。
ネオスチグミン及びその塩は、医薬上、薬理学的に(製薬上)又は生理学的に許容されるものであれば、特に制限されない。ネオスチグミンの塩としては、例えば、メチル硫酸ネオスチグミンが挙げられる。ネオスチグミン及びその塩としては、メチル硫酸ネオスチグミンが好ましい。
セルロース系高分子化合物は、医薬上、薬理学的に(製薬上)又は生理学的に許容されるものであれば、特に制限されない。
抗アレルギー剤:例えば、クロモグリク酸ナトリウム、トラニラスト、ペミロラストカリウム、アシタザノラスト、アンレキサノクス、イブジラスト等。
抗ヒスタミン剤:例えば、ジフェンヒドラミン又はその塩(例えば、塩酸ジフェンヒドラミン)、イプロヘプチン又はその塩(例えば、塩酸イプロヘプチン)、クロルフェニラミン又はその塩(例えば、マレイン酸クロルフェニラミン)、レボカバスチン又はその塩(例えば、塩酸レボカバスチン)、ケトチフェン又はその塩(例えば、フマル酸ケトチフェン)、ペミロラストカリウム、オロパタジン又はその塩(例えば、塩酸オロパタジン)等。
ステロイド剤:例えば、プロピオン酸フルチカゾン、フランカルボン酸フルチカゾン、フランカルボン酸モメタゾン、プロピオン酸ベクロメタゾン、フルニソリド等。
充血除去剤:例えば、塩酸テトラヒドロゾリン、硝酸テトラヒドロゾリン、塩酸ナファゾリン、硝酸ナファゾリン、エピネフリン、塩酸エピネフリン、塩酸エフェドリン、塩酸フェニレフリン、dl-塩酸メチルエフェドリン等。
眼筋調節薬剤:例えば、アセチルコリンと類似した活性中心を有するコリンエステラーゼ阻害剤、具体的にはトロピカミド、ヘレニエン、硫酸アトロピン、塩酸ピロカルピン等。
ビタミン類:例えば、アスコルビン酸、アスコルビン酸ナトリウム等。
アミノ酸類:例えば、L-アルギニン、グルタミン酸、グリシン、アラニン、リジン、γ-アミノ酪酸、γ-アミノ吉草酸、トリメチルグリシン及びそれらの塩等。
収斂剤:例えば、亜鉛華等。
その他:例えば、スルファメトキサゾール、スルフイソキサゾール、スルフイソミジン及びそれらの塩等。
担体:例えば、水、含水エタノール等の水性溶媒。
キレート剤:例えば、エチレンジアミン二酢酸(EDDA)、エチレンジアミン三酢酸、エチレンジアミン四酢酸(EDTA)、N-(2-ヒドロキシエチル)エチレンジアミン三酢酸(HEDTA)、ジエチレントリアミン五酢酸(DTPA)等。
基剤:例えば、オクチルドデカノール、酸化チタン、臭化カリウム、プラスチベース等。
pH調節剤:例えば、塩酸、酢酸、水酸化ナトリウム、水酸化カリウム、水酸化カルシウム、水酸化マグネシウム、トリエタノールアミン、モノエタノールアミン、ジイソプロパノールアミン等。
香料又は清涼化剤:例えば、メントール、メントン、カンフル、ボルネオール、ゲラニオール、シネオール、シトロネロール、カルボン、アネトール、オイゲノール、リモネン、リナロール、酢酸リナリル、チモール、シメン、テルピネオール、ピネン、カンフェン、イソボルネオール、フェンチェン、ネロール、ミルセン、ミルセノール、酢酸リナロール、ラバンジュロール、ユーカリ油、ベルガモット油、ペパーミント油、クールミント油、スペアミント油、ハッカ油、ウイキョウ油、ケイヒ油、ローズ油、樟脳油等。これらは、d体、l体又はdl体のいずれでもよい。
増粘剤:例えば、ポリビニルピロリドン、ポリビニルアルコール等のポリビニル系高分子化合物;カルボキシビニルポリマー;グアーガム;ヒドロキシプロピルグアーガム;アラビアゴム;カラヤガム;キサンタンガム;寒天;アルギン酸及びその塩(ナトリウム塩等);ヘパリン類似物質、ヘパリン、ヘパリン硫酸、ヘパラン硫酸、ヘパリノイド、ヒアルロン酸及びその塩(ナトリウム塩等)のムコ多糖類;デンプン;キチン及びその誘導体;キトサン及びその誘導体;カラギーナン;ブドウ糖等の単糖類等。
安定化剤:例えば、エデト酸、エデト酸塩類(エデト酸二ナトリウム、エデト酸カルシウム二ナトリウム、エデト酸三ナトリウム、エデト酸四ナトリウム)、ナトリウムホルムアルデヒドスルホキシレート(ロンガリット)、モノステアリン酸アルミニウム、モノステアリン酸グリセリン、シクロデキストリン、モノエタノールアミン、ジブチルヒドロキシトルエン、亜硫酸水素ナトリウム、ピロ亜硫酸ナトリウム等。
防腐剤:例えば、アルキルポリアミノエチルグリシン類第四級アンモニウム塩(例えば、塩化ベンザルコニウム、塩化ベンゼトニウム等)、グルコン酸クロルヘキシジン、塩化ポリドロニウム、塩化亜鉛、安息香酸ナトリウム、エタノール、クロロブタノール、ソルビン酸、ソルビン酸カリウム、デヒドロ酢酸ナトリウム、パラオキシ安息香酸メチル、パラオキシ安息香酸エチル、パラオキシ安息香酸プロピル、パラオキシ安息香酸ブチル、硫酸オキシキノリン、フェネチルアルコール、ベンジルアルコール、ビグアニド化合物(具体的には、塩酸ポリヘキサニド(ポリヘキサメチレンビグアニド)、アレキシジン等)、グローキル(ローディア社製 商品名)等。
等張化剤:例えば、塩化カリウム、塩化カルシウム、塩化ナトリウム、塩化マグネシウム、酢酸カリウム、酢酸ナトリウム、炭酸水素ナトリウム、炭酸ナトリウム、チオ硫酸ナトリウム、硫酸マグネシウム、グリセリン、プロピレングリコール、亜硫酸水素ナトリウム、亜硫酸ナトリウム等。
糖アルコール類:例えば、キシリトール、ソルビトール、マンニトール、グリセリン等。これらはd体、l体又はdl体のいずれでもよい。
油類:例えば、ゴマ油、ヒマシ油、ダイズ油、オリーブ油等の植物油;スクワラン等の動物油;流動パラフィン、ワセリン等の鉱物油等。
コンドロイチン硫酸ナトリウム
重量平均分子量約56000 :生化学工業株式会社;グレード N-K
重量平均分子量約28000 :生化学工業株式会社;グレード ND-K
重量平均分子量約25000 :マルハニチロ株式会社;局外規コンドロイチン硫酸ナトリウム
生理食塩水(株式会社大塚製薬工場)に、重量平均分子量が約25000のコンドロイチン硫酸ナトリウム(マルハニチロ株式会社;局外規コンドロイチン硫酸ナトリウム)又は重量平均分子量が約56000のコンドロイチン硫酸ナトリウム(生化学工業株式会社;グレード N-K)をそれぞれ0.5w/v%又は3w/v%となるように溶解させて、各被験物質を調製した。
長野らの方法(あたらしい眼科、13(2)、267-270、1996)に準拠し、5群(n=5)に群分けしたウサギ(日本白色家兎(北山ラベス))に全身麻酔を施した後、手袋の指部分をリング状にしたものを左右の眼球に装着し、強制的に開瞼させた。開瞼直後の各群のウサギの両眼に被験物質を一眼当たり100μLとなるように点眼し、開瞼させた状態で3時間放置した。眼表面に1%メチレンブルー溶液を50μL滴下して染色し、生理食塩水で洗浄した。眼表面から角膜を摘出した後、メチレンブルー色素を抽出し、マイクロプレートリーダー Multiskan GO(サーモフィッシャーサイエンティフィック株式会社)を用いて660nmにおける吸光度を測定した。結果を図1に示す。なお、目の乾燥によって角膜障害が形成され、角膜表面上に付着する色素量が増加することから、吸光度の値が高いほど目が乾燥していると評価できる。
表1に示す組成で常法に従い各眼科組成物を調製し、試験溶液とした。表1における各成分の単位はw/v%である。なお、試験例2及び以下の試験例においては、コンドロイチン硫酸ナトリウムは、重量平均分子量が約28000のもの(生化学工業株式会社;グレード ND-K)及び約56000のもの(生化学工業株式会社;グレード N-K)を使用した。
12ウェルプレート(BD Falcon、No.35-3043)にリン酸緩衝生理食塩水(塩化ナトリウム0.60%、リン酸水素ナトリウム(12水和物)0.60%、リン酸二水素ナトリウム(2水和物)0.05%、pH7.4±0.1)を4mLずつ分注した。コンタクトレンズ(アキュビューオアシス(ジョンソンエンドジョンソン株式会社))を各ウェルに1枚ずつ浸漬し、4時間以上室温で静置した。12ウェルプレートにリン酸緩衝生理食塩水及び各試験溶液を4mLずつ分注した。コンタクトレンズの水分をリントフリーペーパーで軽く拭き取って浸漬し、15分間静置した。ビーカーにリン酸緩衝生理食塩水を100mL分注した。浸漬しておいたコンタクトレンズをリン酸緩衝生理食塩水で軽くすすぎ、リントフリーペーパーを用いて水分を除去した。スライドガラス上にコンタクトレンズを乗せ、接触角測定装置(固液界面解析システム DropMaster500(協和界面科学株式会社))を用いて、リン酸緩衝生理食塩液3μlを滴下後0.10秒における接触角を測定した。結果を表1に示す。なお、接触角が低いほどコンタクトレンズの濡れ性が良好で、コンタクトレンズへの親和性が高いと評価できる。
12ウェルプレート(BD Falcon、No.35-3043)にリン酸緩衝生理食塩水(塩化ナトリウム0.60%、リン酸水素ナトリウム(12水和物)0.60%、リン酸二水素ナトリウム(2水和物)0.05%、pH7.4±0.1)を4mLずつ分注した。コンタクトレンズ(アキュビューオアシス(ジョンソンエンドジョンソン株式会社))を各ウェルに2枚ずつ浸漬し、4時間以上室温で静置した。コンタクトレンズの水分をリントフリーペーパーで軽く拭き取った後、リン酸緩衝生理食塩水及び上記表1記載の各試験溶液を4mLずつ分注した12ウェルプレートにコンタクトレンズをそれぞれ浸漬し、室温で24時間静置した。コンタクトレンズの水分をリントフリーペーパーで軽く拭き取って、塩化コバルト(II)の色の比較原液(和光純薬工業株式会社、販売元コード:031-19041)を2mLずつ分注した12ウェルプレートに浸漬し、室温、200rpmの条件で5分間振盪した。コンタクトレンズの水分をリントフリーペーパーで軽く拭き取って、カバーガラスの上に載せた直後(0分)、載せた後5分、15分及び30分の各時点におけるソフトコンタクトレンズの着色を観察した。なお、本試験例においては、コンタクトレンズが乾燥すると青色に着色する。以下の基準に従って、着色の有無を評価した結果を表2に示す。
A:着色なし
B:わずかに着色(コンタクトレンズ表面全体の30%未満)
C:明らかに着色(コンタクトレンズ表面全体の30%以上)
表3に示す組成で常法に従い各眼科組成物を調製し、試験溶液とした。表3における各成分の単位は表中に明記したもの以外はw/v%である。なお、試験例4及び以下の試験例においては、パルミチン酸レチノールは174万IU/gのものを使用した。生理食塩水2mLに4時間以上浸漬したコンタクトレンズ(アキュビューアドバンス(ジョンソンエンドジョンソン株式会社))の表面の水分をリントフリーペーパーにてよくふき取った後、調製した各眼科組成物の液滴(約1μL)を滴下し、自動接触角計(固液界面解析システム Drop Master、DM-A501(協和界面科学株式会社))を使用して、滴下0.1秒後におけるコンタクトレンズに対する接触角(静的接触角)を測定した。各眼科組成物について接触角の測定を3回行い、その平均値を算出して各眼科組成物の接触角とした。結果を表3に示す。なお、接触角が低いほどコンタクトレンズの濡れ性が良好でコンタクトレンズへの親和性が高いと評価することができる。
表4に示す組成で常法に従い各眼科組成物を調製し、試験溶液とした。表4における各成分の単位はw/v%である。調製した各眼科組成物の液滴(約1μL)をステンレス製金属板(ヘルールキャップ TypeCLF-B)に滴下し、自動接触角計(固液界面解析システム Drop Master、DM-A501(協和界面科学株式会社))を使用して、滴下0.1秒後における金属に対する接触角(静的接触角)を測定した。各眼科組成物について接触角の測定を3回行い、その平均値を算出して各眼科組成物の接触角とした。結果を表4に示す。
表5に示す組成で常法に従い各眼科組成物を調製し、試験溶液とした。表5における各成分の単位は表中に明記したもの以外はw/v%である。Staphylococcus aureus(ATCC6538)を、ソイビーン・カゼイン・ダイジェスト斜面培地の表面に接種して、33℃で24時間培養した。培養菌体を白金耳で無菌的に採取し、適量の滅菌生理食塩水に浮遊させて、約1×107CFU/mLの生菌を含む細菌浮遊液を調製した。なお、浮遊液の生菌数は、別途培養して計測した。次に、材質がPETである15mLのコニカルチューブ(CORNING社)に、調製した各眼科組成物を10mLずつ充填した。これらの各眼科組成物に、生菌数(最終濃度)が約105CFU/mLとなるように、Staphylococcus aureus菌液(生理食塩水で懸濁)を接種し、よく攪拌して試料とした。菌を含む試料を遮光下23℃で3日間保存した。その後、菌を含む試料を計数に適切な濃度となるように調整し、3MTM ペトリフィルムTM 生菌数迅速測定用プレート(RACプレート)上に1mL播種し、33℃にて2日間培養後、観察されたコロニー数をカウントすることにより生菌数を求めた。接種直後の生菌数と、3日間保存後の試料中の生菌数を比較し、菌数の減少量をLog Reductionとして算出した。さらに算出したLog Reductionについて、下記の評価基準に従って十分な保存効力を有しているかを判定した。なお、初期菌数計数のための菌の培養は、33℃にて2日間実施した。結果を表5に示す。
評価基準
Log Reduction<0.7:D
0.7≦Log Reduction<0.8:C
0.8≦Log Reduction<0.9:B
0.9≦Log Reduction:A
表6に示す組成で常法に従い各眼科組成物を調製し、試験溶液とした。表6における各成分の単位は表中に明記したもの以外はw/v%である。調製後の各眼科組成物(600μL)の粘度について、レオメーター(MCR302(AntonPaar社製))にてコーンプレート型測定治具(CP50-1、d:0.102mm)を用いて、34℃でのせん断速度に対する粘度を測定した。せん断速度10000(1/s)での粘度(mPa・s)に関して、下記式に従い試験溶液4又は5(コンドロイチン硫酸ナトリウム単独配合製剤)に対する試験溶液12又は13の粘度低下率を算出した。なお、粘度が低下するということは、応力を与えた場合に粘度が低下することを示しており、また、せん断速度10000(1/s)は瞬目速度を想定している。せん断速度10000(1/s)での粘度の測定によって、瞬目時における眼内の製剤の粘度変化が評価できる。瞬目時の粘度が低下するということは、瞬目がしやすく、また瞬目時の違和感を感じにくいことを表す。
(式)粘度低下率(%)=(1-試験溶液12又は13の粘度/対応する試験溶液の粘度)×100
なお、対応する試験溶液は試験溶液12に対しては試験溶液5であり、試験溶液13に対しては試験溶液4である。
結果を表6に示す。
表7に示す組成で常法に従い各眼科組成物を調製し、試験溶液とした。表7における各成分の単位は表中に明記したもの以外はw/v%である。10mL容量のガラスヘッドスペースバイアル(ジーエルサイエンス社)に各眼科組成物を10mLずつ充填し、光安定性試験装置(LT-120A-WCD(ナガノサイエンス社製))にて、D65蛍光ランプを光源として、室温25℃の下、照度4000lx/hで積算照度120万lxとなるまで照射した。照射前後の各眼科組成物(600μL)について、レオメーター(MCR302(AntonPaar社))にて、コーンプレート型測定治具(CP50-1、d:0.102mm)を用いて、34℃でのせん断速度(1~10000(1/s))に対する粘度を測定した。そして、せん断速度1000(1/s)での粘度(mPa・s)を用いて、下記式に従い、試験前後の粘度安定性を評価した。結果を表7に示す。なお、粘度変化率の値が小さい程、光による粘度変化が生じず、眼科組成物が物性的に同等に保たれていることを示す。
(式)粘度変化率(%)={(各眼科組成物の光照射前粘度-各眼科組成物の光照射後粘度)/各眼科組成物の光照射前粘度}×100
表8に示す組成で常法に従い各眼科組成物を調製し、試験溶液とした。表8における各成分の単位はw/v%である。24wellプレート(コーニング社)に各眼科組成物を各1mLずつ添加し、乾熱乾燥機(池田理化社)にて60℃で2日間保管後、プレート内の各ウェルにおける析出の様子について目視にて観察し、以下の評価基準に従って析出物の発生について評価を行った。結果を表8に示す。
<析出物発生の評価基準>
ウェルの底面に明確に確認できる析出物があり、析出物の底面に占める割合が1/2以上である:+++
ウェルの底面に明確に確認できる析出物があり、析出物の底面に占める割合が1/3以上1/2未満である:++
ウェルの底面に明確に確認できる析出物があり、析出物の底面に占める割合が1/3未満である:+
析出物がない:-
表9に示す組成で常法に従い各眼科組成物を調製し、試験溶液とした。表9における各成分の単位は表中に明記したもの以外はw/v%である。10mL容量のガラスヘッドスペースバイアルに各眼科組成物を10mLずつ充填し、光安定性試験装置(LT-120A-WCD(ナガノサイエンス社製))にて、D65蛍光ランプを光源として、室温25℃の下、照度4000lx/hで積算照度120万lxとなるまで照射した。試験後、分光測色計(CM3500d:コニカミノルタ社製)にて光照射前後の各眼科組成物について、色差変化(b*値)を測定し、下記式1に従って、光照射前後での眼科組成物の外観(色)の変化(色差変化度;Δb*値)を算出し、さらに下記式2に従って色差変化低下率を算出した。結果を表9に示す。なお、Δb*値が小さいほど、眼科組成物の外観(色)の変化(着色)が抑制されていることを示す。
(式1)Δb*=光照射前の各眼科組成物のb*値-光照射後の各眼科組成物のb*値
(式2)色差変化低下率(%)={1-(試験溶液12のΔb*/試験溶液19のΔb*)}×100
表10に示す組成で常法に従い各眼科組成物を調製し、試験溶液とした。表10における各成分の単位は表中に明記したもの以外はw/v%である。各眼科組成物をガラス瓶(10mL)に10mL充填し、35℃において、SUNTESTER XLS+(東洋精機社製、1700W キセノン空冷ランプ光源)を用いて、紫外光照度765(W/m2)、96時間照射した。その後、各眼科組成物を25℃で十分に恒温化させ、分光測色計(CM3500d:コニカミノルタ社製)を用いて、紫外線照射前後の各眼科組成物の色差変化(b*値)を測定し、下記式1に従って、紫外線照射前後での眼科組成物の外観(色)の変化(色差変化度;Δb*値)を算出し、さらに下記式2に従って色差変化低下率を算出した。結果を表9に示す。なお、Δb*値が小さいほど、眼科組成物の外観(色)の変化(着色)が抑制されていることを示す。
(式1)Δb*=紫外線照射前のb*値-紫外線照射後のb*値
(式2)色差変化低下率(%)={1-(試験溶液9又は12のΔb*/対応する試験溶液のΔb*)}×100
なお、対応する試験溶液は試験溶液9に対しては試験溶液20であり、試験溶液12に対しては試験溶液19である。
表11に示す組成で常法に従い各眼科組成物を調製し、試験溶液とした。表11における各成分の単位は表中に明記したもの以外はw/v%である。10mL容量のガラスヘッドスペースバイアルに各眼科組成物を10mL充填し、60℃恒温庫にて3週間静置保管した(熱加速試験)。その後、各眼科組成物を25℃で十分に恒温化させ、分光測色計(CM3500d:コニカミノルタ社製)を用いて、熱加速試験前後の各眼科組成物の色差変化(L*値)を測定し、下記式1に従って、熱加速試験前後での眼科組成物の外観(透明度)の変化(ΔL*)を算出し、さらに下記式2に従って透明度差変化低下率を算出した。結果を表11に示す。なお、L*値は透明度を示す指標として利用されている。このためΔL*値が小さいほど、製剤の外観(透明度)の変化が抑制されていることを示す。
(式1)ΔL*=熱加速試験前のL*値-熱加速試験後のL*値
(式2)透明度変化低下率(%)={1-(試験溶液11又は12のΔL*/対応する試験溶液のΔL*)}×100
なお、対応する試験溶液は試験溶液11に対しては試験溶液21であり、試験溶液12に対しては試験溶液19である。
表12に示す組成で常法に従い各眼科組成物を調製し、試験溶液とした。表12における各成分の単位は表中に明記したもの以外はw/v%である。96ウェルプレート(コーニング社)にヒト角膜上皮細胞株HCE-T細胞を1×105cells/mLの濃度で各ウェルに対し、100μLずつ播種し、37℃、湿度90%、5%CO2の濃度に設定したCO2インキュベーターでコンフルエントになるまで培養した。増殖培地としては、DMEM/F12(ThermoFisher社)にFCS(DSファーマ社)を5%、DMSO(和光純薬社)を0.5%、recombinant human EGF(R&D社)を10ng/mL、insulin solution human(SIGMA社)を5μg/mLとなるように添加したものを用いた。2~4日後に細胞がコンフルエントになったら各ウェルから増殖培地を吸引除去し、各眼科組成物を50μLずつ各ウェルに加え、37℃、5%CO2の条件下で15分間インキュベートした。各ウェルから各眼科組成物を吸引除去した後、クリーンベンチ内で20分放置することにより乾燥ストレスを与え、その後、生細胞数を評価した。生細胞数の評価は、各ウェルに細胞数測定試薬Cellcountingkit-8(同仁化学社)を培地100μLに対して10μL入れて、37℃、5%CO2、湿度90%の条件下で培養を2~3時間培養した後、吸光度計MOLECULAR DEVICES社)を用いて、450nmでの測定することによって行った。なお、吸光度の値が大きいほど、生細胞数が多いことを示す。結果を表12に示す。
表13に示す組成で常法に従い各眼科組成物を調製し、試験溶液とした。表13における各成分の単位はw/v%である。24ウェルプレート(コーニング社)にヒト角膜上皮細胞株HCE-T細胞を1×105cells/mLの濃度で各ウェルに対し、500μLずつ播種し、37℃、5%CO2の濃度に設定したCO2インキュベーターで培養した。増殖培地としては、DMEM/F12(ThermoFisher社)にFCS(DSファーマ社)を5%、DMSO(和光純薬社)を0.5%、recombinant human EGF(R&D社)を10ng/mL、insulin solution human(SIGMA社)を5μg/mLとなるように添加したものを用いた。2~4日後に細胞がコンフルエントになったら各ウェルから増殖培地を吸引除去し、各眼科組成物を50μLずつ各ウェルに加え、37℃、5%CO2の条件下で15分間インキュベートした。ガラスビーズ(アズワン社)を各ウェルに3又は4粒入れ、マイクロプレートシェーカー(Heidlph Instruments GmbH &Co.KG社)を用いて450rpmで1分間振とうした。上清とガラスビーズを取り除き細胞数測定試薬Cellcountingkit-8(同仁化学社)と培地が1:10で混合されている培地を500μL入れて、CO2インキュベーターで2時間培養した後、吸光度計(MOLECULAR DEVICES社)を用いて、450nmでの吸光度を測定した。細胞生存率は下記式にて算出した。
(式)細胞生存率(%)=(各処方における吸光度/コントロールの吸光度)×100
結果を表13に示す。
表14に示す組成で常法に従い各眼科組成物を調製し、試験溶液とした。表14における各成分の単位はw/v%である。10mL容量のPET製の点眼瓶の風袋の重量を測定し、各眼科組成物を5mL充填した。次に充填した各眼科組成物を出し切った後の各点眼瓶の重量を測定し、下記式1及び2に従って、残液量(g)及び試験溶液22の残液量に対する残液量の改善率(%)を算出した。
(式1)残液量(g)=眼科組成物を出し切った後の点眼瓶の重量-点眼瓶の風袋の重量
(式2)残液量の改善率(%)={1-(各試験溶液の残液量/試験溶液22の残液量)}×100
下記表15~19に記載の処方で、常法により点眼剤が調製される。なお、下記表15~19における各成分量の単位は、表中に明記したもの以外はw/v%である。
コンドロイチン硫酸又はその塩は酸性ムコ多糖の一種で、エネルギー代謝を促進させること、新陳代謝や細胞呼吸を促進して目の疲れを解消させること、涙液成分を補給すること等を目的として眼科製剤に配合されている(例えば、特許文献2-1)。
[特許文献]
[特許文献2-1]特開2011-148791号公報
[第2の本発明が解決しようとする課題]
コンドロイチン硫酸又はその塩の中でも特定の重量平均分子量を有するものを含有する眼科組成物では、光に曝露されるとその粘度が小さくなり、安定性が低下するという新たな課題が本発明者らによって見出された。第2の本発明は、特定の重量平均分子量を有するコンドロイチン硫酸又はその塩を含有しながら、光による粘度変化が抑制された安定な眼科組成物を提供することを目的とする。
本発明者らは、重量平均分子量が4万~7万であるコンドロイチン硫酸ナトリウムと特定の成分を含有した眼科組成物が、意外にも光による粘度変化を抑制することを見出した。
[1]
重量平均分子量が4万~7万であるコンドロイチン硫酸及びその塩からなる群より選択される少なくとも1種と、抗ヒスタミン剤、亜鉛塩、充血除去剤、ヒドロキシエチルセルロース及びその塩、並びにポリビニル系高分子化合物からなる群より選択される少なくとも1種とを含有する、眼科組成物。
[2]
抗ヒスタミン剤がクロルフェニラミン及びその塩からなる群より選択される少なくとも1種であり、充血除去剤がテトラヒドロゾリン及びその塩からなる群より選択される少なくとも1種であり、ポリビニル系高分子化合物がポリビニルピロリドンである、[1]に記載の眼科組成物。
第2の本発明によれば、特定の重量平均分子量を有するコンドロイチン硫酸又はその塩を含有しながら、光による粘度変化が抑制された安定な眼科組成物を提供することができる。
以下、第2の本発明を実施するための形態について詳細に説明する。ただし、第2の本発明は以下の実施形態に限定されるものではない。
コンドロイチン硫酸及びその塩は、医薬上、薬理学的に(製薬上)又は生理学的に許容されるものであれば、特に制限されない。
<標準試料調製>
コンドロイチン硫酸又はその塩5mgに、0.1M硝酸ナトリウム水溶液10mLを加え、室温で緩やかに攪拌し、完全に溶解させたもの。
<重量平均分子量の測定条件>
装置 :ゲル浸透クロマトグラフ-多角度光散乱計
検出器 :示差屈折率検出器(Wyatt Technology製 Optilab rEX)
多角度光散乱検出器(Wyatt Technology製 DAWN HELEOS)
カラム :Shodex OHpak SB-806M HQ 2本(φ7.8mm×30cm、昭和電工製)
溶媒 :0.1M硝酸ナトリウム水溶液
流速 :0.7mL/min
カラム温度 :23℃
検出器温度 :23℃
注入量 :0.2mL
データ処理 :Wyatt Technology製データ処理システム(ASTRA)
上記の方法で算出されたコンドロイチン硫酸及びその塩の重量平均分子量は、4万~7万の範囲であれば特に制限されない。重量平均分子量の下限値としては、41000以上、42000以上、43000以上、44000以上、45000以上、46000以上、47000以上、48000以上、49000以上、及び50000以上が例示される。重量平均分子量の上限値としては、69000以下、68000以下、67000以下、66000以下、65000以下、64000以下、63000以下、62000以下、61000以下、及び60000以下が例示される。重量平均分子量の範囲としては、41000~69000、42000~68000、43000~67000、44000~66000、45000~65000、46000~64000、47000~63000、48000~62000、49000~61000、及び50000~60000が例示される。
抗ヒスタミン剤は、抗ヒスタミン作用を有する化合物、及びその塩である。抗ヒスタミン剤は、医薬上、薬理学的に(製薬上)又は生理学的に許容されるものであれば、特に制限されない。
亜鉛塩は、医薬上、薬理学的に(製薬上)又は生理学的に許容されるものであれば、特に制限されない。
ヒドロキシエチルセルロース及びその塩は、医薬上、薬理学的に(製薬上)又は生理学的に許容されるものであれば、特に制限されない。
抗アレルギー剤:例えば、クロモグリク酸ナトリウム、トラニラスト、ペミロラストカリウム、アシタザノラスト、アンレキサノクス、イブジラスト等。
ステロイド剤:例えば、プロピオン酸フルチカゾン、フランカルボン酸フルチカゾン、フランカルボン酸モメタゾン、プロピオン酸ベクロメタゾン、フルニソリド等。
眼筋調節薬剤:例えば、アセチルコリンと類似した活性中心を有するコリンエステラーゼ阻害剤、具体的にはメチル硫酸ネオスチグミン、トロピカミド、ヘレニエン、硫酸アトロピン、塩酸ピロカルピン等。
消炎剤:例えば、サリチル酸メチル、サリチル酸グリコール、アラントイン、トラネキサム酸、リゾチーム、塩化リゾチーム、インドメタシン、プラノプロフェン、イブプロフェン、イブプロフェンピコノール、ケトプロフェン、フェルビナク、ベンダザック、ピロキシカム、ブフェキサマク、フルフェナム酸ブチル、イプシロン-アミノカプロン酸、塩化ベルベリン、硫酸ベルベリン、アズレンスルホン酸ナトリウム、グリチルリチン酸又はその塩(例えば、グリチルリチン酸二カリウム、グリチルリチン酸モノアンモニウム)等。
ビタミン類:例えば、酢酸レチノール、パルミチン酸レチノール、酢酸トコフェロール、フラビンアデニンジヌクレオチドナトリウム、シアノコバラミン、ピリドキシン塩酸塩、パンテノール、パントテン酸カルシウム、アスコルビン酸、アスコルビン酸ナトリウム等。
アミノ酸類:例えば、L-アルギニン、グルタミン酸、グリシン、アラニン、リジン、γ-アミノ酪酸、γ-アミノ吉草酸、トリメチルグリシン、タウリン、アスパラギン酸及びそれらの塩等。
収斂剤:例えば、亜鉛華等。
その他:例えば、スルファメトキサゾール、スルフイソキサゾール、スルフイソミジン及びそれらの塩等。
担体:例えば、水、含水エタノール等の水性溶媒。
キレート剤:例えば、エチレンジアミン二酢酸(EDDA)、エチレンジアミン三酢酸、エチレンジアミン四酢酸(EDTA)、N-(2-ヒドロキシエチル)エチレンジアミン三酢酸(HEDTA)、ジエチレントリアミン五酢酸(DTPA)等。
基剤:例えば、オクチルドデカノール、酸化チタン、臭化カリウム、プラスチベース等。
pH調節剤:例えば、塩酸、酢酸、水酸化ナトリウム、水酸化カリウム、水酸化カルシウム、水酸化マグネシウム、トリエタノールアミン、モノエタノールアミン、ジイソプロパノールアミン等。
香料又は清涼化剤:例えば、メントール、メントン、カンフル、ボルネオール、ゲラニオール、シネオール、シトロネロール、カルボン、アネトール、オイゲノール、リモネン、リナロール、酢酸リナリル、チモール、シメン、テルピネオール、ピネン、カンフェン、イソボルネオール、フェンチェン、ネロール、ミルセン、ミルセノール、酢酸リナロール、ラバンジュロール、ユーカリ油、ベルガモット油、ペパーミント油、クールミント油、スペアミント油、ハッカ油、ウイキョウ油、ケイヒ油、ローズ油、樟脳油等。これらは、d体、l体又はdl体のいずれでもよい。
増粘剤:例えば、メチルセルロース、エチルセルロース、ヒドロキシプロピルメチルセルロース、カルボキシメチルセルロースナトリウム等のセルロース系高分子化合物;グアーガム;ヒドロキシプロピルグアーガム;アラビアゴム;カラヤガム;キサンタンガム;寒天;アルギン酸及びその塩(ナトリウム塩等);ヘパリン類似物質、ヘパリン、ヘパリン硫酸、ヘパラン硫酸、ヘパリノイド、ヒアルロン酸及びその塩(ナトリウム塩等)のムコ多糖類;デンプン;キチン及びその誘導体;キトサン及びその誘導体;カラギーナン;ブドウ糖等の単糖類等。
安定化剤:例えば、エデト酸、エデト酸塩類(エデト酸二ナトリウム、エデト酸カルシウム二ナトリウム、エデト酸三ナトリウム、エデト酸四ナトリウム)、ナトリウムホルムアルデヒドスルホキシレート(ロンガリット)、モノステアリン酸アルミニウム、モノステアリン酸グリセリン、シクロデキストリン、モノエタノールアミン、ジブチルヒドロキシトルエン、亜硫酸水素ナトリウム、ピロ亜硫酸ナトリウム等。
防腐剤:例えば、アルキルポリアミノエチルグリシン類第四級アンモニウム塩(例えば、塩化ベンザルコニウム、塩化ベンゼトニウム等)、グルコン酸クロルヘキシジン、塩化ポリドロニウム、安息香酸ナトリウム、エタノール、クロロブタノール、ソルビン酸、ソルビン酸カリウム、デヒドロ酢酸ナトリウム、パラオキシ安息香酸メチル、パラオキシ安息香酸エチル、パラオキシ安息香酸プロピル、パラオキシ安息香酸ブチル、硫酸オキシキノリン、フェネチルアルコール、ベンジルアルコール、ビグアニド化合物(具体的には、塩酸ポリヘキサニド(ポリヘキサメチレンビグアニド)、アレキシジン等)、グローキル(ローディア社製 商品名)等。
等張化剤:例えば、塩化カリウム、塩化カルシウム、塩化ナトリウム、塩化マグネシウム、酢酸カリウム、酢酸ナトリウム、炭酸水素ナトリウム、炭酸ナトリウム、チオ硫酸ナトリウム、硫酸マグネシウム、グリセリン、プロピレングリコール、亜硫酸水素ナトリウム、亜硫酸ナトリウム等。
糖アルコール類:例えば、キシリトール、ソルビトール、マンニトール、グリセリン等。これらはd体、l体又はdl体のいずれでもよい。
油類:例えば、ゴマ油、ヒマシ油、ダイズ油、オリーブ油等の植物油;スクワラン等の動物油;流動パラフィン、ワセリン等の鉱物油等。
以下、試験例に基づいて第2の本発明を具体的に説明するが、第2の本発明はこれらに限定されるものではない。また、下記試験例で使用されるコンドロイチン硫酸ナトリウムは、下記のとおりであり、重量平均分子量56000のコンドロイチン硫酸ナトリウムはサメ由来である。
コンドロイチン硫酸ナトリウム
重量平均分子量約56000 :生化学工業株式会社;グレード N-K
重量平均分子量約28000 :生化学工業株式会社;グレード ND-K
重量平均分子量約25000 :マルハニチロ株式会社;局外規コンドロイチン硫酸ナトリウム
表20に示す組成で常法に従い各眼科組成物を調製し、試験溶液とした。表20における各成分の単位はw/v%である。10mL容量のガラスヘッドスペースバイアル(ジーエルサイエンス社)に各眼科組成物を10mLずつ充填し、光安定性試験装置(LT-120A-WCD(ナガノサイエンス社製))にて、D65蛍光ランプを光源として、室温25℃の下、照度4000lx/hで積算照度120万lxとなるまで照射した。照射前後の各眼科組成物(600μL)について、レオメーター(MCR302(AntonPaar社))にて、コーンプレート型測定治具(CP50-1、d:0.102mm)を用いて、34℃でのせん断速度(1~10000(1/s))に対する粘度を測定した。そして、せん断速度1000(1/s)での粘度(mPa・s)を用いて、下記式に従い、試験前後の粘度安定性を評価した。結果を表20に示す。なお、粘度変化率の値が小さい程、光による粘度変化が生じず、眼科組成物が物性的に同等に保たれているであることを示す。
(式)粘度変化率(%)={(各眼科組成物の光照射前粘度-各眼科組成物の光照射後粘度)/各眼科組成物の光照射前粘度}×100
表21に示す組成で常法に従い各眼科組成物を調製し、試験溶液とした。表21における各成分の単位はw/v%である。調製した各眼科組成物の液滴(約1μL)をステンレス製金属板(ヘルールキャップ TypeCLF-B)に滴下し、自動接触角計(固液界面解析システム Drop Master、DM-A501(協和界面科学株式会社))を使用して、滴下0.1秒後における金属に対する接触角(静的接触角)を測定した。各眼科組成物について接触角の測定を3回行い、その平均値を算出して各眼科組成物の接触角とした。結果を表21に示す。
表22に示す組成で常法に従い各眼科組成物を調製し、試験溶液とした。表22における各成分の単位はw/v%である。Staphylococcus aureus(ATCC6538)を、ソイビーン・カゼイン・ダイジェスト斜面培地の表面に接種して、33℃で24時間培養した。培養菌体を白金耳で無菌的に採取し、適量の滅菌生理食塩水に浮遊させて、約1×107CFU/mLの生菌を含む細菌浮遊液を調製した。なお、浮遊液の生菌数は、別途培養して計測した。次に、材質がPETである15mLのコニカルチューブ(CORNING社)に、調製した各眼科組成物を10mLずつ充填した。これらの各眼科組成物に、生菌数(最終濃度)が約105CFU/mLとなるように、Staphylococcus aureus菌液(生理食塩水で懸濁)を接種し、よく攪拌して試料とした。菌を含む試料を遮光下23℃で3日間保存した。その後、菌を含む試料を計数に適切な濃度となるように調整し、3MTM ペトリフィルムTM 生菌数迅速測定用プレート(RACプレート)上に1mL播種し、33℃にて2日間培養後、観察されたコロニー数をカウントすることにより生菌数を求めた。接種直後の生菌数と、3日間保存後の試料中の生菌数を比較し、菌数の減少量をLog Reductionとして算出した。さらに算出したLog Reductionについて、下記の評価基準に従って十分な保存効力を有しているかを判定した。なお、初期菌数計数のための菌の培養は、33℃にて2日間実施した。結果を表22に示す。
評価基準
Log Reduction<0.7:D
0.7≦Log Reduction<0.8:C
0.8≦Log Reduction<0.9:B
0.9≦Log Reduction:A
表23に示す組成で常法に従い各眼科組成物を調製し、試験溶液とした。表21における各成分の単位はw/v%である。調製後の各眼科組成物(600μL)の粘度について、レオメーター(MCR302(AntonPaar社製))にてコーンプレート型測定治具(CP50-1、d:0.102mm)を用いて、34℃でのせん断速度に対する粘度を測定した。せん断速度10000(1/s)での粘度(mPa・s)に関して、下記式に従い参考例2(コンドロイチン硫酸ナトリウム単独配合製剤)に対する実施例2の粘度低下率を算出した。なお、粘度が低下するということは、応力を与えた場合に粘度が低下することを示しており、瞬目時における粘度変化が評価できる。よって、瞬目時の粘度が低下するということは、瞬目がしやすく、また瞬目時の違和感を感じにくいことを表す。(式)粘度低下率(%)=(1-実施例2の粘度/参考例2の粘度)×100
結果を表23に示す。
表24に示す組成で常法に従い各眼科組成物を調製し、試験溶液とした。表24における各成分の単位はw/v%である。各眼科組成物をガラス瓶(10mL)に10mL充填し、35℃において、SUNTESTER XLS+(東洋精機社製、1700W キセノン空冷ランプ光源)を用いて、紫外光照度765(W/m2)、96時間照射した。その後、各眼科組成物を25℃で十分に恒温化させ、分光測色計(CM3500d:コニカミノルタ社製)を用いて、紫外線照射前後の各眼科組成物の色差変化(b*値)を測定し、下記式1に従って、紫外線照射前後での眼科組成物の外観の変化(色差変化度;Δb*値)を算出し、さらに下記式2に従って色差変化低下率を算出した。結果を表24に示す。なお、Δb*値が小さいほど、眼科組成物の外観(色)の変化(着色)が抑制されていることを表す。
(式1)Δb*=紫外線照射前のb*値-紫外線照射後のb*値
(式2)色差変化低下率(%)={1-(実施例1のΔb*/比較例1のΔb*)}×100
表25に示す組成で常法に従い各眼科組成物を調製し、試験溶液とした。表25における各成分の単位はw/v%である。24ウェルプレート(コーニング社)にヒト角膜上皮細胞株HCE-T細胞を1×105cells/mLの濃度で各ウェルに対し、500μLずつ播種し、37℃、5%CO2の濃度に設定したCO2インキュベーターで培養した。増殖培地としては、DMEM/F12(ThermoFisher社)にFCS(DSファーマ社)を5%、DMSO(和光純薬社)を0.5%、recombinant human EGF(R&D社)を10ng/mL、insulin solution human(SIGMA社)を5μg/mLとなるように添加したものを用いた。2~4日後に細胞がコンフルエントになったら各ウェルから増殖培地を吸引除去し、各眼科組成物を50μLずつ各ウェルに加え、37℃、5%CO2の条件下で15分間インキュベートした。ガラスビーズ(アズワン社)を各ウェルに3又は4粒入れ、マイクロプレートシェーカー(Heidlph Instruments GmbH &Co.KG社)を用いて450rpmで1分間振とうした。上清とガラスビーズを取り除き細胞数測定試薬Cellcountingkit-8(同仁化学社)と培地が1:10で混合されている培地を500μL入れて、CO2インキュベーターで2時間培養した後、吸光度計(MOLECULAR DEVICES社)を用いて、450nmでの吸光度を測定した。細胞生存率は下記式にて算出した。
(式)細胞生存率(%)=(各処方における吸光度/コントロールの吸光度)×100
結果を表25に示す。
下記表26~29に記載の処方で、常法により点眼剤が調製される。なお、下記表26~29における各成分量の単位は、表中に明記したもの以外はw/v%である。
コンドロイチン硫酸又はその塩は酸性ムコ多糖の一種で、エネルギー代謝を促進させること、新陳代謝や細胞呼吸を促進して目の疲れを解消させること、涙液成分を補給すること等を目的として眼科製剤に配合されている(例えば、特許文献3-1)。
[特許文献]
[特許文献3-1]特開2011-148791号公報
[第3の本発明が解決しようとする課題]
第3の本発明は、コンドロイチン硫酸又はその塩を含有する新たな眼科組成物を提供することを目的とする。
本発明者らは、メントールを配合した眼科組成物においては眼における不快な刺激や灼熱感が感じられることがあるのに対し、重量平均分子量が約56000であるコンドロイチン硫酸ナトリウムにメントールを含有した眼科組成物では、意外にもこれらが顕著に抑制されることを見出した。
[1]
重量平均分子量が4万~7万であるコンドロイチン硫酸及びその塩からなる群より選択される少なくとも1種と、メントールと、を含有する、眼科組成物。
[2]
ホウ酸及びその塩からなる群より選択される少なくとも1種を更に含有する、[1]に記載の眼科組成物。
[3]
クロロブタノールを更に含有する、[1]又は[2]に記載の眼科組成物。
[4]
充血除去剤、眼筋調節剤、抗炎症剤、抗ヒスタミン剤、ビタミンA類、ビタミンB類、ビタミンE類、アミノ酸及びその塩、並びにセルロース系高分子化合物からなる群より選択される少なくとも1種を更に含有する、[1]又は[2]に記載の眼科組成物。
第3の本発明によれば、メントールを含有しながら不快な刺激感が抑制された眼科組成物を提供することができる。
以下、第3の本発明を実施するための形態について詳細に説明する。ただし、第3の本発明は以下の実施形態に限定されるものではない。
コンドロイチン硫酸及びその塩は、医薬上、薬理学的に(製薬上)又は生理学的に許容されるものであれば、特に制限されない。
<標準試料調製>
コンドロイチン硫酸又はその塩5mgに、0.1M硝酸ナトリウム水溶液10mLを加え、室温で緩やかに攪拌し、完全に溶解させたもの。
<重量平均分子量の測定条件>
装置 :ゲル浸透クロマトグラフ-多角度光散乱計
検出器 :示差屈折率検出器(Wyatt Technology製 Optilab rEX)
多角度光散乱検出器(Wyatt Technology製 DAWN HELEOS)
カラム :Shodex OHpak SB-806M HQ 2本(φ7.8mm×30cm、昭和電工製)
溶媒 :0.1M硝酸ナトリウム水溶液
流速 :0.7mL/min
カラム温度 :23℃
検出器温度 :23℃
注入量 :0.2mL
データ処理 :Wyatt Technology製データ処理システム(ASTRA)
上記の方法で算出されたコンドロイチン硫酸及びその塩の重量平均分子量は、4万~7万の範囲であれば特に制限されない。重量平均分子量の下限値としては、41000以上、42000以上、43000以上、44000以上、45000以上、46000以上、47000以上、48000以上、49000以上、及び50000以上が例示される。重量平均分子量の上限値としては、69000以下、68000以下、67000以下、66000以下、65000以下、64000以下、63000以下、62000以下、61000以下、及び60000以下が例示される。重量平均分子量の範囲としては、41000~69000、42000~68000、43000~67000、44000~66000、45000~65000、46000~64000、47000~63000、48000~62000、49000~61000、及び50000~60000が例示される。
メントールは、医薬上、薬理学的に(製薬上)又は生理学的に許容されるものであれば、特に制限されない。
充血除去剤は、目の充血を除去する作用を有する化合物、及びその塩である。充血除去剤は、医薬上、薬理学的に(製薬上)又は生理学的に許容されるものであれば、特に制限されない。
眼筋調節剤は、眼筋(毛様体筋)を緊張又は弛緩させてピントを調節する作用を有する化合物、及びその塩である。眼筋調節剤は、医薬上、薬理学的に(製薬上)又は生理学的に許容されるものであれば、特に制限されない。
抗炎症剤は、抗炎症作用又は消炎作用を有する化合物、及びその塩である。抗炎症剤は、医薬上、薬理学的に(製薬上)又は生理学的に許容されるものであれば、特に制限されない。
抗ヒスタミン剤は、抗ヒスタミン作用を有する化合物、及びその塩である。抗ヒスタミン剤は、医薬上、薬理学的に(製薬上)又は生理学的に許容されるものであれば、特に制限されない。
ビタミンA類は、医薬上、薬理学的に(製薬上)又は生理学的に許容されるものであれば、特に制限されない。ビタミンA類として具体的には、レチノール、レチナール、レチノイン酸及びこれらの誘導体、並びにこれらの塩が挙げられる。
ビタミンB類は、医薬上、薬理学的に(製薬上)又は生理学的に許容されるものであれば、特に制限されない。
ビタミンE類は、医薬上、薬理学的に(製薬上)又は生理学的に許容されるものであれば、特に制限されない。ビタミンE類の具体例としては、例えば、トコフェロール、トコトリエノール及びこれらの誘導体、並びにこれらの塩が挙げられる。トコフェロール及びトコトリエノールは、α-、β-、γ-、及びδ-のいずれであってもよく、またd体及びdl体のいずれであってもよい。
アミノ酸及びその塩は、医薬上、薬理学的に(製薬上)又は生理学的に許容されるものであれば、特に制限されない。
セルロース系高分子化合物は、医薬上、薬理学的に(製薬上)又は生理学的に許容されるものであれば、特に制限されない。
抗アレルギー剤:例えば、クロモグリク酸ナトリウム、トラニラスト、ペミロラストカリウム、アシタザノラスト、アンレキサノクス、イブジラスト等。
ステロイド剤:例えば、プロピオン酸フルチカゾン、フランカルボン酸フルチカゾン、フランカルボン酸モメタゾン、プロピオン酸ベクロメタゾン、フルニソリド等。
ビタミン類:例えば、アスコルビン酸、アスコルビン酸ナトリウム等。
収斂剤:例えば、亜鉛華等。
その他:例えば、スルファメトキサゾール、スルフイソキサゾール、スルフイソミジン及びそれらの塩等。
担体:例えば、水、含水エタノール等の水性溶媒。
キレート剤:例えば、エチレンジアミン二酢酸(EDDA)、エチレンジアミン三酢酸、エチレンジアミン四酢酸(EDTA)、N-(2-ヒドロキシエチル)エチレンジアミン三酢酸(HEDTA)、ジエチレントリアミン五酢酸(DTPA)等。
基剤:例えば、オクチルドデカノール、酸化チタン、臭化カリウム、プラスチベース等。
pH調節剤:例えば、塩酸、酢酸、水酸化ナトリウム、水酸化カリウム、水酸化カルシウム、水酸化マグネシウム、トリエタノールアミン、モノエタノールアミン、ジイソプロパノールアミン等。
(B)成分以外の香料又は清涼化剤:例えば、メントン、カンフル、ボルネオール、ゲラニオール、シネオール、シトロネロール、カルボン、アネトール、オイゲノール、リモネン、リナロール、酢酸リナリル、チモール、シメン、テルピネオール、ピネン、カンフェン、イソボルネオール、フェンチェン、ネロール、ミルセン、ミルセノール、酢酸リナロール、ラバンジュロール、ユーカリ油、ベルガモット油、ウイキョウ油、ケイヒ油、ローズ油、樟脳油等。これらは、d体、l体又はdl体のいずれでもよい。
セルロース系高分子化合物以外の増粘剤:例えば、グアーガム;ヒドロキシプロピルグアーガム;アラビアゴム;カラヤガム;キサンタンガム;寒天;アルギン酸及びその塩(ナトリウム塩等);ヘパリン類似物質、ヘパリン、ヘパリン硫酸、ヘパラン硫酸、ヘパリノイド、ヒアルロン酸及びその塩(ナトリウム塩等)の((A)成分以外の))ムコ多糖類;デンプン;キチン及びその誘導体;キトサン及びその誘導体;カラギーナン;ブドウ糖等の単糖類等。
(C)成分以外の緩衝剤:例えば、リン酸緩衝剤、炭酸緩衝剤、酢酸緩衝剤、乳酸緩衝剤、コハク酸緩衝剤、クエン酸緩衝剤、トリス緩衝剤、AMPD緩衝剤等。
安定化剤:例えば、エデト酸、エデト酸塩類(エデト酸二ナトリウム、エデト酸カルシウム二ナトリウム、エデト酸三ナトリウム、エデト酸四ナトリウム)、ナトリウムホルムアルデヒドスルホキシレート(ロンガリット)、モノステアリン酸アルミニウム、モノステアリン酸グリセリン、シクロデキストリン、モノエタノールアミン、ジブチルヒドロキシトルエン、亜硫酸水素ナトリウム、ピロ亜硫酸ナトリウム等。
防腐剤:例えば、アルキルポリアミノエチルグリシン類第四級アンモニウム塩(例えば、塩化ベンザルコニウム、塩化ベンゼトニウム等)、グルコン酸クロルヘキシジン、塩化ポリドロニウム、安息香酸ナトリウム、エタノール、クロロブタノール、ソルビン酸、ソルビン酸カリウム、デヒドロ酢酸ナトリウム、パラオキシ安息香酸メチル、パラオキシ安息香酸エチル、パラオキシ安息香酸プロピル、パラオキシ安息香酸ブチル、硫酸オキシキノリン、フェネチルアルコール、ベンジルアルコール、ビグアニド化合物(具体的には、塩酸ポリヘキサニド(ポリヘキサメチレンビグアニド)、アレキシジン等)、グローキル(ローディア社製 商品名)等。
等張化剤:例えば、塩化カリウム、塩化カルシウム、塩化ナトリウム、塩化マグネシウム、酢酸カリウム、酢酸ナトリウム、炭酸水素ナトリウム、炭酸ナトリウム、チオ硫酸ナトリウム、硫酸マグネシウム、グリセリン、プロピレングリコール、亜硫酸水素ナトリウム、亜硫酸ナトリウム等。
糖アルコール類:例えば、キシリトール、ソルビトール、マンニトール、グリセリン等。これらはd体、l体又はdl体のいずれでもよい。
油類:例えば、ゴマ油、ヒマシ油、ダイズ油、オリーブ油等の植物油;スクワラン等の動物油;流動パラフィン、ワセリン等の鉱物油等。
以下、試験例に基づいて第3の本発明を具体的に説明するが、第3の本発明はこれらに限定されるものではない。また、下記試験例で使用されるコンドロイチン硫酸ナトリウムは、下記のとおりであり、重量平均分子量約56000のコンドロイチン硫酸ナトリウムはサメ由来である。
コンドロイチン硫酸ナトリウム
重量平均分子量約56000 :生化学工業株式会社;グレード N-K
重量平均分子量約28000 :生化学工業株式会社;グレード ND-K
重量平均分子量約25000 :マルハニチロ株式会社;局外規コンドロイチン硫酸ナトリウム
表30に示す組成で常法に従い比較例1-1、1-2及び実施例1-1、1-2の眼科組成物を調製した。表30における各成分の単位はw/v%である。調製した各眼科組成物を0.2μmメンブランフィルターにてろ過し、滅菌済のPET製点眼容器(容量15mL)に充填して無菌の点眼剤とした。これらの点眼剤を用いてビジュアルアナログスケール(VAS)法により「不快な刺激感」及び「灼熱感」の評価を行った。具体的には、裸眼の6人の被験者に上記点眼剤を左右眼に1滴ずつ点眼し、点眼時に感じられる「不快な刺激感」及び「灼熱感」について、それぞれ10cmの線が引いてある自覚症状調査シートを用いて、「不快な刺激感」及び「灼熱感」が全く感じられない場合を0cm、非常に強く感じられる場合を10cmとして、被験者が感じた「不快な刺激感」及び「灼熱感」の程度のところにチェックしてもらい、自覚症状の強さの程度としてこの長さ(mm)を測定し、これを各項目のスコアとした。6名の被験者のスコア平均値を算出することにより、各項目についての評価を行った。得られた値をもとに下記式(I)を用いて、VAS値の改善率を算出した。実施例1-1に対応する比較例は比較例1-1であり、実施例1-2に対応する比較例は比較例1-2である。
式(I):VAS改善率(%)={(対応する比較例のVAS値-実施例のVAS値)/対応する比較例のVAS値}×100
結果を表30に併せて示す。
表31及び32に示す組成で常法に従い各眼科組成物を調製し、試験溶液とした。表31及び32における各成分の単位は表中に明記したもの以外はw/v%である。10mL容量のPET製の点眼瓶の風袋の重量を測定し、各試験溶液を5mL充填した。次に充填した各試験溶液を出し切った後の各点眼瓶の重量を測定し、下記式(II)に従って、残液量(g)を算出し、各製剤の残液量について、下記式(III)を用いて試験溶液2-1の残液量に対する残液量の改善率を算出した。
式(II):残液量(g)=試験溶液を出し切った後の点眼瓶の重量(g)-点眼瓶の風袋の重量(g)
式(III)試験溶液2-1に対する残液量改善率(%)=(1-各試験溶液の残液量(g)/試験溶液2-1の残液量(g))×100
結果を表31及び32に併せて示す。
表33及び34に示す組成で常法に従い各眼科組成物を調製し、試験溶液とした。表33及び34における各成分の単位は表中に明記したもの以外はw/v%である。各試験溶液をガラス瓶(10mL)に10mL充填し、35℃において、SUNTESTER XLS+(東洋精機社製、1700W キセノン空冷ランプ光源)を用いて、紫外光照度765(W/m2)、96時間照射した。照射前後の各試験溶液(600μL)について、レオメーター(MCR302(AntonPaar社))にて、コーンプレート型測定治具(CP50-1、d:0.102mm)を用いて、34℃でのせん断速度(1~1000(1/s))に対する粘度を測定した。そして、せん断速度100(1/s)での粘度(mPa・s)を用いて、下記式(IV)に従い、試験前後の粘度低下率を算出した。試験溶液3-2については、試験溶液3-1の粘度低下率を1とした場合の粘度低下率の割合を算出した。試験溶液3-3~3-8については、各処方の粘度低下率について、下記式(V)を用いて、試験溶液3-2に対する粘度低下率の改善率を算出した。
式(IV):粘度低下率(%)={(各試験溶液の光照射前粘度(mPa・s)-各試験溶液の光照射後粘度(mPa・s))/各試験溶液の光照射前粘度(mPa・s)}×100
式(V):粘度低下改善率(%)={(試験溶液3-2の粘度低下率-各処方例の粘度低下率)/試験溶液3-2の粘度低下率}×100
結果を表33及び34に併せて示す。なお、粘度低下率の値が小さい程、光による粘度変化が生じず、眼科組成物が物性的に同等に保たれていることを示す。
表35及び36に示す組成で常法に従い各眼科組成物を調製し、試験溶液とした。表35及び36における各成分の単位は表中に明記したもの以外はw/v%である。調製後の各試験溶液(600μL)の粘度について、レオメーター(MCR302(AntonPaar社製))にてコーンプレート型測定治具(CP50-1、d:0.102mm)を用いて、34℃でのせん断速度に対する粘度を測定した。せん断速度10000(1/s)での粘度(mPa・s)に関して、試験溶液4-2については、試験溶液4-1の粘度を1とした場合の粘度の割合を算出した。試験溶液4-3~4-11については、下記式(VI)を用いて試験溶液4-2に対する粘度低下率(%)を算出した。なお、せん断速度10000(1/s)は瞬目速度を想定している。せん断速度10000(1/s)における粘度は、瞬目時における粘度を示しており、この値が低下するということは、瞬目時に違和感を感じにくく、瞬目がしやすいことを表す。
式(VI):粘度低下率(%)=(1-各試験溶液の粘度(mPa・s)/試験溶液4-2の粘度(mPa・s))×100
結果を表35及び36に併せて示す。
表37に示す組成で常法に従い比較例5-1及び実施例5-1の眼科組成物を調製した。表37における各成分の単位はw/v%である。調製した各眼科組成物を0.2μmメンブランフィルターにてろ過し、滅菌済のPET製点眼容器(容量15mL)に充填して無菌の点眼剤とした。これらの点眼剤を用いてビジュアルアナログスケール(VAS)法により「不快な刺激感」及び「灼熱感」の評価を行った。具体的には、裸眼の3人の被験者に上記点眼剤を左右眼に1滴ずつ点眼し、点眼時に感じられる「不快な刺激感」及び「灼熱感」について、それぞれ10cmの線が引いてある自覚症状調査シートを用いて、「不快な刺激感」及び「灼熱感」が全く感じられない場合を0cm、非常に強く感じられる場合を10cmとして、被験者が感じた「不快な刺激感」及び「灼熱感」の程度のところにチェックしてもらい、自覚症状の強さの程度としてこの長さ(mm)を測定し、これを各項目のスコアとした。3名の被験者のスコア平均値を算出することにより、各項目についての評価を行った。得られた値をもとに試験例1における式(I)を用いて、VAS値の改善率を算出した。実施例5-1に対応する比較例は比較例5-1である。
結果を表37に併せて示す。
下記表38~41に記載の処方で、常法により点眼剤及び人工涙液が調製される。なお、下記表38~41における各成分量の単位は、表中に明記したもの以外はw/v%であり、製剤例1~10、21~27、29~32は点眼剤、製剤例11~16、28は人工涙液である。また、製剤例1~32を、ポリエチレンテレフタレート製の容器(容量15mL)に充填し、ポリエチレン製のノズルを装着したものを製剤例1´~32´、最内層がポリブチレンテレフタレート製のノズルを装着したものを製剤例1´´~32´´、最内層がポリエチレンナフタレート製のノズルを装着したものを製剤例1´´´~32´´´とした。
Claims (10)
- 重量平均分子量が4万~7万であるコンドロイチン硫酸及びその塩からなる群より選択される少なくとも1種を含有する、目の乾燥抑制用眼科組成物。
- 重量平均分子量が4万~7万であるコンドロイチン硫酸及びその塩からなる群より選択される少なくとも1種を含有する、コンタクトレンズの乾燥抑制用眼科組成物。
- 重量平均分子量が4万~7万であるコンドロイチン硫酸及びその塩からなる群より選択される少なくとも1種と、抗炎症剤、ビタミンA類、ビタミンB類、ビタミンE類、アミノエチルスルホン酸及びその塩、アスパラギン酸及びその塩、ネオスチグミン及びその塩、並びにセルロース系高分子化合物からなる群より選択される少なくとも1種とを含有する、眼科組成物。
- 抗炎症剤がアラントイン及びその塩、並びにグリチルリチン酸及びその塩からなる群より選択される少なくとも1種であり、ビタミンB類がパンテノール、並びにピリドキシン及びその塩からなる群より選択される少なくとも1種であり、セルロース系高分子化合物がヒドロキシプロピルメチルセルロース及びその塩からなる群より選択される少なくとも1種である、請求項3に記載の眼科組成物。
- 重量平均分子量が4万~7万であるコンドロイチン硫酸及びその塩からなる群より選択される少なくとも1種と、抗ヒスタミン剤、亜鉛塩、充血除去剤、ヒドロキシエチルセルロース及びその塩、並びにポリビニル系高分子化合物からなる群より選択される少なくとも1種とを含有する、眼科組成物。
- 抗ヒスタミン剤がクロルフェニラミン及びその塩からなる群より選択される少なくとも1種であり、充血除去剤がテトラヒドロゾリン及びその塩からなる群より選択される少なくとも1種であり、ポリビニル系高分子化合物がポリビニルピロリドンである、請求項5に記載の眼科組成物。
- 重量平均分子量が4万~7万であるコンドロイチン硫酸及びその塩からなる群より選択される少なくとも1種と、メントールと、を含有する、眼科組成物。
- ホウ酸及びその塩からなる群より選択される少なくとも1種を更に含有する、請求項7に記載の眼科組成物。
- クロロブタノールを更に含有する、請求項7又は8に記載の眼科組成物。
- 充血除去剤、眼筋調節剤、抗炎症剤、抗ヒスタミン剤、ビタミンA類、ビタミンB類、ビタミンE類、アミノ酸及びその塩、並びにセルロース系高分子化合物からなる群より選択される少なくとも1種を更に含有する、請求項7又は8に記載の眼科組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2021/040030 WO2023073925A1 (ja) | 2021-10-29 | 2021-10-29 | 眼科組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2021/040030 WO2023073925A1 (ja) | 2021-10-29 | 2021-10-29 | 眼科組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023073925A1 true WO2023073925A1 (ja) | 2023-05-04 |
Family
ID=86157647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/040030 WO2023073925A1 (ja) | 2021-10-29 | 2021-10-29 | 眼科組成物 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023073925A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006193521A (ja) * | 2004-12-17 | 2006-07-27 | Rohto Pharmaceut Co Ltd | 眼科用組成物 |
JP2011148791A (ja) | 2009-12-25 | 2011-08-04 | Rohto Pharmaceutical Co Ltd | シリコーンハイドロゲルコンタクトレンズ用眼科組成物 |
JP2013525335A (ja) * | 2010-04-21 | 2013-06-20 | オルス、ファルマ | 人工涙エマルション |
WO2021220712A1 (ja) * | 2020-04-30 | 2021-11-04 | ロート製薬株式会社 | 眼科組成物 |
-
2021
- 2021-10-29 WO PCT/JP2021/040030 patent/WO2023073925A1/ja active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006193521A (ja) * | 2004-12-17 | 2006-07-27 | Rohto Pharmaceut Co Ltd | 眼科用組成物 |
JP2011148791A (ja) | 2009-12-25 | 2011-08-04 | Rohto Pharmaceutical Co Ltd | シリコーンハイドロゲルコンタクトレンズ用眼科組成物 |
JP2013525335A (ja) * | 2010-04-21 | 2013-06-20 | オルス、ファルマ | 人工涙エマルション |
WO2021220712A1 (ja) * | 2020-04-30 | 2021-11-04 | ロート製薬株式会社 | 眼科組成物 |
Non-Patent Citations (1)
Title |
---|
NAGANO ET AL., NEW OPHTHALMOLOGY, vol. 13, no. 2, 1996, pages 267 - 270 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5797720B2 (ja) | 眼科用組成物 | |
JP6120785B2 (ja) | 眼科用組成物 | |
JP2018100287A (ja) | 眼科用組成物 | |
WO2021220712A1 (ja) | 眼科組成物 | |
JP6611444B2 (ja) | 眼科用組成物 | |
JP2023010965A (ja) | 視覚機能の再活性化用眼科組成物 | |
JP2019202166A (ja) | 眼科組成物 | |
JP2022157707A (ja) | 眼科組成物 | |
JP2023033557A (ja) | 複合目症状改善用眼科組成物 | |
JP2023025297A (ja) | 摩擦低減用であるコンタクトレンズ用点眼剤、その使用方法、および装用中のコンタクトレンズの摩擦低減方法 | |
WO2023073925A1 (ja) | 眼科組成物 | |
JP7178470B1 (ja) | 眼科組成物 | |
TW202317154A (zh) | 眼科組成物 | |
JP2023008962A (ja) | 眼科組成物 | |
JP7304168B2 (ja) | 点眼剤 | |
JP2022176928A (ja) | 眼科組成物 | |
WO2023054669A1 (ja) | 眼科組成物 | |
JP2017197525A (ja) | 水性組成物 | |
JP2023067803A (ja) | 眼科組成物 | |
JP2022176930A (ja) | 眼科組成物 | |
JP2021187857A (ja) | ソフトコンタクトレンズ用眼科組成物 | |
JP2022164840A (ja) | 眼科組成物 | |
JP2020094036A (ja) | 光線による障害からの細胞保護用眼科組成物 | |
JP2023125656A (ja) | 眼科組成物 | |
JP2023112106A (ja) | 水性眼科組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21962467 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 21962467.3 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2023556031 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021962467 Country of ref document: EP Effective date: 20240327 |